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ABSTRACT 
Ocular surface, consisting of conjunctiva, cornea, tear fluid and eyelids, is the first 
line of defence in the eye, protecting it from environmental threats such as pollution, 
desiccation, injuries, allergens and pathogens. These parts of the ocular surface form 
a functional unit and any dysfunction in it can easily throw the system off balance, 
causing an ocular surface disease. Hence, there are several potential causes for ocular 
surface disease signs and symptoms experienced by patients, which makes diagnosis 
and treatment of these conditions challenging. However, recent advances in the field 
of proteomics have made it possible to study the underlying biological functions of 
ocular surface diseases by evaluating the protein expression levels in tear fluid. With 
current technology, the data analysis can be performed on individual samples, this 
way avoiding pooling and enabling more personalized research approach. This type 
of approach can provide new tools for accurate diagnosis and personalized therapy 
selection for ocular surface diseases. 
This dissertation had two main aims. The first aim was to examine common 
ocular surface diseases and how individual patients’ protein expression levels are 
affected by treatment and/or environment. This type of bioinformatics research 
focuses on the discovery of new biomarkers, which could improve the treatment and 
quality of life of patients suffering from ocular surface diseases. The second main 
aim of this dissertation was to advance the understanding of the factors affecting 
tear fluid proteomics data and the associated bioinformatics analyses. Since the field 
of proteomics, and tear fluid proteomics in particular, is still relatively new, there is 
a lot to be learned about the underlying factors affecting tear fluid proteomics and 
how studies should be conducted most efficiently.  
This dissertation consists of four separate studies, which evaluate both the normal 
and diseased states of the ocular surface. More specifically, as both specific diseases 
as well as non-pathophysiological patient characteristics, such as age and sex, can 
affect the condition of ocular surface, both have been examined with tear fluid 
proteomics. The first two studies are focused on common eye diseases, in this case 
dry eye disease and glaucoma therapy-induced ocular surface disease, which were 
studied in relation to their treatment effects. In both studies, patients’ tear fluids were 
sampled in multiple visits and the samples were analysed with a mass spectrometer 
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implementing sequential windowed acquisition of all theoretical fragment ion 
(SWATH-MS) method, in order to discover what proteins and thus biological 
functions are affected by treatment and/or environmental changes in individual 
patients. The latter two studies of this dissertation examined the effects of normal 
aging and differences between common tear fluid sampling methods on the tear fluid 
proteomics. Both studies consisted of subjects with no previously diagnosed ocular 
surface diseases, which we considered ‘normal’. Tear fluid sampling, mass 
spectrometry and bioinformatics analysis were again conducted in order to discover 
what proteins were changing during normal aging and what proteins were 
differentially expressed or identified between different sampling methods (Schirmer 
strip and capillary). 
The dry eye disease (DED) and glaucoma medication switch studies revealed that 
even when the patients would initially form a relatively homogeneous group based 
on their clinical signs and backgrounds, their proteomic profiles may vary widely and 
enable further patient stratification. These more detailed analyses of proteomic data 
can be used to evaluate a patient’s ocular surface condition more accurately and 
predict the treatment response more reliably than with clinical measures alone. In 
addition, the studies examining the effects of normal aging and tear fluid sampling 
methods confirmed that these aspects should not be overlooked prior or during the 
analysis. Several pro-inflammatory proteins were found to be increased with age and 
hence, treatment groups in tear proteomics studies should always be age-matched or 
corrected for age, depending on the availability of data. Capillary and Schirmer strip 
samples also differed notably in both identification as well as in protein expression 
levels. Therefore, researchers should carefully consider prior to sampling, the type 
of information and proteins they are most interested in and what type of sampling 
would be most suitable for their clinical studies and choose the sampling method 
based on the answers.  
Altogether, the studies in this dissertation provide information on what type of 
bioinformatics analysis could be performed on the available tear fluid proteomics 
data and more specifically, what type of analysis is most suitable for a given dataset. 
As a conclusion, this dissertation shows that analysis of tear fluid proteomics data is 
an efficient and non-invasive way to evaluate the state of the ocular surface and it 
can be used as an additional tool to determine and develop the most suitable 
treatments for individual patients. It also points out the importance to know the 
existing limitations of this technology. Proteomics in general is likely to be an 
important tool in the precision medicine and in development of personalized 
treatments in the future.  
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TIIVISTELMÄ 
Silmän pinta koostuu sidekalvosta, sarveiskalvosta, kyynelnesteestä ja silmäluomista, 
jotka yhdessä suojaavat silmää mm. vammoja, ilman epäpuhtauksia, kuivumista, 
allergeeneja ja taudinaiheuttajia vastaan. Yhdessä silmän pinnan osat muodostavat 
toiminnallisen kokonaisuuden, jonka häiriöt voivat johtaa silmän pintasairauksien 
syntymiseen. Samankaltaisiin silmän pinnan kliinisiin löydöksiin ja koettuihin 
oireisiin on useita mahdollisia syitä, mikä osaltaan vaikeuttaa näiden sairauksien 
tarkkaa diagnosointia sekä hoidon suunnittelua. Proteomiikan alalla viime vuosina 
saavutetut edistysaskeleet ovat kuitenkin mahdollistaneet pienen 
kyynelnestenäytteen proteiinien ilmenemistasojen analysoinnin ja siten myös silmän 
pinnan sairauksien taustalla olevien toimintojen tutkimisen. Nykyteknologian avulla 
proteomiikka-analyysit voidaan suorittaa yksittäisille potilasnäytteille, jolloin 
vältytään näytteiden yhdistämiseltä ja mahdollistetaan potilaiden yksilöllisempi 
tutkimus. Tällainen lähestymistapa tarjoaakin uusia keinoja silmän pinnan sairauksien 
tarkkaan diagnosointiin sekä yksilöllisten hoitojen valintaan. 
Väitöskirjatyössä oli kaksi päätavoitetta. Ensimmäisenä tavoitteena oli tutkia 
yleisiä silmän pinnan sairauksia ja sitä, miten mahdolliset hoidot ja ympäristö 
vaikuttavat yksittäisten potilaiden kyynelnesteproteiinien ilmenemistasoihin. Näillä 
tutkimuksilla pyrittiin löytämään uusia hyödynnettäviä merkkiaineita eli 
biomarkkereita, joiden avulla voidaan parantaa silmän pinnan sairauksista kärsivien 
potilaiden hoitoa ja elämänlaatua. Väitöskirjan toisena tavoitteena oli tutkia 
tarkemmin sitä, mitkä tekijät vaikuttavat kyynelnesteproteomiikalla tuotettuun 
aineistoon ja tulisi siten ottaa bioinformatiikan analyyseissa huomioon. Moderni 
kyynelnesteproteomiikka ja tulosten bioinformatiikka-analyysit ovat suhteellisen 
nuoria tutkimusaloja. Tietoa uusista tutkimuskäytännöistä tarvitaan, jotta 
tutkimukset voidaan tehdä mahdollisimman tehokkaasti ja toistettavasti. 
Tämä väitöskirja koostuu neljästä osajulkaisusta, joissa arvioidaan sekä silmän 
pinnan normaalitilaa että sairauden aiheuttamia muutoksia. Koska potilaiden silmän 
pinnan tilaan voi sairauksien lisäksi vaikuttaa myös normaalit ominaisuudet, kuten 
korkea ikä ja sukupuoli, molempia on tässä työssä tutkittu kyynelnesteen 
proteomiikan avulla. Kaksi ensimmäistä osatyötä keskittyvät kahteen yleiseen silmän 
pintasairauteen, kuivasilmäisyyteen ja glaukooman hoidosta johtuvaan silmän pinnan 
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sairauteen, joita molempia tutkittiin hoitovasteen kautta. Molemmissa tutkimuksissa 
potilaiden kyynelnestettä kerättiin useiden käyntien yhteydessä ja näytteet analysoitiin 
käyttäen massaspektrometriä ja SWATH-MS-menetelmää. Tarkoituksena oli 
selvittää, miten kyseisten sairauksien hoito ja/tai ympäristön muutokset vaikuttavat 
potilaiden kyynelnesteen proteiineihin ja biologiseen toimintaan. Jälkimmäiset kaksi 
tutkimusta tarkastelivat normaalin ikääntymisen ja näytteenottomenetelmien tuomia 
eroja. Molemmat tutkimukset koostuivat ns. normaaleista 
verrokeista/tutkimushenkilöistä, joilla ei ollut aiemmin todettuja silmän 
pintasairauksia. Massaspektrometrian ja bioinformatiikan avulla näissä tutkimuksissa 
analysoitiin sitä, mitkä kyynelnesteproteiinit muuttuivat normaalin ikääntymisen ja 
näytteenottomenetelmän vaihtumisen myötä. 
Kuivasilmäisyys- ja glaukoomalääkevaihtotutkimukset paljastivat, että vaikka 
potilaat muodostaisivatkin alustavasti kliinisten oireidensa ja taustojensa perusteella 
suhteellisen homogeenisen ryhmän, potilaiden proteiiniprofiilit voivat vaihdella, 
mahdollistaen potilaiden jaottelun erilaisiin vasteryhmiin. Proteomiikka-aineistoa voi 
siis käyttää potilaiden silmän pinnan tilan yksilölliseen arviointiin, hoitovaihtoehdon 
valintaan sekä hoitovasteen ennustamiseen, mikä ei välttämättä olisi mahdollista 
pelkkien kliinisten tietojen perusteella. Tutkimukset, joissa tutkittiin normaalin 
ikääntymisen ja kyynelnesteen näytteenottomenetelmien eroja osoittivat molempien 
muuttujien olevan hyvin tärkeitä kyynelnesteproteomiikassa. Useat tulehdusta 
edistävät proteiinit nousevat iän myötä ja tästä syystä 
kyynelproteomiikkatutkimuksissa olisi tärkeää muodostaa potilasryhmät saman 
ikäisistä potilaista tai huomioida potilaiden iät data-analyyseissä. Lisäksi, eri tavoilla 
otetut kyynelnestenäytteet (Schirmer liuska ja kapillaari) eroavat merkittävästi sekä 
proteiinien tunnistuksen että ilmenemistasojen osalta. Tästä syystä tutkijoiden olisi 
hyvä harkita jo tutkimusta suunnitellessaan, millaisesta tiedosta ja proteiineista he 
ovat kiinnostuneita ja valita tämän perusteella tutkimukseen sopivin 
näytteenottomenetelmä. 
Kokonaisuudessaan väitöskirjan tutkimukset antavat tietoa 
kyynelnesteproteomiikan avulla tehtävien tutkimusten mahdollisuuksista ja 
rajoituksista sekä luovat pohjaa parhaiten sopivien data-analyysimenetelmien 
valinnalle. Väitöskirjassa esitetyt tulokset osoittavat, että kyynelnesteproteomiikan 
analysointi on tehokas ja kajoamaton tapa arvioida silmän pinnan tilaa, ja sitä on 
mahdollista käyttää myös lisäkeinona yksittäisten potilaiden diagnostiikassa, 
hoitomenetelmien kehittämisessä ja valinnassa sekä hoitotulosten seurannassa. 
Proteomiikka tulee todennäköisesti olemaan tulevaisuudessa tärkeä osa 
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henkilökohtaisen lääketieteen tutkimusta ja kohdennettujen hoitomenetelmien 
kehitystä. 
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1 INTRODUCTION 
Ocular surface disease is a term used to describe an array of conditions such as dry 
eye disease (DED), Meibomian gland dysfunction, allergic eye diseases, blepharitis, 
conjunctivitis and other inflammatory diseases such as graft-versus-host disease. The 
common denominator of these conditions is that they result in dysfunction of the 
ocular surface, i.e. cornea, conjunctiva, tear fluid and eyelids, causing discomfort and 
changes in vision as well as lowered quality of life. Since the spectrum of ocular 
surface disease causes is wide, diagnosis and treatment of these conditions is 
challenging. Due to population aging, progressively frequent use of devices with 
digital displays and polluted or air-conditioned environments, number of people with 
an ocular surface disease is increasing among all age groups. This is however 
particularly problematic for elderly, who are expected to have longer working careers 
and therefore a continued exposure to digital displays, while being more susceptible 
to age-associated diseases, including ocular surface diseases. There is thus a growing 
body of unmet needs for more accurate diagnosis and effective therapies for this 
increased population suffering from ocular surface diseases.  
There are extensive studies about the signs and symptoms of ocular surface 
diseases (reviewed by Craig et al., 2017). However, the biological processes of the 
underlying diseases have only recently been studied in more detail as different omics 
technologies, in the field of genomics, proteomics and metabolomics, have begun to 
develop more rapidly.  Proteomics, the large-scale study of proteins, can be utilized 
in clinical studies to better understand the individual courses of the disease as well 
as the individual treatment needs of patients based on the expression levels of 
proteins. One particularly interesting aspect of clinical proteomics studies are 
biomarkers, which are measurable indicators of biological/pathogenic processes or 
response to therapeutic treatments. Hence, biomarkers can be considered as 
diagnostic, prognostic, predictive or therapeutic tools towards measuring specific 
clinical conditions. In general, biomarkers for specific diseases can be as simple as 
blood pressure or they can be more complex measures, such as specific substance 
concentrations in plasma. In the case of proteomics, this often means individual 
proteins and specifically their expression levels, which are measured e.g. from plasma 
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or saliva and are used to evaluate the state of the disease in order to set a diagnosis 
or prognosis, or to select the most effective therapeutic options. In ophthalmology, 
there are numerous ways to obtain samples from the eye including biopsies as well 
as conjunctival and corneal impression cytology samples. In ocular surface research 
in particular, recent studies have also been performed with tear fluid proteomics, 
which is able to combine non-invasive tear fluid sampling and highly accurate mass 
spectrometry. In addition to providing detailed information about the individual 
protein expression levels, activated and inhibited pathways and biological functions 
on the ocular surface, tear fluid proteomics could also help us identify new, specific 
biomarkers for ocular surface diseases. 
In this dissertation, two common eye diseases, dry eye disease (DED) and 
glaucoma were studied in relation to their treatment effects. These diseases were 
included as DED is an ocular surface disease itself and although glaucoma mainly 
affects the optic nerve and ganglion cells, the chronic topical treatment of glaucoma 
has well-known effects on the ocular surface. Two of the studies in this dissertation 
thus focused on identifying proteins, which could be used to predict clinical effects 
of the treatments and detecting patient groups, which would benefit most from given 
treatments. The third part of this dissertation was a study examining the effects of 
normal aging on the tear fluid proteomics, in order to obtain better understanding 
of the basic age-effects on ocular surface. The fourth study was focusing on the 
comparison of the most common tear fluid sampling methods, capillary and 
Schirmer strip, therefore providing better understanding on the differences between 
these methods and helping researchers in choosing the most suitable method for 
their purposes. Both knowledge of normal aging effects as well as optimal tear fluid 
sampling method are essential when performing ophthalmic studies involving tear 
fluid collection. 
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2 LITERATURE REVIEW 
2.1 Ocular surface 
Sight is a very vital but at the same time a very vulnerable sense. The surface of the 
eye is directly exposed to various external threats, such as pollution, desiccation, 
injuries, allergens and pathogens, and therefore, its efficient protection is very 
important for vision. For this purpose, the eye has an ocular surface system, which 
provides maintenance and protection, both physical and biological, for the 
underlying eye and this way contributes to the quality of vision (Thoft & Friend, 
1977; Gipson, 2007; Gipson et al., 2007).  
The ocular surface consists of various important components of the eye; corneal 
and conjunctival epithelial cells form a continuous protective epithelium, which is 
nourished and lubricated by tears and protected further by eyelids and a row of 
eyelashes along the lids (Gipson, 2007; Levin et al., 2011). The outflow of the tears, 
produced by Meibomian glands, lacrimal glands and conjunctival goblet cells, is 
enabled by lacrimal drainage system consisting of lacrimal puncta, lacrimal canaliculi, 
lacrimal sac and lacrimal duct (Levin et al., 2011). Figure 1 illustrates the structures 
and locations of these components in the ocular surface. Tear film and its production 
and drainage are further discussed in Section 2.1.1. Since ocular surface system has 
to be delicately balanced in order to provide sufficient protection for the eye, any 
disturbances in this balance can lead to noticeable discomfort and this way affect 
patients’ vision and quality of life. Section 2.2 discusses in more detail how the 
dysfunction of the ocular surface can be manifested in the eye and what factors affect 
the prevalence of ocular surface diseases. 
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Figure 1.  Components of the ocular surface. 
2.1.1 Tear film 
The clear, refractive tear film coats the corneal and conjunctival epithelium and while 
it is approximately 98% water, it has been considered to consist of three distinct 
layers: mucin (or glycocalyx), aqueous and lipid layer. It is, however, easy to 
oversimplify this complex, dynamic functional unit, especially since it contains at 
least 1500 different proteins and its composition varies depending on the tear fluid 
location (Zhou et al., 2012; Willcox et al., 2017). Mucin and aqueous layers in 
particular can be thought to form one mucoaqueous layer. The main components of 
the tear film are all produced in different parts of the ocular surface system and they 
have varying purposes in the tear film (Van Haeringen, 1981; Tiffany, 2008). Mucins, 
produced by conjunctival goblet cells, help hold the tears on top of the eye’s surface 
and assists with even distribution of the tear film, as transmembrane mucins are 
anchored to the surface of the corneal and conjunctival epithelium. The aqueous 
content of the tears is secreted from lacrimal and accessory lacrimal glands and 
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contains various proteins, peptides, metabolites, immune cells, secretory mucins and 
nutrients needed by the ocular surface. The outermost layer of lipids produced by 
Meibomian gland “seals” and stabilizes the tear film, and prevents unwanted tear 
evaporation (Gipson, 2007; Tiffany, 2008). It is further noteworthy that the four 
types of tears, basal, reflex, emotional and closed-eye tears, are thought to have 
varying tear fluid compositions especially in the case of protein concentrations 
(Fullard & Snyder; 1990; Perumal et al., 2015). 
The tear film has several purposes. It provides protection to the tissues 
underneath as it contains various antibacterial proteins. It also supplies nutrients and 
oxygen to ocular surface and non-vascularized cornea in particular and it flushes 
away waste including pollutants, cells, foreign substances and metabolites through 
tear flow (Tiffany, 2008; Tong et al., 2012; Willcox et al., 2017). Tear film also 
smoothens and cleans optically the surface of corneal epithelium in order to provide 
better vision. In practice, as we blink, a thin layer of tear film is placed smoothly on 
top of the epithelium, and tear fluid is then allowed to flow out by the lacrimal 
drainage system. The tear volume can vary from 5 to 10 μl in a healthy eye (Mishima 
et al., 1966) and normal basal secretion rate can vary between 0.5 and 2.2μl/min 
(Dumortier & Chaumeil, 2004). 
2.2 Ocular surface diseases and factors affecting ocular surface 
function 
There are various factors and conditions, e.g. ocular surface diseases, which can 
disturb the function of the ocular surface and hence lower the quality of vision and 
health of the eye. These diseases can stem from disorders either in the lid-margin, 
such as blepharitis, or in tear film, such as Sjögren’s syndrome and dry eye disease, 
which is discussed further in Section 2.2.1. Dysfunction of ocular surface can also 
be initiated by external causes, such as glaucoma and other topical medications with 
strongly cytotoxic ingredients, which cause an immunological response on the ocular 
surface (Pisella et al., 2002; Noecker et al., 2004; Uusitalo et al., 2010; Ghosh et al., 
2012; Pellinen et al., 2012). Glaucoma medication-associated ocular surface disease 
is further discussed in Section 2.2.2. There are also various other factors, which can 
affect the ocular surface, but not necessarily result in the development of ocular 
surface disease. These factors, which can be considered more as risk factors include 
age, gender, previous trauma (e.g. refractive surgery), other medication and illnesses, 
hormonal changes (such as menopause) as well as exposure to various environmental 
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factors such as pollution, dry air or smoke (Schein et al., 1999; Moss et al., 2000; Chia 
et al., 2003; Schaumberg et al., 2003; De Paiva et al., 2006; Schaumberg et al, 2009; 
Paulsen et al., 2014; Brandt et al., 2015). In addition, the constantly increasing use of 
electronic devices with bright digital displays has been considered as one explanation 
to the increasing number of people suffering from ocular surface diseases (Schlote 
et al., 2004). Sullivan et al. (2017) and Stapleton et al. (2017) have also reviewed the 
affecting risk factors extensively in their reports of the Tear Film and Ocular Surface 
Society (TFOS) Dry Eye Workshop (DEWS).  In our research, we decided to focus 
on age as a risk factor in particular and some further discussion on this can be found 
in Section 2.2.3. 
Despite the various causes, the symptoms in ocular surface diseases are often 
similar: dry, itchy, tired and red eyes, blurry vision, foreign body sensation as well as 
increased reflex tearing and sensitivity. Although these symptoms can be alleviated 
and treated, it can be difficult to determine the primary underlying cause of the 
condition, without extensive evaluation of the ocular surface, due to the similarity of 
the symptoms. One possible diagnostic tool, which could help in differentiating the 
ocular surface disease patients and identifying the cause, is tear fluid proteomics. It 
can be used to identify proteins, which have altered expression level in tear fluid of 
specific patients and this way give indication of the underlying cause of imbalance 
and biological pathways involved. This will be further discussed in Section 2.3.3. 
2.2.1 Dry eye disease 
Ocular surface disease and dry eye disease (DED) are often considered to be two 
names for the same condition. This is probably due to dry eye being the most 
common form of ocular surface diseases. Currently, there is no consensus but it is 
estimated that the prevalence of DED is somewhere between 5% and 30%, or even 
50%. The estimate is depending largely on participants’ age range and definitions of 
the severity as well as how the disease is detected, e.g. clinical signs or symptoms or 
both (Moss et al., 2000; Schaumberg et al., 2003; Schaumberg et al, 2009; Paulsen et 
al., 2014; Stapleton et al., 2017). Most well-known risk factors of dry eye include age, 
female sex, contact lens use, ocular surgeries, hormonal changes and the use of 
certain medicines (e.g. antihistamine and antidepressants) (Moss et al., 2000; Moss et 
al., 2008; Schaumberg et al, 2009; Paulsen et al., 2014). 
Despite its name, “dry eye”, which refers to an eye with inadequate tear volume, 
DED is considered to be a complex multifactorial disease of the tears, ocular surface, 
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autoimmune system and nerves encompassing various causes and clinical signs, most 
prominently loss of tear film homeostasis caused by dysfunction of lacrimal 
functional unit (Stern et al., 2013; Craig et al., 2017). The clinical signs include tear 
film instability and hyperosmolarity, damage and inflammation of the ocular surface 
and lacrimal gland, neurotrophic deficiency and Meibomian gland deficiency (Craig 
et al., 2017). It is believed that DED can often be triggered by various harmful stimuli 
leading to a vicious cycle involving inflammation and aforementioned clinical signs. 
The dry eye disease symptoms can vary from mild discomfort to severe symptoms 
and visual disturbance and result to primary and secondary changes and potential 
damage to the ocular surface. Symptoms experienced by patients are similar to other 
ocular surface diseases and can vary from patient to patient: irritation, burning, 
stinging, itching, redness, blurred vision etc. However, all symptoms can affect 
greatly the patients’ quality of life (Miljanović et al., 2007; Stapleton et al., 2017) and 
in fact severe DED condition can be compared to dialysis or severe angina based on 
utility analyses (Schiffman et al., 2003; Buchholz et al., 2006). 
Most commonly, patients suffering from DED have been divided to aqueous-
deficient and lipid-deficient, or evaporative, patients. The aqueous-deficient dry eye 
patients have been previously divided further to Sjögren’s and non-Sjögren’s 
syndrome patients, while lipid-deficient dry eye patients’ conditions were considered 
to be due to intrinsic or extrinsic factors affecting the evaporation rate (Gipson et 
al., 2007). However, the current consensus is that these conditions can and often are 
coexisting in dry eye (Craig et al., 2017). Diagnostic tools for classification of dry eye 
disease and other ocular surface conditions include, for example, imaging techniques, 
such as meibography, confocal microscopy and tear fluid interferometry (reviewed 
by Chan et al. (2018) and Matsumoto & Ibrahim (2018)). In addition, other clinical 
tests, including Schirmer’s test, fluorescein staining, tear break-up time and tear film 
osmolarity measures and various questionnaires are widely used and have been 
reviewed extensively by Wolffsohn et al. (2017). Individual tear fluid markers, such 
as matrix metalloproteinases, cytokines and chemokines are also either being studied 
or are already used as diagnostic tests. For example, InflammaDry® measures the 
levels of matrix metalloproteinase-9 (MMP-9) in tear fluid and helps thus determine 
dry eye-related inflammation on ocular surface (Sambursky et al., 2013).  
Depending on the diagnosis and more specific symptoms, dry eye patients can be 
treated with artificial tears, steroids, non-steroidal medication or physical treatments, 
such as warm compresses, punctal plugs and soft or scleral contact lenses (reviewed 
by Jones et al., 2017). Artificial or biological tear substitutes, such as serum eye drops, 
aim to supply aqueous or lipid supplementation for the ocular surface and they are 
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often first implemented in mild-to-moderate DED cases. Some approaches aim to 
assist with the existing tear fluid flow by preventing excess drainage (punctal plugs 
and moisture chamber spectacles) or by increased tear fluid stimulation (e.g. 
secretagogues), while others target possible lid abnormalities (e.g. warm compresses). 
With more severe cases of DED, treatment of the ocular surface can include 
systemic anti-inflammatory or immunomodulatory agents such as topical 
glucocorticoids, cyclosporine A and antibiotics. In extreme cases, surgical treatment 
methods, such as tarsorrhaphy, where upper and lower eyelids are either partially or 
completely closed, transplantation of amniotic membrane or various stem cell based 
transplants can be implemented. Despite the large amount of varying diagnostic 
tools and treatment methods, there is currently a need for additional diagnostic tools, 
which could be used to obtain further information about the precise biological 
functions taking place on the ocular surface. These tools could thus help further 
personalize the therapeutic measures and determine the most beneficial treatment 
approach for each individual patient in early course of the disease. 
2.2.2 Glaucoma 
Glaucoma is a collection of progressive neurodegenerative diseases threatening the 
retinal ganglion cells (RGCs) and hence, vision. This condition is often cited as the 
second most common cause of blindness worldwide with estimated 64.3 million 
people affected in 2013 (Tham et al., 2014) and 79.6 million by 2020 (Quigley & 
Broman, 2006) and it can come in many forms. For example, open-angle glaucoma 
can be subdivided into normal tension glaucoma (NTG), which does not include 
elevated intraocular pressure (IOP), and primary open-angle glaucoma (POAG), 
which is considered the most common form of glaucoma, associated with high 
intraocular pressure. Other main subtypes of glaucoma include closed-angle 
glaucoma and secondary glaucoma, e.g. exfoliative and pigmentary glaucoma. 
Although many subtypes of glaucoma exist, they usually share the similar 
pathogenesis: death of RGCs and axonal loss of the optic nerve. 
In the eye, aqueous humor fills the anterior and posterior chambers of the eye 
and provides nutrition and support to avascular cornea and lens (Fig. 2). It is secreted 
from the ciliary epithelium and the outflow occurs primarily through the trabecular 
meshwork in the anterior chamber but also via uveoscleral outflow. When normal 
aqueous outflow in the eye is decreased, it can cause an increase in IOP and result 
in the development of glaucoma (Le et al., 2003; Leske et al., 2008). Increased IOP 
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is therefore considered one of the major risk factors of glaucoma and because of the 
lack of therapies directly preventing RGC death, treatment of glaucoma focuses 
heavily on lowering the IOP by reducing the aqueous humor production or by 
enhancing the outflow of aqueous humor though trabecular meshwork or via 
uveoscleral outflow (reviewed by Weinreb et al., 2014). The management methods 
of glaucoma include medical treatment, laser therapy and surgery. Topical 
medication is currently the most commonly used treatment form and includes 
prostaglandin analogues, β-blockers, carbonic anhydrase inhibitors as well as α-
adrenergic and cholinergic agonists, which are administered as eye drops and aim to 
reduce the aqueous humor production and/or increase the tear fluid outflow 
(reviewed by Noecker, 2006). Since glaucoma is a life-long, chronic disease and 
commonly needs more than one topical drug for the successful control of IOP, many 
patients need to use several different topical drugs for years or decades. Therefore, 
even though glaucoma is not itself an ocular surface disease, continuous use of 
topical medication used to treat it increases the prevalence of ocular surface 
problems up to 60% among glaucoma patients (Pisella et al., 2002; Nordmann et al., 
2003; Noecker et al., 2004; Leung et al., 2008; Ghosh et al., 2012). 
 
Figure 2.  Components of the eye. 
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The most common cause for the glaucoma treatment-induced ocular surface disease 
is thought to be the preservatives. Preservatives are used in topical medications in 
order to prevent contamination and biodegeneration of the medication and in 
maintaining its potency. While adding preservatives to the topical medication can 
help the solution to destroy any unwanted pathogens, they can cause adverse effects 
with some glaucoma patients, thus affecting their ocular surface (Baudouin et al., 
2004; Uusitalo et al., 2010; Ghosh et al., 2012; Nättinen, 2015). These effects include 
symptoms and signs similar to DED and other ocular surface diseases (Pisella et al, 
2002; Nordmann et al., 2003; Jaenen et al., 2007; Leung et al., 2008). Although the 
symptoms of this condition are very similar to DED, the underlying pathways are 
thought to differ. Why some patients are more sensitive to the preservatives is still 
unknown. However, switching to a preservative-free medication has been found to 
lower the adverse reaction occurrence and improve the corneal health, while 
maintaining the IOP-lowering effects (Hamacher et al., 2008; Uusitalo et al., 2010; 
Giménez-Gómez et al., 2013; Uusitalo et al., 2016; Pillunat et al., 2017; Rossi et al., 
2019). In the future, diagnostic tools are hopefully capable of identifying sensitive 
glaucoma patients, who should be treated very carefully with topical medication by 
avoiding all preservatives or by choosing laser or surgical options already in the early 
course of their disease. 
2.2.3 Age 
Age is a very common risk factor when it comes to many inflammatory diseases, and 
ocular surface diseases are no exception. With increased age, the tear film stability is 
lowered, tear film composition changes and evaporation increases, lacrimal and 
Meibomian gland secretions are altered and inflammation in the ocular surface is 
increased (McGill et al., 1984; Mathers et al., 1996; Van Haeringen, 1997; Patel et al., 
2000; Sullivan et al., 2006; Arita et al., 2008; Rocha et al., 2008; Ozdemir & 
Temizdemir, 2010; Guillon & Maïssa, 2010; Maïssa & Guillon, 2010; Borchman et 
al., 2012; Rico-del-Viejo et al., 2018). There is also some evidence to suggest that 
these changes in ocular surface physiology are more common and severe among 
post-menopausal women (Moss et al, 2000; Brandt et al., 2015). However, studies 
examining these age- or gender-related alterations in the tear fluid are still scarce 
(McGill et al., 1984; Micera et al., 2018). In the era of population aging, it is of vital 
importance to understand better the effects of aging on the ocular surface in order 
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to provide better treatment for patients with ocular surface disease, possibly even 
before the condition itself is manifested. 
2.3 Proteomics 
Proteomics means the large-scale study of proteins in a given tissue, blood or other 
body fluid at a given time and under defined conditions. As a research field, 
proteomics has gone through a long development process. This is illustrated by the 
fact that in 1952, Swiss-Prot, a curated protein sequence database, had only 1 protein 
in its database, while currently the number of known proteins in the database exceeds 
560,000 (Boutet et al., 2016; The UniProt Consortium, 2018). In addition to the 
growing databases, recent decades’ developments and advancements in mass 
spectrometry (MS), protein fractionation and bioinformatics have enabled 
proteomics to become an efficient analytical tool in medical research together with 
other “omics” techniques, such as genomics, transcriptomics and metabolomics 
(Ginsburg & Willard, 2010). 
In comparison to genomics and transcriptomics, which can be thought to answer 
questions such as “what is possible to happen” and “what appears to be happening” 
proteomics tries to answer the question “what makes it happen”. While the genes in 
the genome can be considered to remain relatively unchanged throughout a person’s 
life, they can be transcribed and translated into proteins in different ways through 
alternative splicing, epigenetic modulation, polymorphisms, deletions and 
replications. Therefore, proteomics is a way to have a closer look at the final outcome 
of the regulatory processes in the cells, although this process is also highly 
challenging. The journey from a transcript into a mature protein can consist of many 
alterations, such as varying post-translational modifications, resulting in a very large 
spectrum of distinct proteins arising from the same genomic material (Ginsburg & 
Willard, 2010). For this reason, the analysis of the complete proteome has not yet 
been possible. These post-translational modifications are likely to be one of the 
reasons why protein and RNA expression levels rarely have direct, highly positive 
correlations (Gygi et al., 1999a; Chen et al., 2002; Ghazalpour et al., 2011; Vogel & 
Marcotte, 2012; Latonen et al., 2018). However, this also suggests that both 
proteomics and transcriptomics methods are able to uncover some new information 
that would otherwise be lost by using just one or the other. In general, 
transcriptomics and proteomics can be thought to describe the same cellular 
functions from slightly different perspectives. While transcriptomics can also 
 28 
provide additional information of the early steps in cellular regulation, proteomics 
can be examined closer in order to understand the functional and physiological 
conditions better. Therefore, it is not surprising that the numbers of proteomic and 
proteogenomic studies are increasing. 
In addition to proteogenomic studies, proteomics has several other applications 
in research. It can be implemented in examining protein-protein interactions 
(functional proteomics), the structures of given proteins (structural proteomics) or 
the type and quantity of proteins in a given sample or patient group (expression 
proteomics). This dissertation will be focusing on the latter, i.e. study of protein 
expression levels, which compares the relative expression levels of proteins between 
groups or during time. Expression proteomics studies are often performed with mass 
spectrometry technique, which enables high-throughput discovery studies, where 
thousands of proteins are quantified for each sample. 
2.3.1 Mass spectrometry 
The process of obtaining amino acid sequence information from a given sample is 
complex, but recent advances in mass spectrometry have made it more readily 
available for researchers to conduct even large discovery studies, instead of targeted 
analyses focusing on few preselected proteins. In general, the MS proteomics process 
has three main parts; it starts with extraction of proteins from the sample material, 
such as tissue or tears, which are then digested into tryptic peptides. Next, the 
peptides are separated by techniques such as liquid chromatography (LC) to reduce 
complexity. Finally, the peptides are ionized in MS and the ions go through a mass 
analyzer, which sorts the ions based on their mass-to-charge ratio (m/z) so that a 
detector can measure the number of ions at each m/z. This final step is, however, 
subject to variation as it is more common these days to combine two mass analyzers 
in one mass spectrometer, this way conducting an MS/MS, or tandem MS, analysis. 
Aebersold and Mann (2003) describe the basics of MS process comprehensively in 
their review article. 
The MS/MS analysis, as the name suggests, includes two rounds of MS. This 
analysis strategy further includes different possible approaches, the two main ones 
being shotgun proteomics and selected reaction monitoring (SRM). In shotgun 
MS/MS, which implements data-dependent acquisition (DDA), the ions are sorted 
by m/z as previously described (MS1, survey scan), but next, precursor ions with a 
specific m/z are isolated and fragmented, e.g. by collision-induced dissociation 
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(CID) and the resulting fragments go through another separation based on m/z 
(MS2) before being detected (Fig. 3). The resulting spectra of m/z, retention time 
and intensity are used then to identify the original, fragmented peptides for example 
by database search. This technique can be implemented in discovery studies, as it is 
able to produce large amounts of data relatively fast. However, it does suffer from 
irreproducibility and under sampling (Liu et al., 2004; Bell et al., 2009; Tabb et al., 
2010; Michalski et al., 2011), which is not the case for SRM, the other MS/MS 
approach mentioned. SRM uses a priori information and only queries for preselected 
peptides, which are then identified and quantified from the samples. This way, the 
accuracy and reproducibility are enhanced, but this method is not capable in 
quantifying large sets of proteins and the acquisition method development is 
laborious (Lange et al., 2008). 
 
Figure 3.  Mass spectrometry (MS)-based shotgun proteomics overview. 
Due to the notable drawbacks by shotgun proteomics and SRM alone, there are 
other data independent acquisition (DIA)-based techniques, which record fragments 
ion spectra for all precursor ions in preselected isolation windows in LC time range. 
This way, the stochastic precursor ion selection of DDA no longer poses 
reproducibility issues (Gillet et al., 2012; Jylhä et al., 2018). Several DIA methods 
exist, however, many of them suffer from complex fragment ion spectra, which 
make further processing challenging. Sequential windowed acquisition of all 
theoretical fragment ion mass spectra (SWATH-MS) combines the benefits of the 
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two previously described approaches, by implementing targeted data extraction as it 
queries the fragment ion spectra from a spectral library, which has been produced a 
priori from previously identified proteins (Gillet et al., 2012). By combining high 
specificity DIA with targeted data extraction, SWATH-MS enables a highly 
reproducible and accurate high throughput proteomics analysis, without laborious 
acquisition method development (Gillet et al., 2012; Anjo et al., 2017). The 
reproducibility, among other benefits of SWATH-MS has been demonstrated in 
various studies, since its development making it an ideal technique for complex study 
structures in particular (Vowinckel et al., 2014; Collins et al., 2017; Jylhä et al., 2018). 
2.3.2 Protein identification and quantification 
Once the proteins have been digested into peptides, and then further fragmented, 
one of the main computational challenges is the processing of the raw spectral data 
back into relative protein expression data. Peptide identification of the data can be 
performed by locating a matching peptide sequence from a database or a library, or 
alternatively, peptide identification can be achieved by de novo spectrum 
identification or tag-based methods (Noble & McCoss, 2012). Once the peptides 
have been successfully identified, protein identification is followed by using the 
previously gathered peptide fragment information. For all tasks mentioned above, 
there are various software programs to pick from. For example, Trans-Proteomic 
Pipeline (Deutsch et al., 2010), Skyline (Pino et al., 2017) and ProteinPilot-PeakView 
pipeline are all very powerful proteomics tools, yet they still face similar challenges 
in the processing. Most notably, both peptide and protein identification suffer from 
the increasing complexity and presence of noise, which are fundamental issues in the 
processing of raw spectral data (Aebersold & Mann, 2003). Possible 
misclassifications and inability to identify low abundance proteins can lead to 
information loss and in fact, it has been estimated that approximately 75% of spectra 
from an MS/MS is not identified (Griss et al., 2016). This is at least partially due to 
proteins with unexpected post-translational modifications and novel sequences, 
since these proteins can go unidentified in the process, especially in the case of 
database search.  
Once the peptides and proteins have been identified from an MS/MS analysis, 
quantification is often the next natural step in data processing. Quantified data, 
which allows hypothesis testing and comparison of different groups under varying 
conditions, can be again obtained with different techniques. Stable isotope labeling 
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methods require expensive heavy isotope tags, which allow comparison of the 
intensities of tagged and other peptides, this way providing relative protein 
expression information (Gygi et al., 1999b; Gevaert et al., 2008). Spectral counting 
is relatively simple as in this method the number of spectra of a specific protein is 
counted as the name suggests (Liu et al., 2004; Old et al., 2005). Peptide 
chromatographic peak intensity provides the relative expression data by evaluating 
the area under the precursor ion (Bondarenko et al., 2002; Chelius & Bordarenko, 
2002), and this approach has been implemented in our studies as well. All of these 
quantification methods give an output of relative expression levels, which allow 
comparisons between patients or samples. However, for absolute expression of 
proteins, other approaches, such as SRM are still required and often studies combine 
both discovery proteomics, with relative expression, and SRM, where a few selected 
proteins and their expression are then verified using isotopically labeled standard 
peptides, which is currently referred as the gold-standard method. 
2.3.3 Tear fluid sampling and proteomics 
Tear proteomics has become a popular subfield in ophthalmology and ocular surface 
research, since it is a non-invasive way to obtain protein-rich data and information 
about the condition of the ocular surface. Tear sampling is also fast and 
comparatively easy and therefore enables its use as an ideal diagnostic tool. Other 
relatively accessible sample types include impression cytology samples and more 
invasive aqueous and vitreous humor specimens. Semba et al. (2013) have discussed 
extensively the proteomics of different parts of the eye in connection to the Human 
Eye Proteome Project (HEPP). However, this dissertation restricts its focus on tear 
fluid. 
Tear sampling is commonly performed either by capillary or Schirmer strip, 
although other absorbent-based methods and eye wash have also been implemented 
in tear sampling. Schirmer strip, which can be used in tear fluid sampling as well as 
in clinical testing of tear fluid volume, is a strip of filter paper, which is placed 
partially under the lower eyelid. It is often preferred to capillary by patients and 
clinicians alike as it is considered more familiar and pleasant for the subject (Posa et 
al., 2013). Capillary sampling uses a small glass capillary, which is similarly placed in 
the cul-de-sac for fluid collection. It requires more experience in comparison to 
Schirmer strip, especially in the case of dry-eyed patients.  
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Although both capillary and Schirmer strip have been extensively used in tear 
fluid studies, some differences between these methods exist. Studies have argued 
that Schirmer strip, through being in direct contact with the conjunctiva, causes 
contact irritation and increased tear flow, which could cause the tear samples to 
resemble reflex tear profiles instead of basal tear. In addition, since the filter paper 
is in contact with both bulbar and palpebral conjunctiva, the Schirmer strip samples 
also contain superficial cells, which are not present in the capillary samples (Choy et 
al., 2001). This has been shown in a study by Green-Church et al. (2008); secreted 
proteins were identified in capillary samples and secreted and cellular proteins were 
identified in Schirmer strip samples. In addition, increased expression levels of 
albumin, IgG, transferrin and several antioxidants have been identified in Schirmer 
strips (Stuchell et al., 1984; Choy et al., 2001), which could be caused by increased 
conjunctival irritation. Despite these differences, some studies argue that both 
sampling methods are equally appropriate in comparative tear proteomics studies 
(Posa et al., 2013). Relative and absolute expression differences between these 
sampling methods are yet to be studied. In addition to the potential variations caused 
by different sampling methods, post-translational modifications, which have been 
identified in tear proteomics (Li et al., 2005), can result in misclassification and 
information loss and variations in the data. Both sampling methods and potential 
post-translational modifications need further studies, in order to improve the quality 
and understanding of tear fluid proteomics. 
Despite these limitations or unknowns, the number of studies implementing tear 
proteomics is on the rise. Great efforts have been put into tear proteome 
characterization and identification (Li et al., 2005; Zhou et al., 2006; de Souza et al., 
2006; Zhou et al., 2012) and to the study of various ocular surface diseases. Many 
studies have identified altered expression levels for example between DED patients 
and controls (Grus et al., 2005; Zhou et al., 2009; Versura et al., 2010; Tong et al., 
2011; Srinivasan et al., 2012; Boehm et al., 2013; Versura et al., 2013; González et al., 
2014; Perumal et al., 2016; Soria et al., 2017; Jung et al., 2017). Other diseases, which 
have been studied implementing tear proteomics include blepharitis (Koo et al., 
2005), keratoconus (Lema et al., 2010; Pannebaker et al., 2010), conjunctivochalasis 
(Acera et al., 2011), Sjögren's Syndrome (Tomosugi et al., 2005; Li et al., 2014; 
Aqrawi et al., 2017), autoimmune thyroid eye disease (Okrojek et al., 2009) and 
glaucoma (Pieragostino et al., 2012). In addition, patients using contact lenses 
(Green-Church & Nichols, 2008; Markoulli et al., 2012; Funke et al., 2012) and 
topical glaucoma medication (Wong et al., 2011; Funke et al., 2016; Nättinen et al., 
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2018a) or undergoing ocular surface surgery (Zhou et al., 2004) have been subjects 
to tear proteomics studies. 
Tear fluid proteomics studies on various ocular surface diseases are ongoing, as 
tear fluid could become an ideal testing material for these conditions in the future, 
once fully functioning biomarkers are identified and validated (von Thun und 
Hohenstein-Blaul et al., 2013). Currently, the individual proteins most commonly 
differing between control and case populations of DED include antibacterial 
proteins, e.g. lysozyme (LYZ) and lactoferrin (LTF), pro-inflammatory proteins, e.g. 
S100A8, S100A9 and alpha-enolase, as well as cystatins and proline-rich proteins 
(Zhou et al., 2009; Tong et al., 2011; Srinivasan et al., 2012; Boehm et al., 2013; Soria 
et al., 2017; Jung et al., 2017). However, as the analysis methods are developing, more 
proteins are being identified. One aim is that in the future, a panel of tear fluid 
biomarkers could differentiate the sick from the healthy subjects, determine the 
condition and its severity and indicate the most suitable treatment method for the 
patient. Perhaps even more importantly, the proteins and biomarkers could be used 
in the development of new types of medicine needed for effective treatment of 
ocular surface conditions. 
2.4 Bioinformatics and statistical analysis of quantified 
proteomics data 
The analysis of large proteomics datasets requires implementation of bioinformatics, 
a blend of mathematics, statistics, computer science and molecular biology, in order 
to provide information of the differentially expressed proteins and their connections 
to the wider set of biological processes and pathways (Fig. 4). Since proteomics is 
still a relatively new field in omics, analysis of proteomics data borrows many steps 
from genomics and transcriptomics. However, proteomics studies often do result in 
notably smaller number of quantified proteins in comparison to expression results 
of mRNA transcripts and the data can be biased against lower abundance proteins, 
mainly due to methodological limitations (Kumar & Mann, 2009). In addition, the 
relative protein expression levels can vary notably between individuals, which can 
result in higher variance and p-values. Hence, these inter-subject, and sometimes 
even intra-subject, variations should be kept in mind during the analysis by, for 
example, taking into account protein baselines, when possible. This becomes evident 
for example in Study II. 
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In addition to the study of proteins expression levels in a given sample or patient 
group, protein-protein interactions and the structures and post-translational 
modifications of given proteins also need the computationally powerful methods of 
bioinformatics; however, we focus on this dissertation on the first, i.e. expression 
proteomics. It is also noteworthy that protein identification and quantification, 
discussed in Section 2.3.2, can be considered as a part of the bioinformatics process 
and indeed, most identification and quantification software implement complex 
bioinformatics algorithms. Nevertheless, these are not the focus in this section. 
Instead, we will focus on the typical bioinformatics methods, which would be 
implemented in analysis of quantified proteomics data produced with SWATH-MS 
approach. 
 
Figure 4.  Bioinformatics workflow in proteomics study. Protein identification and quantification, 
discussed in Section 2.3.2, can also be considered as a part of this workflow, although 
these initial steps have not been included in this workflow figure. 
2.4.1 Preprocessing of proteomics data 
Prior to any further analysis, preprocessing including normalization and data quality 
should be conducted to ensure that the data meets the requirements of further 
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analyses. All necessary data clean-up will also take place in this step, e.g. possible 
handling of missing values and checking of the sample and protein names. It is worth 
noting that some proteomics data, e.g. SWATH-MS, can be considered complete 
data, which is free from gaps, although a proportion of zeros is possible due to 
protein abundance below detection capacity (Välikangas et al., 2018). These zeros 
are marked as NA (not available) for ease of calculation. The small proportion of 
these NA values means that missing value imputation or other methods for handling 
missing data are often not needed and hence, these methods are not discussed 
extensively here. However, it is noteworthy that missing or gapped data is often an 
issue in other types of proteomics data. 
Usually, data transformations are conducted in order to reduce the effects of 
extreme measurements and smoothen the data. Typically, in proteomics and other 
omics data, this means log2-transformation, which converts the data to follow log2-
normal distribution, which has various computational benefits later on in the analysis 
and it is, in fact, required for many of the possible normalization methods, which 
follow data transformation (Callister et al., 2006). Log-transformation can also help 
remove or reduce the large variation in magnitude and skewness, which are both 
present commonly in omics data (Mertens, 2017). 
The aim of normalization step is to reduce the inevitable bias, resulting from 
systematic measurement errors originating from any point from sample collection 
and processing to device calibration and protein quantification. With proteomics 
data normalization, again, much is borrowed from the genomics and transcriptomics; 
central tendency normalization, lowess regression, quantile normalization and linear 
regression are all methods implemented in analysis of both data types. Several studies 
have compared a varying group of normalization methods for MS-based proteomics 
data (Callister et al., 2006; Karpievitch et al., 2012; Välikangas et al., 2018). Although 
some methods do appear to perform better than others, most acknowledge that in 
practice, several normalization methods are often tested and the one with the best 
performance is chosen for subsequent analysis steps. 
Determining the best normalization method falls under the last step in 
preprocessing, i.e. quality control. Quality of data is often assessed by examining the 
technical and biological variation before any prior preprocessing and then after 
subsequent normalizations and transformations, in order to assess the possible 
improvement. For technical variation, the variance between technical replicates 
originating from the same sample are often evaluated and in our publications, 
replicate MS-analyses, i.e. replicate MS runs, were used to measure the quality. One 
common method to determine the variation is using coefficient of variation, or CV, 
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which is expected to decrease with lower variation (Molloy et al., 2003). However, 
this type of measure becomes meaningful only with three or more technical 
replicates available and hence, with only two replicates, correlation methods can be 
more feasible. In addition to CV and correlation measures, data visualization, e.g. in 
the form of boxplots displaying the sample distribution for each sample, can be 
crucial part in this step, as it can provide information on the variation between 
biological and technical samples and help in identification of possible outliers. Once 
variation of the data is evaluated and suitable normalization method implemented, 
the technical replicates can be combined using for example arithmetic or geometric 
mean or kept separate, in which case statistical methods further down should take 
the separate replicates into account. 
2.4.2 Identification of patterns and groups from the dataset 
Several efficient unsupervised machine learning methods, such as clustering and 
dimensionality reduction, are available for exploring the unknown protein profile 
patterns and clusters in the proteomic data. Examples of these methods include 
principal component analysis (PCA) and hierarchical clustering. These methods are 
not only capable in helping to identify patterns and groups within the samples, but 
they may also help discover differing samples or proteins. In this sense, PCA and 
clustering can be considered as necessary steps, which provide further information 
about the structure of the data and can in fact help direct potential differential 
expression analysis to the right direction. 
PCA and hierarchical clustering methods are both effective unsupervised analysis 
tools, but since hierarchical clustering is implemented in one of the publications of 
this dissertation (Study II), it will be discussed further as an example of these 
methods. Hierarchical clustering clusters samples into a dendrogram based on the 
provided proteomics data using either agglomerative or divisive strategies. In order 
for the hierarchical algorithm to decide which clusters to combine (agglomerative) 
or divide (divisive) it requires distance measures between clusters and a linkage 
method. For both distance and linkage methods, there are varying options, which 
can be specified by the user and for example a previous article by Meunier et al. 
(2007) reported Pearson correlation (distance) combined with Ward’s agglomeration 
method most suited for their proteomic data according to their results. Further 
studies are necessary to examine how SWATH-MS data react to different distance 
and linkage methods. The results of hierarchical clustering can be visualized easily 
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with a dendrogram or a heat map (see Study II). Hierarchical clustering, together 
with other clustering and classification methods in the analysis of proteomic data are 
extensively reviewed by Karimpour-Fard et al. (2015). 
2.4.3 Differential expression analysis and correlation to clinical variables 
Differential expression, together with the classification and dimensionality 
reduction, can be thought as the main part of the bioinformatics analysis as this part 
often provides answers to the scientific questions and hypotheses proposed in the 
beginning of the study. The purpose of differential expression analysis is most 
commonly to evaluate statistically if there are significant differences, e.g. between 
two or more groups or other features present in the data. The choice of statistical 
method to implement at this step depends on the structure and properties of the 
data, but traditional statistical tests such as Student’s t test, analysis of variance 
(ANOVA) and their nonparametric counterparts, which do not assume the data to 
follow any specific distribution, are often appropriate for simpler research questions. 
Various statistical tests, e.g. Shapiro-Wilk test of normality and Levene’s test of equal 
variances, can be implemented on the data in order to evaluate, which type of 
statistical analysis is the most suitable for a given dataset, as choosing incorrectly 
could lead into biased results or lowered statistical power. When more variables need 
to be included in the model or controlled for, linear and logistic regression models 
and analysis of covariance (ANCOVA) can be implemented, again depending on the 
data type. In addition, if the clinical variables of interest are continuous, correlation 
(either Pearson’s or Spearman’s) can be implemented to evaluate the dependence 
between the clinical variable and protein expression levels. 
Differential expression analysis is usually conducted for each protein separately, 
in order to identify the specific proteins, which separate the feature groups. This 
results in a multiple comparison problem with an increased false discovery rate. In 
order to avoid reporting false positive results as statistically significant, several 
multiple testing correction methods are available, which adjust the p-value based on 
the number of tests performed. Bonferroni correction controls the family-wise error 
rate (FWER) by considering only p-values below α/N as statistically significant (α = 
p-value threshold, usually 0.05, N = number of statistical tests conducted). This 
method is however considered highly conservative, which is particularly true for 
proteomics data, where initial number of quantified proteins and hence significant 
proteins are already low (Pascovici et al., 2016). Benjamini and Hochberg correction 
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(Benjamini & Hochberg, 1995), which controls for false discovery rate (FDR) 
instead, is thought to be less conservative and it is in fact implemented in all of our 
publications. However, Pascovici et al. (2016) makes very valid arguments about why 
p-value corrections are not always appropriate in proteomics analyses, which often 
have lower effect sizes and power due to technical issues and cost. They suggest 
instead, that by implementing other FDR lowering methods such as effect size cut-
offs, peptide-level information and enrichment analyses, multiple comparison testing 
could be adequately accounted for. 
2.4.4 Enrichment analysis 
Once a set of statistically significant proteins has been identified, functional 
enrichment analyses can help the researcher identify how the set of proteins is 
connected to the biological processes and pathways. Although enrichment analyses 
can result in differing output depending on the chosen databases and methods, 
similar steps are taken in the processing. First, each protein in the set needs a unique 
identifier. Protein annotation has improved considerably and for example manually 
annotated and reviewed protein sequence database UniProtKB/Swiss-Prot has 
evolved from just 1 protein sequence in 1952 to nearly 560,000 sequences in 2018. 
The purpose of the unique annotations is to connect each protein to its relevant 
biological processes and pathways. These relevant biological processes and pathways 
can be stored as public repositories such as Kyoto Encyclopedia of Genes and 
Genomes (KEGG) (Kanehisa & Goto, 1999) and hierarchically clustered Gene 
Ontology (GO) (Ashburner et al., 2000), which list the identifier-associated 
“biological processes”, “molecular functions” and “cellular components”. 
In addition to the unique identifiers for the proteins of interest, the enrichment 
analyses need a background (“universe”), which is typically a comprehensive 
annotation list containing for example all proteins measured in a given study or 
proteins known to be present in a given sample type or tissue. The differentially 
expressed proteins are then compared to this background, in order to identify the 
significantly enriched terms. Therefore, as described by Bessarabova et al. (2012), 
the selection of the background list is very crucial as it affects the resulting 
enrichment p-values. 
Once proteins have been connected to their correct functional or pathways terms 
and the appropriate background list has been established, the next step is to estimate, 
which terms are overrepresented. Often an associated p-value is calculated to 
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evaluate, which GO or pathway terms are most enriched. The enrichment can be 
calculated using various algorithms including singular enrichment analysis (SEA), 
gene set enrichment analysis (GSEA) and modular enrichment analysis (MEA). 
Schmidt et al. (2014) review these methods, together with other bioinformatics 
approaches. The first one, SEA, is considered relatively simple as it uses a pre-
selected list of interesting proteins and it then calculates p-value for each functional 
term by implementing hypergeometric, binomial, chi-squared or Fisher’s exact test 
and passes on a list of the statistically significant terms to the user. GSEA is more 
complex, as it takes the full list of proteins (no threshold filtering), this way allowing 
the full protein data set to contribute to the outcome. MEA again builds on SEA, 
but these algorithms also take into account the term-term and protein-protein 
relationships, which might contain extra information not found by simpler methods 
(Schmidt et al., 2014). Huang et al. (2008) summarizes these algorithms in more detail 
for those interested, but it is noteworthy that the choice of the database, algorithm 
and the specific tool for implementing it are not entirely trivial but can affect the 
outcome (Khatri & Drăghici, 2005; Green & Karp, 2006; Müller et al., 2011). 
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3 AIMS OF THE STUDY 
The aim of this dissertation was to implement modern proteomic technology and 
bioinformatics to study the biological functions of ocular surface in health and 
disease, and to identify specific proteins and pathways, which are connected to the 
development and optimal treatment of these conditions. Since the main focus of this 
dissertation is on the bioinformatics, this work was also aimed to advance and utilize 
bioinformatics methods on mass spectrometry produced proteomics data, which are 
expected to become more widely studied, especially in the field of precision 
medicine. The specific objectives of this dissertation were: 
1. To identify and implement the most efficient, pre-existing bioinformatics 
methods in the analysis of tear fluid proteomics data (Studies I-IV). 
2. To identify biological functions and potential biomarkers, which could 
provide predictive information of the most suitable approach to patient’s 
dry eye disease (Study I) or glaucoma (Study II) treatment in the future. 
3. To examine the normal biological changes in the ocular surface during aging 
and evaluate their connection to dry eye and other ocular surface conditions 
(Study III). 
4. To evaluate the differences between Schirmer strip and capillary tear fluid 
sampling methods on tear fluid proteomics data (Study IV). 
 41 
4 MATERIALS AND METHODS 
4.1 Ethical issues 
All research presented in this dissertation was conducted in accordance with the 
International Conference of Harmonization (ICH) Good Clinical Practice (GCP) 
Guideline and the Declaration of Helsinki. Informed consent was obtained from the 
subjects in each study after explanation of the nature and possible consequences of 
the study. Furthermore, tear sample collection is a painless and non-invasive sample 
collection method, which causes no harm to the patients.  
The collection of tear fluid samples from DED patients undergoing desiccating 
stress (Study I) was approved as a clinical trial by clinicaltrials.gov (identifier 
NCT0205102313). In addition, as the patient visits and tear fluid collection took 
place in Spain, it was approved by an Ethics Committee at University of Valladolid 
(Spain) and by the Spanish Regulatory Agency with EUDRA (European Union Drug 
Regulating Authorities) number 2013-002183-63.  
The Ethics Committee at Tampere University Hospital approved all other studies 
presented in this dissertation (Studies II-IV), i.e. the collection of tear fluid samples 
and clinical information from glaucoma patients undergoing a medication switch 
(Study II, ethical permission number R10076M) and from refractive and strabismus 
surgery patients (Studies III and IV, ethical permission numbers R13166 and 
R13074). Study II was also registered in EU clinical trials register (EUDRA number: 
2010-021039-14). 
4.2 Study populations and outlines 
4.2.1 Dry eye disease patients and desiccating stress (I) 
All 41 patients participating in Study I had been diagnosed with either moderate or 
severe DED. This single randomized, double-masked, vehicle-controlled, parallel-
group, phase 3 clinical trial, was conducted with 4 patient visits under controlled 
 42 
environment (Controlled Environmental Research Laboratory, CERLab, Instituto 
Universitario de Oftalmobiología Aplicada, University of Valladolid) (López-Miguel 
et al., 2014; López-Miguel et al., 2016). Patients were exposed to either normal 
controlled environment (NCE) with 50% relative humidity and 23°C temperature or 
adverse controlled environment (ACE) with the same temperature, but only 5% 
relative humidity and localized airflow of 0.43 m/s. In the beginning of the 22-day 
trial, at visit 1 (V1) (NCE), patients were randomized into two groups; patients in 
one group were using 0.1% fluorometholone (FML) and patients in the other group 
its vehicle, polyvinyl alcohol (PA), four times per day for 21 days. After 21 days, 
patients were first sampled under NCE (visit 2, V2), and then under ACE, i.e. 
desiccating stress, (visit 3, V3). After 24 h recovery, a final visit (visit 4, V4), was 
conducted under NCE. Tear fluid sampling and clinical examinations were 
performed during each visit. The study outline is visualized in Figure 5 and Pinto-
Fraga et al., 2016, also provide some further information on the patient population 
and clinical procedures in a related article. 
 
Figure 5.  Study outline of the dry eye disease and desiccating stress study (Study I), which included 
4 visits (V) in an environmental chamber with either normal or controlled environment 
(NCE or ACE respectively). At baseline (V1), patients with moderate to severe dry eye 
were randomized to use either 0.1% fluorometholone (FML) or its vehicle, polyvinyl alcohol 
(PA). After a 21-day treatment period, patients were evaluated first in NCE (V2) and then 
after an exposure to desiccating stress (V3). The following day, after recovery (24 h) 
during which the patients still took their assigned topical medication, the study was 
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concluded after NCE visit (V4). Image reproduced with permission of the rights holder, 
Elsevier. (Nättinen et al., 2018b) 
4.2.2 Glaucoma patients undergoing a medication switch (II) 
Initially in Study II, 30 glaucoma patients exhibiting adverse effects from their 
current treatment were enrolled to a 12-month clinical trial, where their preserved 
latanoprost treatment (Xalatan) was switched to a preservative-free tafluprost 
treatment (Taflotan). Inclusion criteria in the study was that the patient had primary 
open angle glaucoma or capsular glaucoma, had been receiving preserved latanoprost 
for at least 6 months and exhibited at least two ocular symptoms or one symptom 
and one sign of ocular surface irritation/inflammation. The patients had 6 visits 
during the study: a baseline visit (V1), visits at 1.5, 3, 6 and 12 months after the 
baseline (V2-V5), and a final follow-up visit 1-4 weeks after the 12-month visit (V6) 
(Fig. 6). For all patients, the right eye was included in the study although both were 
examined and sampled. At each visit, in addition to tear fluid collection, ocular 
examination, including ocular symptoms, conjunctival hyperaemia, fluorescein 
staining of cornea and nasal and temporal conjunctiva, FTBUT, lid redness, and 
Schirmer’s test, was performed for each patient. One patient died during the study 
and one patient discontinued the study. Therefore, the final number of participants 
in the study was 28. 
 
Figure 6.  Study outline of the glaucoma medication switch study (Study II). Glaucoma patients 
suffering from dry eye-like signs and symptoms had their medication switched from 
preserved latanoprost (L) to preservative-free tafluprost (T) after the screening/baseline 
visit (V1). During the follow-up visits at 1.5, 3, 6 and 12 months after the baseline (V2-V5), 
clinical measurements and tear sample collection were performed and at the post-study 
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visit (V6), final clinical measures were recorded but tear samples were no longer collected. 
Modified from an image reproduced with permission of the rights holder, Springer Nature. 
(Nättinen et al., 2018a). FTBUT = fluorescein tear break-up time 
4.2.3 Patients undergoing refractive or strabismus surgery (III) 
The study examining the effects of aging in tear fluid proteomics (Study III) 
consisted of 115 patients from two projects; 30 patients were undergoing a 
strabismus surgery and 85 a femtosecond laser in situ keratomileusis (FS-LASIK), 
i.e. a refractive surgery. The samples were collected prior to the operations and none 
of the patients had any known, ongoing ocular surface diseases. Basic medical 
background was recorded from each patient including age and sex, which were 
focused on in this study. 
4.2.4 Strabismus patients undergoing surgery (IV) 
Thirty-one patients were sampled with both Schirmer strip and capillary from the 
same eye during the same visit in Study IV. All samples were taken prior to surgery, 
before any surgery-related medication was administered. Medical backgrounds, 
including age, gender and the presence and duration of ophthalmic treatment 
solutions were recorded from all patients. 
4.3 Tear fluid sample collection 
Tear fluid samples were collected using either 1 μl microcapillary tubes (Drummond, 
Broomall, PA, USA) (Study I), 2 or 3 μl glass microcapillary tubes (Studies III and 
IV) or Schirmer strips without anaesthesia (Tear Touch, Madhu Instruments, New 
Delhi, India) (Studies II and IV). Capillary samples were collected from an open 
eye, while Schirmer strips were placed under the lower eyelids of patients and 
removed after 5 minutes. All samples were taken prior to any further tests or eye 
drops to avoid contamination and the samples were stored at -80°C immediately 
after the sampling. 
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4.4 Sample processing and NanoLC-MSTOF 
Majority of the sample processing was performed similarly in all studies (by Saara 
Lähdekorpi). Tear samples from Studies I, III and IV were dissolved from the 
capillary tubes with 0.5% sodium dodecyl sulphate (SDS) in 50 mM ammonium 
bicarbonate (ABC) supplemented with protease inhibitor cocktail (Thermo Fisher 
Scientific Inc., Waltham, MA, USA). For Schirmer strips (Studies II and IV), the 
tear protein extraction was performed by first cutting the strips into small pieces and 
solubilized in 50 mM ABC solution containing protease inhibitor cocktail. For all 
samples, protein concentration was measured using DC protein assay (Bio-Rad 
laboratories Inc, Hercules, USA) using bovine serum albumin as a standard. Limit 
for total protein concentration was set at 5-6 μg of total protein. Samples were then 
subjected to reduction, alkylation and tryptic digestion. After the clean-up, the 
samples were vacuum dried and stored in -20°C to wait for further analysis. 
The samples were next analysed using Eksigent 425 NanoLC coupled with high 
speed TripleTOF 5600+ mass spectrometer (Sciex, Concord, Canada). The analysis 
was performed using SWATH-MS approach and for the mass spectrometry analysis 
samples were eluted to the same concentration and 2.6 μg of each sample was 
injected into NanoLC-MSTOF. More detailed information about the sample 
processing as well as MS steps, settings and eluents can be found in the 
supplementary methods of Studies I and II. Mr Jylhä carried out the mass 
spectrometry processing. 
4.5 Protein identification and quantification with SWATH-MS 
For SWATH-MS analysis method, spectral libraries were created with ProteinPilot 
software (Sciex, Redwood City, Canada). The libraries were more specifically created 
using tear samples of the studies included in this dissertation (Studies I-IV) and all 
DDA runs’ spectra were identified against UniprotKB/SwissProt database. False 
discovery rate (FDR) analysis was performed in ProteinPilot and FDR < 1% 
threshold was set for protein identification. Only distinctive peptides were used in 
the quantification, which, including assigning the correct peaks to correct peptides 
in the library, was performed using PeakView and MarkerView (Sciex, Redwood 
City, USA). Retention time calibration was implemented for all samples using up to 
three proteins identified specifically for each analysis and 1-15 peptides were used 
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for peak intensity calculations. Shared peptides were excluded from the analysis and 
SWATH plug-in “FDR Analysis” was implemented in peptide selection. 
Furthermore, all proteins considered statistically significant in further data 
analyses were separately reviewed using the same software as mentioned above. The 
manual inspection consisted of checking correct peak selection in the chromatogram 
(FDR 1%, 99% peptide confidence level), alignment of fragment ion spectra in 
chromatogram, examination of signal to noise ratio (>7) and chromatogram 
inspection in relation to library chromatogram. Peptides, which did not meet the 
criteria, were removed from final results. Data are presented as a combination of 
protein specific peptides peak intensities from SWATH-MS measurement and 
referred to as protein expression. 
4.6 Bioinformatics analysis of proteomics data 
The basic normalization and quality check steps were very similar in all studies 
included in this dissertation. Log2-transformation was implemented in all Studies I-
IV, central tendency normalization in Studies I, III and IV and quantile 
normalization in Study II were used to normalize the protein quantification data. In 
all studies, replicate MS analyses were in most cases run twice and the replicates’ 
variation was evaluated by calculating the intraclass correlation (ICC package in R 
(Wolak et al., 2012)) and by permutation tests using Spearman’s rank correlation to 
generate p-values (n = 1000 permutations / technical replicate). The replicate MS 
analyses were combined by taking geometric means. 
Further statistical tests implemented in the analyses varied between Studies I-
IV. In Study I, the main methods included analysis of covariance (ANCOVA), 
which was used to evaluate the differences in protein levels between the treatment 
groups at each visit. The assumptions of ANCOVA, including normality of residuals, 
homogeneity of variance, parallel slopes and independence of covariate and 
independent variable were all tested accordingly. Pairwise Tukey tests on adjusted 
means was implemented as a post hoc analysis. In addition, multiple linear regression 
was implemented to evaluate the linear relationships between percentage changes in 
specific clinical signs and baseline protein expression levels as well as treatment 
effects. Finally, Wilcoxon rank sum test was used to compare the baseline protein 
expression levels between severe and moderate DED patients. 
In Study II, the changes in clinical signs and symptoms during the five visits were 
evaluated with paired t-test (for continuous) and paired 2-group Wilcoxon signed 
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rank test (for ordinal clinical signs). Hierarchical clustering (Euclidean distance 
measure and Ward’s method as the criteria) was used to cluster the proteins as well 
as patients based on their relative expression changes between V1 and V5. Welch’s 
analysis of variance (ANOVA) was then used to find proteins, which had 
significantly differing expression levels at baseline between the stratified patient 
groups. Further pairwise comparisons were conducted to the proteins, which 
differed significantly and did not suffer from heteroscedasticity according to 
Levene's test for homogeneity of variance (p-value > 0.05). Mixed model regression 
or cumulative link mixed model was used to measure relationship between protein 
expression levels and clinical signs while accounting for the repeated measures from 
the same patients. 
For Study III, the relationship between age and relative quantification data was 
evaluated with Pearson's product-moment correlation. Protein expression level 
differences between males and females were tested using Wilcoxon rank sum test. 
Study IV included analyses of both combined data (both capillary and Schirmer 
strip samples processed together) and separate capillary and Schirmer strip datasets. 
The datasets obtained using separate, sample type-specific libraries were analysed 
using Panther Classification System (Mi et al., 2017) in order to evaluate, how the 
identified protein sets differed between the two sample types. In the analysis of the 
combined dataset, the differential expression analysis of the two sampling methods 
implemented Wilcoxon signed rank test, assuming dependence between the capillary 
and Schirmer strip samples originating from the same patient. Adjusted p-value 
threshold of 0.05 and mean fold change (FC) thresholds of 1.5 and 0.667 were used 
to filter the significant results, which were used to assess the differences between the 
sample types and their associated expression levels (Panther Classification System 
and Ingenuity Pathway Analysis (IPA®, QIAGEN Redwood City, USA). 
In all studies, IPA was implemented to evaluate the enriched biological functions 
and diseases based on the proteins of interest, whether these were a list of protein 
names (Studies I, II and IV) or statistically significant correlation results (Study 
III). Study IV also examined gene ontology (GO) percentages of the protein groups 
(from Panther Classification System (Mi et al., 2017)) obtained with the two sampling 
methods (capillary and Schirmer strip) as well as the differences in expression 
between them. In addition, Benjamini-Hochberg adjustment was applied to all p-
values resulting from repeated statistical testing and only proteins with an adjusted 
p-value below a threshold of 0.05 were considered statistically significant unless 
otherwise stated. I performed all statistical analyses for the proteomics data in 
Studies I-IV using R software (R Core Team, Vienna, Austria). 
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5 SUMMARY OF THE RESULTS 
5.1 Patient groups’ varying responses to ocular treatment can 
be connected to tear fluid proteomics 
5.1.1 The effects of dry eye disease and FML treatment on ocular surface 
and tear proteomics 
In Study I, which examined the moderate to severe DED patients and their response 
to desiccating stress and FML treatment, 758 proteins were successfully quantified 
from each 1-μl sample. The data analysis itself consisted of two parts. First, we 
evaluated the effects of FML based on the tear protein profiles before and after 
desiccating stress by implementing ANCOVA while also testing associated 
assumptions, i.e. normality of residuals, homogeneity of variance, parallel slopes, and 
independence of covariate and independent variable. Based on the protein 
expression levels, we identified 9 proteins differing between FML and control (PA) 
groups after 3-week treatment and 7 proteins differing after desiccating stress (Study 
I, Table 1). According to the linked gene ontology (GO), many of the identified 
proteins were connected to inflammation terms, confirming the anti-inflammatory 
properties of FML, which is a synthetic glucocorticoid. 
In the second part of the analysis, we examined if individual protein expression 
levels could help predict changes in clinical signs. Ocular surface integrity, i.e. corneal 
and conjunctival staining, as well as conjunctival hyperemia were focused on, as they 
indicated statistically significant changes among the FML-treated patients during the 
study (Study I, Table C.1). Changes in these signs between the initial baseline and 
after the 3-week treatment period (V1-V2) were hence studied in connection to 
baseline protein expression levels (V1) and between the two treatment methods. 
Several potentially predictive proteins were identified to be connected to changes in 
conjunctival staining change (68 proteins), corneal staining (38 proteins) and 
conjunctival hyperemia (28 proteins) (Study I, Tables D.1-3). The IPA analysis of 
biological functions showed that the statistically significant proteins were connected 
to apoptosis-, migration- and inflammation-related pathways. Complement C3 (C3), 
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ig mu chain C region (IGHM) and 14-3-3 protein sigma (SFN) were associated with 
both corneal and conjunctival staining changes. Calmodulin like 5 (CALML5) was 
found to be connected to all three clinical signs and their changes. These proteins 
were examined in more detail and were further found to be connected to pro-
inflammatory cytokines and nuclear factor kappa-light-chain-enhancer of activated 
B cells (NF-κB). Most notably, the analysis indicated that low baseline expression 
levels of C3, IGHM and SFN and a high baseline expression of CALML5 among 
FML-treated patients resulted in a greater improvement in staining scores (Table 1). 
In addition, moderate and severe patients had significantly different baseline 
expression levels of C3 and CALML5 (P = 0.009 and P = 0.002 respectively). For 
severe DED patients, CALML5 had lowered (log2 FC of -0.79) and C3 had increased 
protein expression levels (log2 FC 0.93). 
Table 1.  Summary of the proteins of interest and their predictions on conjunctival and corneal 
staining after a 3-week treatment of FML. 
Proteins Protein expression at baseline 
Effects of 3-week treatment on conjunctival 
and corneal staining 
FML PA 
C3, IGHM, SFN 
+++ No change No change 
+ Alleviated No change 
CALML5 
+++ Alleviated No change 
+ No change No change 
C3, complement C3; CALML5, calmodulin-like 5; FML, fluorometholone; IGHM, ig mu chain C 
region; PA, polyvinyl alcohol; SFN, 14-3-3 protein sigma 
The relationship between clinical sign changes after the 2 h controlled adverse 
environment exposure (V2-V3) and the protein expression levels were also analysed. 
Sixty-eight proteins were found to be associated with conjunctival staining change. 
Several proteins were found in common with the previous analysis (V1-V2 
conjunctival changes) and these included proteins related to ocular surface health 
such as prolactin-inducible protein (PIP), LYZ and cystatins (cystatin-S (CST4), 
cystatin-SN (CST1), cystatin-B (CSTB). Patients receiving FML did not experience 
changes in clinical signs regardless of the protein expression levels prior to the 
desiccating stress. However, some patients receiving PA experienced worsened 
clinical signs depending on the protein expression levels before the adverse 
environment exposure. Greater conjunctival staining was connected to lower 
expression levels of LYZ, PIP and PRR4 prior to the desiccating stress (Table 2). 
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Table 2.  Summary of selected proteins and their predictions of conjunctival staining after 2 h of 
desiccating stress. 
Proteins Protein expression before DS 
Effects of DS on conjunctival staining 
FML PA 
LYZ, PIP, PRR4 
+++ No change No change 
+ No change Worsened 
ENO1 
+++ No change Worsened 
+ No change No change 
DS, desiccating stress; ENO1, alpha-enolase 1; FML, fluorometholone; LYZ, lysozyme; PA, polyvinyl 
alcohol; PIP, prolactin-inducible protein; PRR4, proline rich 4 
5.1.2 Stratification of glaucoma patients based on their response to 
medication switch 
In Study II, glaucoma patients with DED-like signs and symptoms were switched 
from preserved latanoprost to preservative-free formula for a 12-month period. 
During the one year, patients were clinically evaluated and their tear fluid was 
sampled with Schirmer strips in six separate visits. According to the clinical signs 
and symptoms, including conjunctival and lid redness, FTBUT and Schirmer’s test, 
most of the adverse effects were alleviated after switching the patients to 
preservative-free tafluprost (Study II, Tables 1 and 2). Although some of the 
improvements in clinical signs and symptoms were not statistically significant, the 
changes in means suggested that overall the conditions of patients had improved by 
the end of the study. 
As the clinical data was behaving as described in previous studies, we wanted to 
further examine whether these results matched patients’ protein profiles during the 
12-month treatment period. Although we were able to quantify 785 proteins from 
the Schirmer strip samples, there were no consistent, i.e. statistically significant, 
changes in protein expression levels between time points when differential 
expression analysis was performed using all patients.  Therefore, we decided to 
examine next if the proteomics data could be clustered based on the patients. We 
initially clustered the protein log2 fold changes between the first and final visit. In 
order to obtain information on the protein clusters, we performed a pathway analysis 
and identified three clusters with notable inflammatory proteins. These three protein 
clusters displayed clearly changing patterns between baseline and final visit and 
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stratified the patients into three groups based on these changes (Fig. 7a). The first 
protein cluster included several protective ocular surface biomarkers, such as LYZ, 
proline-rich protein 1 (PROL1) and various cystatins. Patient groups 1 and 2 had an 
increase of these proteins’ expression during the 12 months, while patients in group 
3 experienced a decrease. The second cluster comprised of inflammatory biomarkers 
such as albumin (ALB), serotransferrin (TF), protein S100A8 and annexins, similar 
to the third cluster, which also contained known inflammation biomarkers such as 
C3, alpha-enolase (ENO1) and protein S100A9. For these clusters, patient groups 1 
and 2 experienced a decrease in protein expression (patient group 1 more clearly so), 
while patient group 3 had an increase (Fig. 7a). 
Once we had identified proteins of interest and potential patient stratifications, 
we next studied if there were any differences in baseline protein expression between 
these patient groups. We identified 22 statistically significant proteins, which satisfied 
the necessary statistical assumptions as well as technical requirements (Study II, Fig. 
2) and Figures 7b and 7c display the proteins with similar patterns in baseline 
expression levels. 
 52 
 
Figure 7.  Summary of the main results of Study II. a) The heat map visualizes the protein 
expression level changes between baseline (V1) and the 12-month visit (V5). The white 
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rows include proteins linked to ocular surface protection while the grey rows (light grey and 
dark grey) include known ocular surface disease biomarker proteins connected to pro-
inflammation. Baseline expression was missing from two patients resulting in only 26 
patients in this step of the analysis. b) Baseline expression level (x-axis) differences 
between the patient groups show a group of pro-inflammatory proteins, which have the 
highest expression levels for patients in group 1, followed by patients in group 2, and 
patients in group 3. c) Alternatively, several cystatins, proline-rich protein 1 (PROL1), and 
beta-2-microglobulin (B2M), considered to be protective ocular surface proteins, show 
highest expression levels for patients in group 3, followed by patients in group 2. Patients 
in group 1 have notably lower protein expression levels. Measures are shown as mean ± 
S.E.M. (standard error of mean) and all proteins missing a specification (* or a) differ 
significantly between patient groups 1 and 2, and 1 and 3 (Welch’s analysis of variance). * 
All patient groups have statistically significant differences in expression levels; a Patient 
group 3 differs significantly from other groups. Image reproduced with permission of the 
rights holder, Springer Nature. (Nättinen et al., 2018a). 
After identifying the proteins, which could potentially differentiate the patient 
groups even prior to the medication switch to those who were likely to benefit and 
those were not, our next aim was to see how these proteins correlated with the 
clinical signs and symptoms. Therefore, we first performed mixed effects model 
analysis and discovered that all except one of the pro-inflammatory proteins 
displayed in Figure 7b, as increased, caused a decrease in Schirmer’s test results 
(Study II, Fig. 3a). In addition, similarly an increase in four of the pro-inflammatory 
proteins caused a decrease in FTBUT score (Study II, Fig. 3b). On the contrary, 
increased expression levels of cystatins, PROL1 and beta-2-microglobulin (B2M), 
which had the highest baseline expression among the patients in group 1, resulted in 
increased Schirmer’s test values (Study II, Fig. 3a). 
In the second and final step in combining the findings from the proteomic data 
with the clinical data, we examined how the clinical signs and symptoms changed 
within the three identified patient groups. Due to the small amount of patients in 
group 1 (n=4), we combined groups 1 and 2 into one group of patients, who 
appeared to benefit from the drug switch and group 3, as previously, included 
patients who did not. These results confirmed to some degree our results originating 
from the proteomics; while patients in all groups seemed to overall benefit from the 
switch, combined patient group 1+2 had more often a significant improvement in 
comparison to group 3 (Study II, Fig. 4). Similar results applied to the clinical 
symptoms (Study II, Fig. 5). 
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5.2 Factors affecting the tear fluid 
5.2.1 Aging affects the inflammatory proteins 
Tear fluid samples were collected from 30 strabismus surgery and 85 refractive 
surgery subjects with no known, current eye diseases prior to their operation. The 
sample population consisted of 61 females (13 strabismus and 48 refractive surgery 
subjects) and 54 males (17 strabismus and 37 refractive surgery subjects), with a total 
median age of 41 years [95% CI 38-43.9] and ranging from 18 to 83. The age did not 
differ significantly between the female (median = 40 [95% CI 37-43.8]) and male 
(median = 42 [95% CI 37.3-46.7]) groups (P = 0.6) according to Wilcoxon rank sum 
test.  
In the MS analysis, we used a quantification library with 950 proteins, of which 
849 proteins were successfully quantified in all 115 samples. These protein profiles 
were used to evaluate the relationship between tear protein expression and age as 
well as expression level differences between males and females. Of these two clinical 
parameters, age correlated significantly with several well-known tear proteins 
associated with biological functions connected to aging, such as cell death as well as 
inflammatory and immune response. Figure 8 summarizes the results by age groups 
and shows how the most notable changes in expression levels occur among the aging 
subjects after the age of 60. The correlating proteins, as well as their associated 
biological functions can be also found from Study III, Table 1 and further, age-
specific information on the expression level profiles of these proteins, including 
interquartile ranges and pairwise t-test p-values, can be found in Study III, 
Additional file 1. 
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Figure 8.  Proteins, which correlate significantly with age, are visualized with boxplots by age groups 
(x-axis). The protein expression levels’ ranges in y-axis are kept the same between the 
graphs. †CEACAM7 expression is based on only 1 unique peptide in the data. *p-value < 
0.05, **p-value < 0.01, ***p-value < 0.001 
The other clinical parameter of interest, i.e. sex, was not significantly affecting 
protein expression levels in tears on its own as became evident from differential 
expression analysis (not shown). However, some sex-dependent differences were 
observed when the previously discussed age-correlating proteins were compared 
between male and female groups (Study III, Fig. 1). As shown, the proteins appear 
to correlate with age among both females and males, but the protein-age-correlations 
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were more often statistically significant and more consistent with male subjects, 
mammaglobin-A (SCGB2A2) being the only protein contradicting this. 
The proteins correlating with age were further studied by performing pathway 
analysis on data with relaxed thresholds (unadjusted p-value < 0.05). Additional file 
1 (Study III) includes further information about this protein list. The pathway 
analysis focused on enriched biological functions (Study III, Fig. 2 and Table 2) and 
upstream regulators (Study III, Fig. 3 and Table 3). Biological functions, which were 
increased in the tear fluid among the aging subjects according to IPA, included 
immune, inflammatory and cell death responses as well as migration of immune cells. 
Cell viability and survival as well as growth of organism on the contrary were 
decreased among the aging subjects. 
5.2.2 Schirmer strip and capillary tube collection methods have differences 
in proteomics studies 
In Study IV, the SWATH-MS processing, and therefore comparison of capillary and 
Schirmer strip samples, was conducted in three ways. First, sample type-specific 
spectral libraries were used to produce separate capillary and Schirmer strip datasets. 
Next, a combined library consisting of both types of samples was implemented to 
produce separate capillary and Schirmer strip datasets. Finally, the combined library 
was used to process all samples together, thus enabling relative expression level 
comparisons between the sample types. The separate approaches are clarified 
visually in Figure 9. 
The first approach, with separate spectral libraries and thus separate datasets, was 
used to examine what type of data could be obtained if either only capillary or 
Schirmer strip samples were used in a study. The capillary and Schirmer strip libraries 
on their own were already very different in size as the capillary library consisted of 
445 proteins and the Schirmer strip library contained 1076 proteins. Further data 
processing using these libraries resulted in 404 and 909 successfully quantified 
proteins for capillary and Schirmer strip data respectively. In total 316 proteins were 
in common between the datasets. In addition to the size of the data, the types of 
proteins, which could be obtained with the two sampling methods, differed. 
Capillary-specific data contained proportionally more extracellular and membrane 
proteins, while Schirmer strip-specific data had more organelle and other cell-related 
proteins. The proteins quantified in the capillary samples were also more frequently 
associated with immune system, biological regulation and response stimulus. Further 
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results can be seen in Study IV, Figure 2. In the second approach, when capillary- 
and Schirmer strip-specific datasets were produced with the combined library with 
958 proteins, the number of successfully quantified proteins increased to 770 in the 
capillary data and decreased to 841 in Schirmer strip data. The number of common 
proteins increased to 761. 
 
Figure 9.  Types of datasets produced and analysed in Study IV.  
In order to compare the relative expression levels between the two sample types, 
within the same subjects, a combined dataset with 855 quantified proteins was 
produced in the third approach. The clustering and principal component analysis 
indicated that the two sample types had very different protein profiles (Study IV, 
Fig. 4) and this was further confirmed by the differential expression analysis. 
Altogether 191 proteins had higher expression levels in the capillary samples while 
251 proteins were increased in the Schirmer strip samples. The GO terms associated 
with these protein groups supported the results obtained with the separate datasets; 
extracellular proteins associated with immune system process had higher expression 
levels in capillary samples while Schirmer strip-specific proteins with higher 
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expression levels were more often metabolic and catalytic activity-associated proteins 
originating from cells or organelles (Fig. 10). 
 
Figure 10.  Volcano plot (a) of differential expression analysis results comparing the capillary and 
Schirmer strip samples and associated gene ontology terms in b) cellular component, c) 
biological process and d) molecular function. a) In volcano plot, y-axis represent the 
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adjusted p-value (displayed in –log10 scale) and x-axis the associated fold change (FC, 
log2 scale). Chosen proteins with an adjusted p-value < 0.05 (horizontal dashed line) and 
FC > 2 or < 0.25 (vertical dotted lines), and with higher expression levels in capillary 
(green) or Schirmer strip samples (orange), are labelled. The vertical dashed lines indicate 
the 1.5 FC threshold. b-d) Bar plots display the percentage of proteins (x-axis) associated 
with a given GO term subgroup (y-axis) by category. Pearson's Chi-squared test was used 
to estimate differences between distributions. * p-value < 0.05, ** p-value < 0.01 and *** p-
value < 0.001. 
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6 DISCUSSION 
6.1 Tear fluid proteomics studies on ocular surface diseases – 
theoretical and practical implications 
The longer different ocular surface diseases are studied, the clearer it becomes that 
the signs of the multifactorial conditions do not tend to correlate directly with the 
symptoms experienced by the patients. This poses challenges to clinicians and 
researchers alike as diagnosing the patients may be less accurate and without 
correctly specified diagnosis, assigning the most suitable treatment becomes more 
challenging. Assigning correctly diagnosed patients to clinical studies is also crucial 
in obtaining clinically and biologically relevant results. 
Analysis of omics data, proteomics data in particular in the case of 
ophthalmology, can help provide a more comprehensive image of the ocular surface 
condition and stratify patients to groups in order to help with diagnosis and 
treatment. Tear fluid proteomics has been recently studied due to the ease of 
sampling, i.e. fast and non-invasive, and the large amount of data mass spectrometry 
is able to produce from samples as small as 1 μl. It is also noteworthy that often in 
ocular surface diseases, the correlation between clinical signs observed by the 
clinician and symptoms experienced by the subject is low (Begley et al., 2003; Nichols 
et al., 2004; Moore et al., 2009). Clear reasons for this phenomenon are not known, 
but it can be hypothesized that proteomics could help uncover information, which 
cannot be obtained from other clinical testing/research methods alone. This new 
information can be either specific proteins, which have not been previously known 
to be connected to the given condition, but also more general biological functions, 
both of which could be very useful and applicable to treatment development.  
In the case of the two clinical studies presented in this dissertation, Study I and 
II, we identified several specific, potential biomarkers as well as more general 
biological functions for the proposed research questions. In Study I, we initially 
identified FML-effect related proteins, which indicated a difference between FML- 
and PA-treated patients after a treatment period of 3 weeks. These proteins could 
be implemented in the development of new, more effective DED treatments, which 
would have similar treatment effects but lack the unwanted side effects of prolonged 
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use of corticosteroids such as cataract development (Black et al., 1960), IOP increase 
as well as other complications (reviewed by Carnahan and Goldstein (2000)). 
Similarly, the changes between FML- and PA-treated patients after desiccating stress 
were evaluated and these proteins could also contribute to corticosteroid treatment-
type drug development.  
In addition to possible treatment development targets, the clinical signs and their 
connections to the FML treatment in DED were examined in Study I. Several 
proteins were identified to have linear relationship with the treatment method 
specific protein expression and various clinical sign changes between visits. The main 
findings from the clinical and proteomics data comparisons indicate that FML-
treated patients with less severe DED, according to C3, IGHM, SFN and CALML5, 
were more likely to benefit from the (3-week) FML treatment based on the changes 
in conjunctival and corneal staining. In addition, the effects of desiccating stress to 
the clinical and proteomic expression were examined and the results suggested that 
while FML-treated patients were relatively unaffected by the stress, PA-treated 
patients’ clinical response varied depending on the prior expression level of various 
protective (PIP, proline rich 4 (PRR4) and CST4) proteins. More specifically, PA-
treated patients with worse ocular surface condition prior to desiccating stress were 
more severely affected by the environmental stress they were exposed to. 
In Study II the main aim was to identify proteins, which could help identify 
treatment effects, this time after a medication switch from preserved to preservative-
free glaucoma medication. By clustering the proteins, most relevant pro-
inflammatory proteins were identified and by further clustering their changes 
between visits, patient stratification into three groups was possible. The patient 
stratification based on proteomics proved very useful, as we were able to identify 
patient groups, which benefitted from the switch and a group that did not. Baseline 
expression differences between these patient groups suggested that patients with the 
most severe ocular surface condition prior to the switch (increased expression of 
heat shock and 14-3-3 proteins and decreased expression of cystatins), would benefit 
the most when their treatment was changed from preserved to preservative-free 
treatment. The resulting patient groups were further evaluated with the clinical data, 
which supported the previous findings in proteomics as they indicated a more 
significant improvement of e.g. FTBUT and Schirmer’s test score for the benefitting 
group, while the improvements in clinical signs of the patients not benefitting from 
the switch were less notable and significant. 
Resulting information from both Studies I and II contribute to the personalized 
medicine research and once further validation has been carried out, it could be 
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applied to help clinicians decide, which patients would be most likely to benefit from 
a given treatment or a change in treatment. Development of more targeted treatment 
approaches and new types of medication would have large implications to the health 
care, which in the case of ocular surface diseases often has to rely on trial-and-error 
approach, where the most suitable treatment is eventually found from a selection of 
relatively similar products. Pharma industry would also benefit from possible patient 
stratification approaches in their studies, as this would enable the development of 
more targeted treatments, while also having the potential ability to lower unwanted 
adverse effects and choose more targeted patient groups for their drug trials. For 
these reasons, research of biomarkers has been recently gaining focus, as it could 
help provide more accurate diagnosis and identify the most suitable treatment 
separately for each individual. Tear fluid biomarkers have already been studied in 
relation to Sjögren’s syndrome, keratoconus as well as DED and its subcategories, 
such as Meibomian gland dysfunction and ocular surface diseases caused by 
refractive surgery, contact lens wear or topical glaucoma medication (see Section 
2.3.3). Specific point of care tear fluid biomarkers are, however, still rare. 
InflammaDry, an FDA-approved test for evaluating pro-inflammatory MMP-9 
expression levels, is currently in wider clinical use (Sambursky et al., 2013) and a 
diagnostic kit measuring the LTF and immunoglobulin E expression is available by 
Advanced Tear Diagnostics (Birmingham, AL, USA). 
With the current knowledge, the number of proteins found in the tear fluid is 
estimated to be around 1800 (Willcox et al., 2017) although approximately 1500 have 
been possible to identify (Zhou et al., 2012) and throughout the years, several tear 
fluid proteins have been identified as potential biomarkers for given ocular surface 
diseases. Some proteins may have varying regulation, i.e. up- and downregulation, 
depending on the condition of interest, which can complicate the identification of 
the relevant biomarkers. Thorough reviews on tear fluid proteomic-associated 
protein expression levels and specific biomarkers for ocular diseases have been 
written by Hagan et al. (2016), Willcox et al. (2017) and Zhou and Beuerman (2017) 
but in general, there are several extracellular and intracellular proteins, which have 
been identified as increased or decreased in various ocular surface diseases. The 
extracellular proteins increased in ocular surface diseases are often associated with 
cell adhesion, cell growth and immune response. These proteins include more 
specifically growth factors, chemokines and interleukins (Massingale et al., 2009; Na 
et al., 2012; Choi et al., 2012; Guyette et al., 2013), which often remain undetected 
in discovery MS/MS analyses due to their small molecular weight and low 
abundance, but can be instead examined by using e.g. immunoassays and targeted 
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MS/MS. However, the slightly larger extracellular proteins often found increased in 
ocular surface diseases, e.g. ALB, ENO1, C3, S100A8 and S100A9 (Zhou et al., 2009; 
Versura et al., 2010; Srinivasan et al., 2012; Versura et al., 2013; Li et al., 2014; 
Perumal et al., 2016), can be quantified. For these proteins, we have been able to 
obtain similar results indicating an increase in severe dry eye patients (Study I) and 
in aging subjects (Study III) as well as a decrease after a switch to preservative-free 
glaucoma medication (Study II). Extracellular proteins decreased in ocular surface 
diseases, are often associated with antimicrobial response (e.g. cystatins, 
immunoglobulins, LYZ and LTF), anti-apoptotic processes (e.g. PIP, PROL1 and 
PRR4) and binding of steroids and proteins (e.g. secretoglobins and LCN1) (Zhou 
et al., 2009; Srinivasan et al., 2012; Choi et al., 2012; Soria et al., 2013; Versura et al., 
2013; Li et al., 2014; Perumal et al., 2016). Many of these proteins were identified to 
be increased among the glaucoma patients benefitting most from the switch to 
preservative-free tafluprost (Study II). 
The number of intracellular proteins identified as increased or decreased in ocular 
surface diseases is also relatively high (Willcox et al., 2017). However, the method of 
collection is likely to affect the identification and quantification of these proteins in 
particular as further discussed in Study IV. At least annexins A1 and A11 (ANXA1 
and ANXA11) as well as S100 calcium-binding proteins S100A6, S100A11 and 
S100A12 have been shown to be increased in aqueous-deficient dry eye as well as in 
Sjögren’s syndrome (Zhou et al., 2009; Soria et al., 2013; Li et al., 2014). Our studies 
are again coinciding with these findings as we identified an age-related increase in 
ANXA1 (Study III), while patients with high initial inflammation and most 
benefitting from the switch to a preservative-free glaucoma medication had a high 
expression level of S100A6 at baseline (Study II). 
Despite the promising results on tear fluid proteomics alone, more accurate 
diagnosis and treatment identification of ocular surface diseases could require further 
‘omics’ information. For example, the knowledge of the metabolites, lipids and, 
especially in the case of hereditary conditions, genes and RNA, originating ideally 
from ophthalmic surface tissue could provide further data necessary for a more 
comprehensive understanding of the patient’s health and underlying condition. In 
addition, as is the case in any discovery proteomics study including Studies I-IV, 
validation of the results is important and in tear fluid proteomics, the small sample 
amounts pose a particular issue, which is discussed further in Section 6.3.  More 
research and focus are still needed in the precision medicine in order to enable more 
customized medical treatment for patients, but proteomics together with other 
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omics has begun to lead the way on this field, thanks to the repeatable, sensitive and 
quantitative measures. 
6.2 Clinical parameters and sampling methods affecting tear 
fluid proteomics 
The second half of the dissertation, consisting of Studies III and IV focused more 
on the general research of tear fluid proteomics, while still being applicable to clinical 
studies in ophthalmology. In tear fluid proteomics, similar to lipidomics and 
metabolomics, the normal tear fluid composition and factors affecting it are still 
being studied, but from clinical studies, it is known that at least age and sex do affect 
the tear fluid composition together with environmental factors, thus affecting the 
ocular surface health (see Section 2.2). However, there are many unknown aspects 
still requiring further studies in order for fully understand the optimal method for 
sampling, study population selection and result interpretation.  
Many non-pathophysiological aspects can affect the tear film and Willcox et al. 
(2017) have extensively reviewed these factors. For example, contact lens wear is 
known to increase the risk for DED (Paulsen et al., 2014) and previous proteomics 
studies have in addition noted that the contact lens type also affects the protein 
profile changes, which occur after contact lens wear (Kramann et al., 2011; Manicam 
et al., 2018). Hormonal alterations have also been observed to affect the tear film 
and especially androgen deficiency affecting post-menopausal women has been 
identified as a risk factor (Mathers et al., 1998). However, although some tear 
proteomics studies on the effects of menopause have been published (Srinivasan et 
al., 2010), a large-scale discovery study implementing MS is still lacking. 
Environmental factors such as low humidity, air-conditioned or windy 
environments, air pollution, and extreme temperatures can induce DED and change 
the tear composition profile (López-Miguel et al., 2014). Still, more studies are 
needed to establish the specific changes occurring in tear fluid proteomics as well as 
tear film as a whole. Age, similar to the other non-pathophysiological factors above, 
is known to affect the tear fluid composition and increased age is considered a DED 
risk factor. Although some studies on age-associated changes on tear fluid proteins 
have been published previously (McGill et al., 1984; Micera et al., 2018), Study III 
is to our knowledge the first SWATH-MS-based proteomics discovery study on this 
topic. 
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The aim of Study III was simply to identify the proteins, which correlated with 
increasing age. Altogether, we identified 16 such proteins and majority of these 
proteins were connected to inflammatory or immune responses and cell death, as 
expected. Several well-known ocular surface inflammation biomarkers, e.g. ALB, TF, 
S100A8 and S100A9 (Zhou et al, 2009; Versura et al., 2013; Perumal et al., 2016), 
were upregulated in the tear fluid, while no clear reduction in for example 
antimicrobial proteins was present. It would therefore appear that the main cause of 
increased DED risk during aging is more due to general increase in inflammation, 
which could be potentially treated with anti-inflammatory treatment. The associated 
biological functions and upstream regulators confirmed, what had already been 
established in several other studies examining the normal effects of aging, such as 
the upregulation of NF-κB (Adler et al., 2007; Salminen et al., 2008). Although the 
results from this study were not surprising, it was nonetheless important to confirm 
similar biological functions taking place in the aging tear film as well as to identify 
the specific key proteins, which change with age. 
In addition to the pathophysiological and non-pathophysiological factors, 
technical aspects of tear collection could also affect the tear composition and as a 
result, the obtained protein profile data. For example, application of topical 
anesthesia as well as the choice of sampling method may affect the type of tears 
obtained, as reflex tearing occurs during stimulus and differs from basal tears 
according to previous studies implementing proteomics (Fullard & Tucker, 1991; 
Perumal et al., 2015). Similarly, samples obtained from closed and open eyes differ 
notably (Willcox et al., 1997; Sack et al., 2007) and the location of the sampling could 
also have an effect. Although a more thorough analysis of all these factors together 
is required, we decided to conduct a proteomics comparison of the two most 
common sampling methods: capillary and Schirmer strip (Study IV).  
The main findings of this study showed that the counts and types of quantified 
proteins varied depending on the sample type (capillary vs Schirmer strip) as well as 
on the structure of the used spectral library (sample type-specific vs combined). 
When capillary and Schirmer strip samples were processed separately with sample 
type-specific spectral libraries, the protein counts varied notably and Schirmer strip 
samples yielded much higher (doubled) number of proteins in both its spectral 
library and related quantified proteomics dataset. Of the capillary and Schirmer strip 
datasets’ proteins, 316 were common between the datasets, leaving capillary-specific 
data with 88 and Schirmer strip-specific data with 592 unique proteins. The notably 
larger number of proteins quantified with the Schirmer strip samples is most likely 
explained by the fact that Schirmer strips are in closer contact with the ocular surface 
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tissue, resulting in higher total amounts of both extracellular and intracellular 
proteins, although technical aspects in sample processing are likely be partially 
responsible for the variation as well. Capillary samples on the other hand appear to 
contain mainly extracellular proteins and have a smaller abundance of intracellular 
proteins (Choy et al., 2001; Green-Church et al., 2008) and therefore, the total 
protein amount is notably smaller. Further examination of the biological functions 
associated with the unique proteins revealed that the hypothesis of the protein 
origins was correct. In addition, the proteins unique to capillary samples were 
proportionally more frequently associated with immune response and biological 
regulation, suggesting that capillary samples quantify in proportion more proteins 
found from the mucoaqueous layer of the tear film.  
The capillary and Schirmer strip samples were processed separately also with the 
combined library, this time resulting in more similar protein counts (770 proteins in 
capillary and 841 in Schirmer strip data) and higher number of common proteins 
(761 proteins). This would suggest that although separate capillary and Schirmer strip 
samples do contain very different quantities of proteins, resulting in a much smaller 
capillary datasets if processed “alone”, when using comprehensive, combined 
spectral libraries with a wider spectrum of samples, this issue can be overcome. 
However, researchers should carefully evaluate the need for a larger number of 
quantified proteins, possibly at the cost of some proteins with lower abundance, 
when appropriate sampling method is chosen. 
The samples were also processed together using the combined spectral library, 
this way enabling differential expression analysis between the sample types. The 
statistically differentiated proteins again showed that extracellular and membrane 
proteins had a higher expression levels in the capillary samples, and organelle and 
cell proteins had higher expression in the Schirmer strip samples. This further 
supported the results obtained from separately processed samples. In addition to 
evaluating the expression level changes of protein groups associated with specific 
biological functions, we also examined the more specific protein families’ and 
common tear proteins’ expression levels between the two sample types. The results 
showed that e.g. ALB, TF, heat shock proteins, annexins and S100 proteins had 
higher expression levels in the Schirmer strip samples, while LTF, lacritin, 
immunoglobulins, keratins and secretoglobins were increased in the capillary 
samples. Stuchell et al., 1984 has previously presented similar findings on ALB and 
TF but wider discovery proteomics evaluating these sample type differences have 
not been reported. Based on our results, in addition to possibly differing protein 
counts and types, the sample type affects the actual protein expression levels and this 
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should be noted especially in studies examining the absolute quantification levels of 
proteins. In the future, it would be of interest to extend the comparison of sampling 
methods to case-control studies examining the protein expression level differences 
between groups. 
6.3 Reliability and validity of the studies 
The main limitation often affecting tear fluid proteomics, which was present in all 
Studies I-IV and which can also be considered a strength of the method, is the small 
sample quantity. Whilst it is very beneficial that a tear fluid sample as small as 1-2 μl 
can be analysed separately for each patient using the SWATH-MS, this means that 
after the sample processing, no material is usually left for validation. Although both 
eyes are often sampled, variations between the eyes may exist and there are no 
guarantees of a successful sample processing, which may result in smaller datasets, 
possibly lacking the most interesting subjects. In future studies, collection of multiple 
samples from the same eye when feasible could be worth considering. The validation 
step would also benefit from an overall larger sample size, which would enable the 
use of a validation set. However, due to the time and effort still required in the 
sample processing, the sample sizes in discovery proteomics remain relatively small. 
As the sample processing and analysis steps are enhanced in the future, even larger 
datasets in proteomics studies become more feasible, enhancing the reliability of the 
results and enabling the detection of even smaller changes between patient groups. 
Another limitation or more specifically an issue with applicability, which applies 
to at least three of the studies (Studies II-IV) is the relatively homogeneous 
sampling population of only Finnish subjects. Study I consists of only Spanish 
subjects so this may also be relevant to it. Many basic research questions, such as 
effects of aging, gender etc. should be therefore also evaluated with subjects from 
other ethnic and environmental backgrounds. Another similarity between subjects is 
the age, which can also be considered a minor issue in Studies II and IV. The 
sample population age is commonly very high, as expected with many ocular 
conditions. However, this issue only proves the need for more studies such as Study 
III, which help identify age-associated differences. 
In sample processing, the main technical issues with data independent 
acquisition-based SWATH-MS are that the data analysis requires very specific 
software tools as well as time and effort for spectral library generation (Ludwig et 
al., 2018). Whilst the method is very sensitive for the proteins it is able to identify, 
 68 
many proteins may go unnoticed due to the technical limitations of the method, e.g. 
detection limits and composition of the generated library. Thus, some potentially 
useful biomarkers are not identified with this method, instead requiring the 
implementation of other methods for a more complete view of the tear fluid 
proteome. However, in comparison to DDA, the benefits of DIA, such as 
reproducibility and retrospective analysis, can be considered to outweigh its 
limitations. 
For bioinformatics analysis, technical issues were also present. The large variation 
between subjects has always been an issue in proteomics and has affected the 
significance of the results. As most of the bioinformatics approaches have been 
initially developed for the analysis of genomics, some analysis aspects, such as p-
value adjustments, can potentially be too strict for proteomics data. In addition, it 
should be noted that traditional statistical testing could for example result in 
overestimation of dispersion, lowering further the significance of results. Newer 
methods, specifically designed for DIA would be useful in taking proteomics analysis 
further in our analyses. For example, analyses incorporating prior information, e.g. 
knowledge of protein up- and downregulation in given diseases and under specific 
biological conditions, could help provide information and strengthen the existing 
methods. 
The benefit of SWATH-MS method approach in proteomics has always been 
that it can be implemented in very complex study settings, e.g. with multiple time 
points and still maintain the ability to reanalyse the data together with additional 
samples and compare any subject groups to answer questions set post-MS analysis. 
This type of data availability is not the case for e.g. isobaric tags for relative and 
absolute quantitation (iTRAQ), which requires research questions to be set prior to 
any MS analysis. Although this is certainly a positive aspect in SWATH-MS analyses, 
the bioinformatics analyses in more complex settings can be more demanding. Many 
MS analysis tools are available to users and indeed, majority of software are meant 
for processing the ‘raw’ SWATH files to relatively quantified datasets do provide 
some additional tools for the comparison of groups of patients etc. However, these 
tools remain relatively simple, and for the purposes of complex data setups possible 
in e.g. SWATH-MS, they are of no use. Hence, bioinformatics is in those cases 
forced to be built up ‘from scratch’ each time, making the bioinformatics analysis 
more time consuming, depending on the research question. R software does provide 
some packages specifically meant for MS-produced proteomics data, but these often 
require data in a specific format, not necessarily readily available for all users. 
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However, as the field is developed, new and more sophisticated software for specific 
MS-based data analysis are likely to become available. 
6.4 Future perspectives 
The research presented in this dissertation is merely a small part of a large collection 
of tear fluid proteomics studies, which are carried out in order to discover diagnosis 
and treatment biomarkers for various ocular surface diseases. The type of patient 
stratification, which was also performed in Studies I and II, and could be achieved 
with various other ocular conditions with the use of proteomics, is currently part of 
a growing trend in precision medicine and hence there is a need for this type of 
research. Personalized medicine, which aims to provide more detailed diagnostic 
tools for medical research, has gained interest in the recent years and the proteins 
identified in this dissertation can work as basis for a product, which could help 
predict the most suitable treatment for each individual patient.  
The identification of biomarkers for ocular conditions in general should 
obviously not be restricted to tear fluid and similar analyses have already been 
performed for example with vitreous samples, which enable the study of conditions 
affecting interior parts of the eye. Co-analysis of samples from varying parts of the 
eye as well as combining proteomics and lipidomics as well as metabolomics in order 
to better understand the true ocular surface condition, would be highly beneficial in 
future studies. In addition, combining omics data with background information, 
more accurate and comprehensive data analysis would be possible. These type of 
analyses merging various sample and data types could be expected to be increasingly 
popular but also more computationally demanding as the data are growing in size 
and hence becoming more complex to analyse. Machine learning tools, such as 
neural networks and random forest approaches could help tackle the 
aforementioned problems and aid researchers in the identification of e.g. classifiers 
or predictive biomarkers from the vast datasets (reviewed by Swan et al., 2013). 
The more basic research, displayed in Studies III and IV, is also important, in 
addition to the specific biomarkers, if we wish to understand the full biological 
functions in tear fluid and ocular surface. Further studies on this matter that would 
be of interest include SWATH-MS studies evaluating the differences between 
females and males, with and without ocular surface diseases. Especially post-
menopausal women would be of interest, in order to simultaneously study the 
hormonal effects to tear fluid. Here, a combination of proteomics and lipidomics 
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could be most suitable as the hormones can be assumed to be closely connected to 
the lipids. In addition, larger studies on the differences between basal, reflex and 
emotional tears could help us understand and identify undesirable samples and also 
having the ability to choose the most appropriate type of tears. Air pollution effects 
would also be important in order to understand better the pathophysiological effects 
of exposure to air impurities for prolonged periods. 
Last but not least, since tear fluid is so easily accessed and its sampling is non-
invasive, it could also be used in the study and even in diagnosis of other, non-ocular 
diseases as briefly reviewed by Hagan et al., 2016. For example cancer, and 
specifically breast cancer, which is often studied with tissue biopsy samples and 
genomics, has also been previously examined with quantitative proteomics generated 
from tear fluid samples, albeit some of the sample sizes have been relatively small 
(Evans et al., 2001; Lebrecht et al., 2009; Böhm et al., 2012). Further studies 
evaluating tear protein expression levels in for example different stages of breast and 
other cancers could be of interest. It has been already shown by proteogenomic 
analyses of e.g. prostate cancer that proteomics can provide additional information 
and evidence about biological processes at least in tissue samples (Latonen et al., 
2018). Other non-ocular conditions with potential applications in tear fluid 
proteomics are neurological diseases such as Alzheimer’s disease, multiple sclerosis 
and Parkinson’s disease. Early tear proteomics studies on multiple sclerosis focused 
on oligoclonal bands in order to provide accurate and especially non-invasive 
diagnosis tools for the disease (Coyle et al., 1987; Devos et al., 2001), however, now 
the approach has widened towards discovery-based studies in order to identify new 
biomarkers (Salvisberg et al., 2014). Similarly, tear proteomics studies on Parkinson’s 
disease (Çomoğlu et al., 2013; Boerger et al., 2019) and Alzheimer’s disease (Kalló et 
al., 2016) are still in their early stages, but previously published work suggests that 
tear fluid could be used to identify biomarkers and thus potentially become a fast 
and non-invasive diagnostic tool for these conditions as well. 
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7 CONCLUSIONS 
The aim of this dissertation was to implement proteomic technology and 
bioinformatics to ophthalmic studies in order to identify specific proteins, pathways 
and biological functions, which are affected by changes in ocular surface health and 
are connected to the development and optimal treatment of these conditions. All of 
the studies were carried out with SWATH-MS approach, which enabled relative 
quantitation of the tear protein profiles and thus the comparison between treatments 
and time points as well as correlation to other clinical signs and symptoms. With this 
approach, we were able to develop a comprehensive data analysis workflow for these 
SWATH-MS data and apply it to gain further insight into tear proteomics. 
The separate studies included in this dissertation can be divided into two main 
parts. The first part consists of Studies I and II, which both described the treatment 
effects on the ocular surface and tear fluid protein profiles during time. Analysis 
results of both studies included tear proteins, which could indicate the efficacy of 
the treatment in changing conditions (Study I) and during time (Study II) even prior 
to the treatment administration. The most notable aspect in these studies was that 
the initial sample populations appeared relatively homogeneous in their clinical signs, 
yet their proteomics profiles differed and enabled further patient stratification. In 
the future, as personalized treatment becomes more common, the proteins 
presented in our studies could be validated further and used as predictive biomarkers 
in effective treatment of DED and glaucoma. 
The second part of the dissertation focused on the confounding factors and 
differences in the tear protein profiles caused e.g. by normal aging in sample 
population (Study III) and differing sampling methods (Study IV). Study III 
revealed how many well-known tear proteins were affected by normal aging among 
healthy subjects, indicating not only how and why the prevalence of DED is likely 
to increase with age, but also why age should be carefully controlled in tear 
proteomics studies. Study IV also showed large differences in the protein expression 
levels between the two sample types, i.e. capillary and Schirmer strip, depending on 
the processing approach. These results indicated that researchers should carefully 
consider what type of information and data they are interested in and choose the 
sampling and processing methods based on that.  
 72 
In conclusion, this dissertation shows that analysis of tear fluid proteomics can 
provide an efficient and non-invasive way to evaluate the state of the ocular surface 
and be used as an additional tool to determine the most suitable treatment for 
individual patients. Proteomics in general is likely to be an important tool in the 
precision medicine and in development of personalized treatments in the future. 
However, it is crucial to know the limitations and confounding factors affecting the 
proteomics data, such as population characteristics and sampling methods as well as 
establish the most suitable methods for efficient analysis of the data. 
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a b s t r a c t
Purpose: It was hypothesized that tear protein biomarkers could predict the effects of topical steroid
treatment and desiccating stress in patients with dry eye disease (DED). To test this concept, a ran-
domized, double-masked, controlled clinical trial with 41 patients was conducted.
Methods: The patients were treated topically with either 0.1% ﬂuorometholone (FML) or polyvinyl
alcohol (PA). Tear samples were collected using 1 ml glass capillaries at recruitment into the study and
after a 3-week treatment period, both before and after 2 h exposure to desiccating stress, in a controlled
environment chamber. Relative quantiﬁcation of tear proteins was conducted by NanoLC-MSTOF using
sequential window acquisition of all theoretical mass spectra (SWATH). Ocular surface integrity (corneal
and conjunctival staining and conjunctival hyperemia) was selected as the key DED-related sign and
analyzed with proteomic data. Analysis of covariance (ANCOVA) and linear models were used to analyze
the data with R.
Results: 758 proteins were identiﬁed and relatively quantiﬁed from each tear sample. Analysis revealed 9
differentially expressed proteins between FML and PA treatments after 3 weeks and 7 after desiccating
stress (P < 0.05). We also identiﬁed several differentially expressed proteins at the initial collection,
which could be used to predict changes of conjunctival and corneal staining and conjunctival hyperemia
after FML treatment and after desiccating stress. These proteins include complement C3 (C3) and
calmodulin like 5 (CALML5), which could also differentiate the severity of DED at baseline.
Conclusions: The identiﬁed proteins could be further used as biomarkers to identify patients most
beneﬁting from FML treatment.
© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Tear ﬂuid is a complex, extra-cellular ﬂuid from various secre-
tory sources, including the lacrimal glands, cornea, conjunctival
cells and blood ultra-ﬁltrates [1]. Tears bathe the ocular surface as
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they deliver and remove nutrients andmetabolic products from the
anterior surface of the eye, improve the retinal image, and
contribute to the mechanical, antimicrobial and anti-inﬂammatory
defense of the ocular surface [2,3]. Any dysfunction in tear ﬂow,
production or composition can cause adverse effects to the health
of the ocular surface and the visual process.
Dry eye disease (DED) is an immune-based multifactorial dis-
ease of the ocular surface resulting from a dysfunction of the
lacrimal functional unit, which maintains a homeostatic environ-
ment of the ocular surface [4e6]. Management of DED usually be-
gins with artiﬁcial tears, whichmainly increase the aqueous layer of
the tear ﬁlm and may dilute inﬂammatory cytokines, which are
upregulated in DED [6,7]. In more severe DED, topical steroids or
other anti-inﬂammatory medications such as topical cyclosporine
are commonly used [6,8]. Several studies have shown that corti-
costeroids suppress the expression of tumor necrosis factor-alpha
(TNF-a), mitogen-activated protein kinase (MAPK) and nuclear
factor-kappaB (NF-kB) pathways [9e11]. They have been demon-
strated to be effective, in particular during and after desiccating
stress, but are used with caution in long-term treatment due to
adverse side effects [8,12].
The present study continues from a publication by Pinto-Fraga
et al. (2016) revealing the positive action of topical 0.1% ﬂuo-
rometholone (FML) in DED patients in adverse environments in
comparison to polyvinyl alcohol vehicle (PA) treatment [13].
Conjunctival hyperemia as well as corneal and conjunctival staining
were signiﬁcantly decreased in patients with FML treatment in
comparison to vehicle, PA. In our study, tear samples collected from
these patients were used for proteomics analysis. The hypothesis of
the current study was that topical FML treatment would beneﬁt the
patients, ameliorating the desiccating stress effects, and that this
would be reﬂected in changes of the tear proteome. Additionally,
another aim was to identify proteins speciﬁcally indicating and
predicting the treatment effects combined with desiccating stress.
2. Methods
2.1. Study outline
The study was a single randomized, double-masked, vehicle-
controlled, parallel-group, phase 3 clinical trial (clinicaltrials.gov:
identiﬁer NCT0205102313) with 41 patients who had been previ-
ously diagnosed with either moderate or severe DED. This clinical
trial was fully approved by an Ethics Committee and followed the
tenets of the Declaration of Helsinki. Informed consent was ob-
tained from the subjects after explanation of the nature and
possible consequences of the study.
As shown in Fig. 1, the clinical trial was conducted during a 22-
day period during which DED patients underwent 4 visits in the
environmental chamber within the Controlled Environmental
Research Laboratory (CERLab, Instituto Universitario de Oftalmo-
biología Aplicada, University of Valladolid) [14,15]. Clinical infor-
mation and tear samples were collected from the patients during
each visit [13]. Clinical examinations included ﬂuorescein corneal
staining, lissamine green conjunctival staining, and slit-lamp bio-
microscopy, among others. Clinical examinations were conducted
on both eyes and a randomly chosen eye was used in this study,
along with tear samples from the same eye.
2.2. Tear collection
Unstimulated tear samples were collected from one eye of all 41
DED patients using 1 ml Microcap® tubes (Drummond, Broomall, PA,
USA) from the open eye [14,15], avoiding tissue contact to prevent
reﬂex tearing. Tear collection was the ﬁrst test performed in order
to avoid any inﬂuence from other tests. Samples were immediately
transferred to storage tubes at 80 C until processed.
2.3. Chemicals and materials
Acetonitrile (ACN), formic acid (FA), water (UHPLC-MS grade),
Fig. 1. Flowchart of the study workﬂow. The 22-day study period included 4 visits (V) to the environmental chamber with either NCE or ACE, where relative humidity, tem-
perature and localized airﬂow were controlled. DED patients were recruited in baseline (V1) and randomized to use either 0.1% ﬂuorometholone (FML) or its vehicle, polyvinyl
alcohol (PA), four times per day for 21 days, i.e. 3 weeks (V2). Immediately after V2 patients were exposed to desiccating stress for 2 h (V3). After one day (24 h) recovery, during
which the patients still took their assigned topical medication, the study was concluded (V4). Tear capillary samples were collected from patients during each visit (V1-V4) after the
exposures to either NCE or ACE.
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triethylammonium bicarbonate buffer 1 M (TEAB), sodium dodecyl
sulfate (SDS), iodoacetamide (IAA), triﬂuoroacetic acid (TFA),
ammonium bicarbonate (ABC) and urea were all purchased from
Sigma Aldrich (St. Louis, MO, USA). Halt™ Protease Inhibitor
Cocktail and sample clean up tips (C18) were from Thermo Fisher
Scientiﬁc (San Jose, CA, USA). Bio-Rad DC™ kit and bovine serum
albumin standard were purchased from Bio-Rad (Hercules, CA,
USA) and 30 kDa molecular weight cut off (MWCO) centrifugal
devices from PALL (Port Washington, NY, USA). Retention time
calibration peptides (Hyper reaction monitoring (HRM) Calibration
Kit) were purchased from Biognosys AG (Zurich, Switzerland).
2.4. Sample preparation and analysis
Tear samples were dissolved from capillary tubes in 0.5% SDS,
50 mM ABC, HALT™ protease inhibitor, incubated on ice for 60 min
and centrifuged with low rpm to avoid the breaking of the capil-
laries (3000 rpm, 2 min). Protein concentration was measured us-
ing Bio-Rad DC protein quantiﬁcation kit. Average amount of
protein recovered per sample was 20 ± 9 mg (SD). The smallest
amount taken to tryptic digestion was 6 mg of total protein. Seven
patients had less than 6 mg of protein in the tear samples and were
therefore not analyzed further. Two additional patients were
excluded from the study for other reasons.
Samples were then subjected to reduction, alkylation, and
tryptic digestion. These steps were performed according to the
description in the supplementary method materials. For mass
spectrometry, analysis samples were eluted to the same concen-
tration and 2.6 mg of sample was injected into NanoLC-TripleTOF
(Sciex 5600). Two technical replicates were produced from each
sample. Analysis of the samples was done by NanoLC-TripleTOF
mass spectrometry using SWATH acquisition as described in the
supplementary method material.
2.5. Protein identiﬁcation and quantiﬁcation
As part of the SWATH analysis method, a relative protein
quantiﬁcation library, consisting of >870 tear proteins, was created
using tear samples from this study and from another clinical study
consisting of glaucoma patients and their controls. Overall library
consisted of 37 different patients/samples and 64 data- dependent
analysis (DDA) runs with same LC gradient and instrument settings,
whichwere used for SWATH analyses. The library was created using
Protein Pilot® 4.5 (Sciex, Redwood City, USA) and all DDA runs
spectra were identiﬁed against UniprotKB/SwissProt. Quantiﬁca-
tion was done by Peak Viewer® and Marker viewer® (Sciex, Red-
wood City, USA). FDR 1% was used in the library creation and only
distinctive peptides were used in the quantiﬁcation. Retention time
calibration was done for all samples using HMR retention time
calibration peptides. Five transitions per peptide and 1e15 peptides
were used for peak area calculations. All proteins with signiﬁcant or
interesting ﬁndings in the data analysis were subjected to manual
inspection of peptides. This consisted of checking correct peak se-
lection in the chromatogram (FDR 1%, 99% peptide conﬁdence
level), sufﬁcient signal to noise ratio inspection (>7) and chro-
matogram inspection in relation to library chromatogram. Also,
variation of technical replicate results were calculated as means to
all samples/protein. Peptides were eliminated from result pro-
cessing if manual inspection requirements were not fulﬁlled. Pro-
teins with missing values were excluded from consideration.
Results are presented as combination of protein-speciﬁc peptides
peak areas from SWATH mass spectrometry measurement and
referred to as protein expression.
2.6. Data analysis
Data processing included log2-transformation and percentile
normalization in which the sample distributions were normalized
based on the global median. The quality of the technical replicates
was analyzed by analysing the intraclass correlation (ICC) and
Pearson correlation was used to generate p-values (P) in permu-
tation tests (n ¼ 1000 permutations/technical replicate). Means of
the dependent technical replicates were used for further analysis.
The treatment effect was analyzed using analysis of covariance
(ANCOVA) in order to evaluate the differences in protein levels at
each visit to control for protein expression in the previous visit. The
normality of residuals was tested using the Shapiro-Wilk normality
test and the homogeneity of variance was tested using the Bartlett
test of homogeneity of variances. Additional assumptions of
ANCOVA, i.e., the assumption of parallel slopes and independence
of covariate (previous visit) and independent variable (treatment
effect) were in addition tested accordingly. Post hoc analysis in
ANCOVA was conducted using pairwise Tukey tests on adjusted
means, using the multcomp package in R (R Core Team. Foundation
for Statistical Computing, Vienna, Austria). Protein associations for
given biological functions (inﬂammation) were identiﬁed in R
based on their UniProt (UniProt.ws) term and its offspring terms as
well as by using the associated terms provided by Ingenuity®
Pathway Analysis (IPA, QIAGEN Redwood City, USA).
Multiple linear regression was used to evaluate which proteins
were related to percentage changes in speciﬁc clinical signs. The
protein expression level of the previous visit and treatment effect
were accounted for as independent variables. The interaction terms
of treatment effect and the baseline levels of protein expression
were included in the model and were of main interest. The clinical
signs were evaluated in percentage changes as in the previously
published work as qualitative variables (1). The severity compari-
sons at baseline were conducted using Wilcoxon rank sum test.
if
8>>><
>>>:
Ypost >Ypre/DY ¼ Ypost  YpreYmax  Ypre*100
Ypost ¼ Ypre/DY ¼ 0
Ypost <Ypre/DY ¼ Ypost  YpreYpre  Ymin
*100
(1)
where Ymax ¼ maximum value; Ymin ¼ minimum value;
Ypre ¼ initial value; Ypost ¼ final value; DY ¼ percentage change.
Benjamini-Hochberg adjustment was applied to all initial p-
values (P) where applicable to account for the multiple testing is-
sues. The signiﬁcance threshold was chosen as alpha ¼ 0.05. R
software version 3.2.3 was used to analyze data. IPA was used to
conduct pathway analysis and identify proteins connected to in-
ﬂammatory pathways.
3. Results
Altogether, 758 proteins were identiﬁed and relatively quanti-
ﬁed from each 1 ml sample (32 patients, 128 samples). The SWATH
data consisted of reproducible results with a mean intraclass cor-
relation (ICC) coefﬁcient of 0.97 between technical replicates. Per-
mutation tests using Pearson correlation with the technical
replicates showed that 80% of the technical replicates had a
P < 0.05, which suggests that the technical replicates are of rela-
tively good quality. Two approaches were adopted to analyze the
proteomic data; the ﬁrst was to evaluate the effects of FML on the
tear proteome as such and after a desiccating stress at the planned
visits, and the secondwas the incorporation of the clinical signs and
their relationship to the proteomic data. The patient characteristics
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of different treatment and severity groups can be found from
Appendix A (Tables A.1 and A.2).
3.1. FML treatment and desiccating stress effects on tear proteins
When the protein expression levels were examined, 9 proteins
were found to differ between FML and vehicle (PA) groups after 3-
week treatment period (adjusted model P < 0.05 and treatment
effect P < 0.05), and 7 proteins were differentially expressed in
these groups after desiccating stress (Table 1). Most of these pro-
teins were associated to inﬂammation according to the linked gene
ontology (GO) terms. In addition, similar tests were conducted for
the follow-up (V4) data but only one protein showed statistically
signiﬁcant changes between the groups. This was more speciﬁcally
Ig heavy chain V-I region V35 (P23083) (Baseline (P) < 0.001;
Treatment (P) ¼ 0.019; log2 ratio (post hoc) ¼ 0.52). The signiﬁ-
cant proteins were analyzed further to test ANCOVA assumptions,
and the results can be found in Appendix B (Table B.1).
3.2. Proinﬂammatory proteins and their connections to clinical
signs
The ability of the expressed proteins to predict subsequent
clinical sign changes was evaluated next. Ocular surface integrity
(corneal and conjunctival staining) and conjunctival hyperemia
were selected as the key DED-related signs since they showed
statistically signiﬁcant clinical changes in this patient group
(Appendix C, Table C.1).
Individual protein expression levels and treatment, FML or PA,
were used to predict the DED-related sign changes between initial
baseline and after the 3-week treatment period (V1-V2). Sixty-
eight potentially predictive proteins (model P (adj.) < 0.05 and
interaction term P < 0.05) were identiﬁed for conjunctival staining
change and 38 potentially predictive proteins for corneal staining
change. In addition, there were 28 proteins with potential con-
nections to the conjunctival hyperemia change between V1 and V2.
Appendix D (Tables D.1-4) shows the statistically signiﬁcant results.
Corneal and conjunctival staining change results had 7 proteins in
common: complement C3 (C3), ig mu chain C region (IGHM) and
14-3-3 protein sigma (SFN), calmodulin like 5 (CALML5), LIM and
SH3 domain protein 1 (LASP1), quinone oxidoreductase (CRYZ) and
proline-rich protein 4 (PRR4). CALML5 was also associated with
conjunctival hyperemia. C3, IGHM, SFN and LASP1 displayed similar
regression patterns in comparison to each other and similarly
CALML5, CRYZ and PRR4 behave similarly according to the data.
All statistically signiﬁcant proteins were analyzed further by
pathway analysis (IPA). The top results are listed in Appendix E
(Table E.1), indicating that many identiﬁed proteins are connected
to apoptosis-, migration- and inﬂammation-related pathways.
Three inﬂammation-associated proteins common for corneal and
conjunctival staining (C3, IGHM and SFN) and CALML5 were
examined in more detail (Fig. 2). These proteins were further found
to be connected to proinﬂammatory cytokines and NF-kB
(Appendix E, Fig. E.1). The analysis showed that FML-treated pa-
tients with low initial baseline expression levels in C3, IGHM and
SFN and high baseline expression of CALML5 were more likely to
exhibit greater improvement in staining scores compared to pa-
tients with higher initial expression levels. Alternatively, FML-
treated patients with low CALML5 expression and/or high C3,
IGHM and SFN expression in the baseline appear to be less likely to
have a great improvement in their clinical signs (Fig. 2). PA treat-
ment of DED patients had little effect on corneal or conjunctival
staining and the protein baseline expression levels but higher
CALML5 expression in the baseline predicted worsening of
conjunctival hyperemia.
3.3. DED severity differences on baseline protein expression
The relationship of CALML5, C3, IGHM and SFN baseline
expression levels and the DED severity status, i.e., moderate or
severe, was examined next. Expression differences of CALML5 and
C3 were signiﬁcantly different in moderate and severe patients
(P ¼ 0.002 and P ¼ 0.009 respectively) (Fig. 3). In severe DED pa-
tients CALML5 was downregulated (log2 fold change of 0.79) and
C3 was upregulated (log2 fold change 0.93). The correlation
(Spearman's rank correlation) between C3 and CALML5 baseline
expression levels was negative and statistically signiﬁcant
(rho ¼ 0.5, P ¼ 0.004), which indicates that these proteins are
connected suggesting that they could be used as predictivemarkers
for DED severity at baseline.
Table 1
Protein abundance difference between treatments (0.1% ﬂuorometholone (FML), polyvinyl alcohol (PA)) after 3-week treatment period and after desiccating stress.
Time point UniProt Full name Gene name Baseline (P) Treatment (P) Model (P) Model (Adj. P) Log2 ratio
After 3-week treatment period P63261b Actin, cytoplasmic 2 ACTG1 <0.001 0.029 <0.001 <0.001 0.552
P08758b Annexin A5 ANXA5 <0.001 0.009 <0.001 0.001 0.567
P00751a,b Complement factor B CFB <0.001 0.046 <0.001 <0.001 0.485
P01042a,b Kininogen-1 KNG1 <0.001 0.005 <0.001 <0.001 0.891
P01743 Ig heavy chain V-I region HG3 0.001 0.040 0.002 0.013 0.452
P02511b Alpha-crystallin B chain CRYAB 0.019 0.040 0.013 0.050 1.206
P11766b Alcohol dehydrogenase class-3 ADH5 0.230 0.028 0.010 0.043 0.773
P47755 F-actin-capping protein subunit alpha-2 CAPZA2 0.008 0.048 0.009 0.040 0.595
P18827a,b Syndecan-1 SDC1 0.114 0.007 0.012 0.049 1.322
After desiccating stress P98160b Basement membrane-speciﬁc heparan sulfate
proteoglycan core protein
HSPG2 <0.001 0.050 <0.001 <0.001 0.281
P00558b Phosphoglycerate kinase 1 PGK1 0.01 0.046 0.007 0.035 0.496
P06744b Glucose-6-phosphate isomerase GPI <0.001 0.039 <0.001 0.002 0.578
P20061b Transcobalamin-1 TCN1 <0.001 0.049 <0.001 <0.001 0.426
P10599b Thioredoxin TXN <0.001 0.010 <0.001 <0.001 0.767
Q13510 Acid ceramidase ASAH1 <0.001 0.011 <0.001 0.002 0.767
P04746b Pancreatic alpha-amylase AMY2A <0.001 0.030 <0.001 0.001 0.565
Positive log2 ratio values (bold) indicate higher protein expression in FML than PA and negative values lower expression in FML.
a Proteins connected to inﬂammation based on UniProt accession.
b Connections to inﬂammation based on Ingenuity® Pathway Analysis (IPA).
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3.4. Desiccating stress effects in conjunctival staining differ based
on the treatment and protein expression
The clinical signs before and after the 2 h controlled adverse
environment exposure (V2-V3) were also analyzed in connection to
the proteomics data and 68 statistically signiﬁcant proteins were
associated with conjunctival staining change (%). Signiﬁcant pro-
teins found in V1-V2 and V2-V3 for conjunctival staining change
had 12 proteins in common and these included proteins related to
lacrimal gland (prolactin-inducible protein (PIP), lysozyme C (LYZ),
Proline-rich protein 4 (PRR4)), cystatins (cystatin-S (CST4),
cystatin-SN (CST1), cystatin-B (CSTB)), as well as alcohol dehydro-
genase class 4 mu/sigma chain (ADH7), 60S acidic ribosomal pro-
tein P2 (RPLP2), nucleobindin-2 (NUCB2), histone H1.4 (HIST1H1E),
secreted frizzled-related protein 1 (SFRP1). Fig. 4 shows some of
these results along with the severity of staining. Proteins unique to
only these results included alpha-enolase (ENO1), plasma serine
protease inhibitor (SERPINA5) and phospholipid transfer protein
(PLTP) which had similar patterns as CSTB but are not visualised
further here.
Patients receiving FML were not greatly affected by the protein
expression levels prior to the desiccating stress, but patients
receiving PAwere (Fig. 4A). For most proteins, excluding only CSTB,
lower expression levels prior to desiccating stress indicated greater
conjunctival staining. DED severity and protein expression levels
were again compared. At both visits, CST4 decreased with patients
with severe DED in comparison to moderate DED (P ¼ 0.025 and
P ¼ 0.005 respectively) in baseline (log2 fold change ¼ 1.019) and
after 3-week treatment (log2 fold change ¼ 1.341) (Fig. 4B). In
addition, CST1 (log2 fold change ¼ 1.58, P ¼ 0.004), ADH7 (log2
fold change ¼ 0.573, P ¼ 0.033) and NUCB2 (log2 fold
change ¼ 0.832, P ¼ 0.024) were statistically signiﬁcant in pa-
tients after the 3-week treatment but were omitted from the vis-
ualisation for simplicity. There were no statistically signiﬁcant
proteins related to the desiccating stress effect (V2-V3) in corneal
staining or conjunctival hyperemia and no proteins were related to
clinical changes after the desiccating stress effect and follow-up,
i.e., V3-V4.
4. Discussion
The results of this study show that the tear proteome reﬂects the
biological status of the ocular surface and that DED and desiccating
stress change the proteome to amore inﬂammatory status, which is
remediated by steroid treatment. Two of the proteins upregulated
in FML-treated patients, ANXA5 and CRYAB, have been associated
with epithelial wound healing [16] and anti-inﬂammatory func-
tions via e.g. suppressing of NF-kB activation [17e21] while another
protein also upregulated in FML-treated patients, ACTG1, has been
associated with keratoconus [22]. In addition, FML treatment
downregulated CFB, KNG1, ADH5 and SDC1, which are all proin-
ﬂammatory proteins [23,24], acting most likely via NF-kB [25], as
well as through TNF-a and IFN-g [26]. These differentially
expressed proteins associated with FML treatment suggest that
Fig. 2. Summary of the clinical sign changes during 3-week treatment and their connections to protein baseline expressions. A: Complement C3 (C3), ig mu chain C region
(IGHM) and 14-3-3 protein sigma (SFN) expression levels in the baseline (x-axis) can be used to predict the corneal and conjunctival staining change (%) (y-axis) in patients treated
with 0.1% ﬂuorometholone (FML). Treatments are ﬁtted by separate lines and each dot represents a patient. B: Calmodulin like 5 (CALML5) expression level in the baseline (x-axis)
could be used to predict corneal and conjunctival staining and conjunctival hyperemia change (%). C: The results for these four proteins for different treatments are summarized.
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Fig. 4. Summary of the clinical sign changes after desiccating stress and their connections to protein expressions prior to stress. A: Lysozyme C (LYZ), proline-rich protein 4
(PRR4), cystatin-S (CST4), prolactin-inducible protein (PIP), cystatin-SN (CST1) and cystatin-B (CSTB) expression levels after 3-week treatment (x-axis) can be used to predict the
conjunctival staining change (%) after the desiccating stress (y-axis) in patients treated with polyvinyl alcohol (PA). Treatments are ﬁtted by separate lines and each dot represents a
patient. B: CST4 separated patients based on severity at baseline and after the 3-week treatment period. C: The results from the analysis are summarized.
Fig. 3. Complement C3 (C3) and calmodulin like 5 (CALML5) baseline expression levels between different dry eye (DED) severity levels in baseline. Upregulation of C3 and
downregulation of CALML5 at baseline (y-axis) are associated with severe DED (x-axis). In the boxplots, the bottom and the top of the box are the ﬁrst and third quartiles
respectively and the horizontal line in the middle is the median. The vertical lines show the lowest and highest values still within 1.5 interquartile range (IQR) of the lower or upper
quartile and the points represent outliers. *P < 0.05.
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proinﬂammatory activity is reduced in DED patients as a result of
FML, possibly via NF-kB pathway. This is also supported by the
preceding clinical study [13]. Thus, the results of these studies
conﬁrm the anti-inﬂammatory properties of FML, a synthetic
glucocorticoid. FML is weaker than many other glucocorticoids e.g.,
prednisolone and dexamethasone, but, in particular with DED pa-
tients, it tends to lead to less pressure elevations than other steroids
commonly used to reduce inﬂammation [27,28]. These identiﬁed
proteins are potential biomarkers for FML-treatment and should be
examined further in future.
In desiccating stress, PGK1, GPI, and TXN, were signiﬁcantly
upregulated in FML-treated patients. These proteins have been
associated with proinﬂammatory functions in patients with rheu-
matoid arthritis [29e31], but the connections to the eye have not
been extensively studied. An FML-downregulated protein, HSPG2
has been connected to the barrier functions of the eye and cell
adhesion and it is potentially upregulated when IOP increases [32],
while another FML-downregulated protein, TCN1, has also been
shown to be downregulated in DED [33]. Based on these results,
cellular stress, likely due to the desiccating stress, appears to be
worse for FML-treated patients. Alternatively, the effects of the
stress may occur later for PA-treated patients and the process is
simply accelerated for FML-treated patients. In any case, no dif-
ferences at the ﬁnal 24 h post-stress visit, were observed. These
desiccating stress effects with FML-treated patients do require
further work, potentially with more time points, in order to better
understand the occurring changes.
Pinto-Fraga et al. (2016) [13], as well as our own analysis,
revealed that corneal and conjunctival staining and conjunctival
hyperemia improved during the 3-week FML treatment period, and
the effects of desiccating stress were reduced among moderate to
severe DED patients receiving FML treatment. Integrating prote-
omics data with the clinical signs suggested that initial baseline
protein expression levels could be used to predict the treatment
effect. Four proteins with predictive relationships were highlighted
in this study: CALML5, C3, IGHM and SFN.
CALML5 regulates barrier function proteins and terminal
epidermal differentiation genes, and it has been reported that a
knockout of CALML5 disrupts both of these biological functions
[34]. In our results, this proteinwas downregulated in patients with
a more severe DED condition, which could be explained by
disruption of barrier functions and epidermal differentiation. One
recently discovered interaction partner of CALML5 is SFN [34],
which was also identiﬁed as a protein of interest. SFN is an
epithelial cell speciﬁc, secreted 14-3-3 family protein and there is
evidence of ocular surface expression in the corneal and conjunc-
tival epithelium [35]. It has been shown that as CALML5 is depleted
in differentiated keratinocytes, many SFN interactors have altered
abundance, which suggests that CALML5 is in some way modu-
lating SFN. Therefore, our results, which suggest that both of these
proteins are signiﬁcant to FML-treatment effect prediction, seem
feasible based on previous studies.
C3 is well-known for its important role in the activation of
complement system, which has been previously connected to DED
[36]. Furthermore, C3 is increased in severe inﬂammatory diseases
[37] and primary Sj€ogren's syndrome onset was reduced in C3-gene
knockout mice [38]. IGHM, similar to C3, has been shown to be a
secreted tear protein [3] connected to the immune system. Both of
these proteins have a similar relationship to changes in clinical
signs as SFN, suggesting that the immune system and complement
cascade related proteins, such as C3 could be further used to
identify which patients would beneﬁt most from the FML treat-
ment. In addition, C3, similar to CALML5, does separate clinically
assigned severe and moderate patients from each other, and these
two proteins had a statistically signiﬁcant (negative) correlation,
which suggests that they could be connected to each other and
changed expression of either of the two, could indicate the severity
of DED of a given patient.
IPA pathway analysis showed that the four proteins associated
with FML-treatment prediction were connected to proin-
ﬂammatory cytokines and P38 MAPK, as well as phosphoinositide
3-kinase (PI3K) and NF-kB complexes, either directly or via, e.g.,
immunoglobulins and caspases. Proinﬂammatory cytokines are
some of the main targets of corticosteroids, and they are known to
also inhibit NF-kB [39,40], which is a transcription factor regulating
the synthesis of several proinﬂammatory proteins, and there is also
evidence that NF-kB-mediated pathways are activated in DED
related chronic graft-versus-host disease [41]. In addition, topical
modulation of NF-kB activation leads to improvement of clinical
markers of DED in mice exposed to desiccating stress [42]. The
effects of FML could therefore explainwhy these proteins, andmore
speciﬁcally their initial baseline expression levels, would provide
usmore information as to how patients will react to FML treatment.
Similarly to the treatment effects, the severity and individual
protein expression levels mattered during the desiccating stress,
but only for patients who were not receiving FML. Patients who
continued to have high proinﬂammatory protein expressions while
also suffering from lowered lacrimal gland production (based on
LYZ, PIP and PRR4) after the 3-week treatment, were likely to
experiencemore severe desiccating stress effects in the conjunctiva
if they were not treated with FML. Hence, in the desiccating stress,
the initial severity of the patient no longer matters as long as they
have been treated with FML prior to the desiccating stress. From
these results CST4 was most notable, since it could separate the
severe andmoderate patients in both baseline and after the 3-week
treatment period. Hence, in addition to providing information of
the severity of desiccating stress reaction, it again could tell us of
the severity of the dry eye, even after corticosteroid treatment.
CST4 has previously been connected to DED and meibomian gland
dysfunction, where it was notably reduced in comparison to control
samples [43].
These results were only applicable with conjunctival staining,
while corneal staining and conjunctival hyperemia did not display a
similar relationship with the proteomics. This could be due to the
V3 sampling/visit time point taking place immediately after the
desiccating stress, resulting in inconsistency between the clinical
and proteomic data. Following the development of clinical signs
and proteomics more closely, i.e., including more time points,
during the 24-h window after the desiccating stress could have
provided us with better understanding of the speed and timing of
stress effects in the ocular surface.
Small sample amount (1 ml/patient/time point) could be
considered as a limiting factor of this study. Due to the small
quantities of samples, it was not possible to carry out further
validation of the results, and the reproducibility of sample recovery
on 1 ml tear samples could not be fully conﬁrmed. Furthermore, due
to limitations in proteomic sample preparation, sensitivity, and
technological features of LC-MSTOF, we were unable to quantify
small proteins such as cytokines as well as some of the well-known
markers for dry eye, such asmatrixmetalloproteinase-9 (MMP9), in
this study. Improved results for MSTOF could potentially be ac-
quired by optimizing the digestion protocol to, e.g., MMP9, but this
would be likely to have negative effects on other proteins of anal-
ysis. The results presented in this study should be complemented
and validated by independent clinical studies using either immu-
noassays or targeted MS/MS approach.
The reasons why there were no statistically signiﬁcant results in
proteomic comparisons immediately after the desiccating stress
(V3) and after 24 h recovery time (V4) can only be speculated. The
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24 h may not have been a sufﬁcient time for the effects of recovery
to occur. When C57BL/6 mice were exposed to desiccating stress,
tear volume and ocular surface parameters recovered within 2
weeks, while non-obese diabetic mice, which are known develop
spontaneous dry eye and other related conditions, did not show
signs of recovery during the study (1 month after the desiccating
stress was removed) [44]. Hence, considering the individual pro-
teomic proﬁles of severe-to-moderate dry eye patients and their
individual initial recovery patterns, it can be expected that more
uniform changes in proteomics can be seen only several days or
evenweeks later. Our results further highlight the value of tear ﬂuid
proteomics in DED and for the development of therapeutic options.
5. Conclusions
Our study identiﬁed several differentially expressed proteins
between the FML and PA treatments. Our results suggest that the
FML treatment reduces the inﬂammation more efﬁciently than PA
treatment during the 3-week period. In addition, the clinical signs
were examined together with the proteomic data, and we identi-
ﬁed several proteins that could be considered potential biomarkers.
These proteins could not only indicate the changes in clinical signs,
but in some cases, could also differentiate moderate and severe
DED patients. Further validation is needed to verify these
biomarkers.
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Glaucoma is a collection of diseases, which can all ultimately result in degeneration of the optic nerve and blind-
ness1. In order to halt the glaucomatous changes in the eye, glaucoma treatments attempt to lower the elevated 
intraocular pressure (IOP), one of the most frequent characteristics of glaucoma, via topical and oral drugs, 
laser procedures or surgery. Topical treatment is currently the most common glaucoma management method. 
However, a number of previous studies have shown that prolonged use of topical glaucoma medication may 
induce symptoms and signs of ocular surface disease, chronic inflammation and other anterior segment dis-
eases2–4. The exact cause of the adverse effects are debated, but they could be caused by the active compounds 
in the eye drops or by the solution preservative such as benzalkonium chloride (BAK) – the most well-known 
and commonly used preservative in topical glaucoma medication3,5,6. Clinical evidence suggests that patients 
suffering from adverse reactions whilst using preserved topical treatments generally benefit from a switch to 
preservative-free eye drops: their adverse reactions diminish without compromising the control of IOP7–12.
Tear proteome has shown its potential in identifying biomarkers for inflammatory responses associated with 
glaucoma medication; Wong et al.13 studied the differences in tear proteomics between glaucoma and control 
patients and Funke et al.14 examined the common proteomic changes after medication switch during a 6-month 
follow-up study with pooled patient samples. Proteomic biomarkers have also been successfully utilized to mon-
itor other eye diseases including dry eye, diabetic retinopathy and age-related macular degeneration15–22. To 
achieve the necessary precision, stratified patients within subgroups must have individual analysis. This is now 
feasible with label-free mass spectrometry methods, such as sequential window acquisition of all theoretical mass 
spectra (SWATH-MS), which enable studies of proteomic profiles of each individual patient even in large clinical 
trials15,23. Benefits of label-free MS include analysis of complex comparisons between clinical findings and the 
individual tear proteome24. This approach could become more widely used, if successful bioinformatic methods 
are developed. For example, we were able to examine why patients react in different ways to the same therapy and 
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study the underlying biological explanation. Focusing on patient stratification is the next natural step in medical 
research and is expected to become more popular in the future as the need for precision medicine rises25,26.
The aim of this study was to evaluate tear protein profiles of individual patients with ongoing glaucoma ther-
apy including BAK-preserved prostaglandin analogue, and proteomic changes after switching to preservative-free 
medication for a 12-month follow-up period. Our hypotheses were that the patients affected by the switch would 
also have noticeable changes in their tear protein profiles and that patient stratification could help identify novel 
recovery patterns in both proteomics and clinical data. Tear proteomics studies on glaucoma have been published 
previously13,14; however, our study is the first to our knowledge to use a precision medicine approach as well as 
SWATH and to stratify the glaucoma patients into groups based on their individual proteomic responses to med-
ication switch.

Ǥ The study population consisted of 28 patients (7 
men and 21 women). Twenty-five patients were diagnosed with primary open-angle glaucoma and 3 with capsu-
lar glaucoma. The mean age of the patients in the beginning of the study was 67.4 years (95% CI: 64.5–70.3). The 
patients had been on preserved latanoprost treatment for 7.7 years on average (95% CI: 6.1–9.2).
Majority of the clinical signs and symptoms steadily improved throughout the 12 months after switch (Tables 1 
and 2). More specifically, the conjunctival redness and lid redness decreased while (fluorescein tear break-up time 
in seconds) FTBUT and Schirmer’s test values increased. Although the corneal and conjunctival staining scores 
did not change considerably, the overall means suggest that the scores decreased. In addition, all symptoms expe-
rienced by the patients improved after the switch, although some of these improvements were not statistically 
significant.
Ǥ We identified a total of 25,487 
peptides from 270 samples/MS analysis replicates, corresponding to 388,273 identified spectra in an assembly of 
1439 protein groups using FDR of 1.0%. Total of 950 proteins with distinctive peptides were included to quan-
tification library and from this library, 785 proteins had distinct peptide sequences with matching spectra to 
SWATH analysis and were quantified in all samples. The proteomic data exhibited good quality and reliability 
with p-value < 0.05 in 89% of replicate MS analyses (permutation tests, Spearman’s rank correlation) and mean 
intraclass correlation coefficient of 0.97.
We wanted to establish how each patient’s protein profile changed during the 12-month treatment period. 
To achieve this, we first clustered the log2 fold changes between the first and final visit, and based on the den-
drogram and visual inspection of results we set the cut-off at 7 clusters (Fig. 1). We then conducted pathway 
analysis with Ingenuity Pathway Analysis (IPA) for all 7 protein clusters and identified three clusters of interest, 
enriched with inflammatory proteins as shown in Supplementary Table S1. Within these clusters, protein profiles 
among patients became clearer during the 12-month follow-up (Fig. 1). The first protein cluster included several 
Clinical sign Baseline values
Change from baseline
1.5 months 3 months 6 months 12 months
Conjunctival redness
Mean 1.750 −0.286 −0.607 −0.75 −0.964
95% CI [1.459, 2.041] [−0.541, −0.03] [−0.873, −0.341] [−1.022, −0.478] [−1.188, −0.741]
Pa 0.04* <0.001*** <0.001*** <0.001***
Lid redness
Mean 0.857 −0.357 −0.214 −0.464 −0.519
95% CI [0.605, 1.109] [−0.574, −0.14] [−0.48, 0.052] [−0.733, −0.196] [−0.836, −0.201]
Pa 0.004** 0.12 0.003** 0.005**
Fluorescein tear 
break-up time
Mean 5.393 1.786 2.179 3.214 4.444
95% CI [4.284, 6.501] [0.453, 3.118] [0.735, 3.622] [1.531, 4.897] [2.184, 6.705]
Pb 0.01* 0.005** <0.001*** <0.001***
Corneal staining
Mean 0.607 −0.429 −0.357 −0.286 −0.393
95% CI [0.252, 0.963] [−0.785, −0.072] [−0.741, 0.026] [−0.732, 0.16] [−0.792, 0.007]
Pa 0.02* 0.08 0.25 0.06
Conjunctival staining 
(nasal)
Mean 1.393 −0.25 −0.286 −0.393 −0.179
95% CI [1.070, 1.715] [−0.654, 0.154] [−0.633, 0.062] [−0.806, 0.02] [−0.614, 0.257]
Pa 0.31 0.12 0.07 0.53
Conjunctival staining 
(temporal)
Mean 1.571 −0.321 −0.393 −0.464 −0.357
95% CI [1.265, 1.878] [−0.656, 0.013] [−0.819, 0.034] [−0.852, −0.077] [−0.755, 0.041]
Pa 0.07 0.07 0.02* 0.08
Schirmer’s test
Mean 12.000 4.214 4.964 4.786 5.429
95% CI [8.511, 15.489] [1.987, 6.441] [1.349, 8.579] [1.288, 8.283] [2.622, 8.236]
Pb <0.001*** 0.009** 0.009** <0.001***
Table 1. Changes in clinical signs between baseline and the visits after medication switch. CI, confidence 
interval. *P < 0.05; **P < 0.01; ***P < 0.001; a2-group Wilcoxon Signed Rank Test; bPaired t-test.
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protective ocular surface biomarkers, such as lysozyme (LYZ), proline-rich protein 1 (PROL1) and various cys-
tatins. Altogether 71 proteins were in this cluster and the top enriched disease and function terms, according 
to IPA, included “activation of neutrophils” and “chronic inflammatory disorder”. The second cluster included 
inflammatory biomarkers such as albumin (ALB), serotransferrin (TF), protein S100A8 and annexins, with a total 
of 116 proteins all displaying similar fold changes. The top enriched terms for this cluster included “inflammation 
of organ” and “cell death”. The third cluster also included known inflammation biomarkers such as complement 
C3 (C3), alpha-enolase (ENO1) and protein S100A9. The 135 similarly expressed proteins in this cluster had 
enrichments relating to cell death, cell movement and inflammation of organ.
Next, it was possible to stratify patients into three groups, based on the changes in filtered proteomic profiles 
(Fig. 1). The patients in groups 1 and 2 showed somewhat similar improvement based on their proteomic pro-
file: expression of protective proteins increased and pro-inflammatory protein expression decreased. Heat map 
and clustering analysis further differentiated these groups; protein expression changes were more consistent for 
group 1 patients, while there was some variation among patients in group 2. The patients in group 3 experienced 
a decrease in protective proteins’ expression and an increase in expression of pro-inflammatory proteins, suggest-
ing that they were not benefitting from the drug switch.

Ǥ Next, we examined if baseline expression levels of individual proteins would differ between 
the three patient groups. After p-value adjustment, out of 322 clustered proteins, 31 remained statistically signifi-
cant (p-value < 0.05). We excluded one protein without a gene symbol (immunoglobulin), two proteins with une-
qual variance (heteroscedasticity, Levene’s test p-value < 0.05) and six proteins with poor peak matches, yielding a 
total of 22 proteins which differed between the patient groups at the baseline (Fig. 2). Many of the statistically sig-
nificant proteins were ordered in a similar manner; proteins in Fig. 2a had the highest expression among patients 
in group 1, then 2 and patients in group 3 had the lowest relative expression levels. This order was reversed for 
proteins in Fig. 2b, where group 1 patients had the lowest relative expression. The results also included some 
less consistent results, which could none-the-less provide further, interesting information of the patient groups 
(Fig. 2c). More detailed statistics results are provided in Supplementary Table S2.
ǯ	Ǥ Next, we wanted 
to compare clinical results with tear proteomics data and performed mixed effects model analysis. All 
pro-inflammatory proteins that differed between the patient groups at baseline (Fig. 2a), excluding pro-apoptotic 
cytosolic non-specific dipeptidase (CNDP2), correlated negatively with Schirmer’s test results (Fig. 3a), and four 
correlated negatively with FTBUT (Fig. 3b). The cystatins, PROL1 and beta-2-microglobulin (B2M) (Fig. 2b) 
correlated positively (Fig. 3a) and acyl-CoA-binding protein (DBI) (Fig. 2c) correlated negatively with Schirmer’s 
test. Full statistical results are available in Supplementary Table S3. To conclude, we observed that Schirmer’s 
test and FTBUT values correlate negatively with pro-inflammatory proteins and the correlation is positive with 
protective proteins.
ơǤ Finally, we analysed how the 
clinical signs and symptoms changed within the identified patient groups. Since patient group 1 had only four 
patients, we decided to combine groups 1 and 2 and this way, patients groups 1 and 2 together show patients, 
who appear to benefit from the drug switch and group 3 includes patients who do not. The results for the clinical 
sign changes showed that while there was beneficial development for both groups 1 and 2 together and group 3, 
the changes for patient group 3 were not often statistically significant (Fig. 4). For example, Schirmer’s test and 
Clinical symptom Baseline values
Change from baseline
1.5 months 3 months 6 months 12 months
Irritation, 
burning, 
stinging
Mean 1.143 −0.071 −0.179 −0.143 −0.143
95% CI [0.629, 1.657] [−0.738, 0.595] [−0.855, 0.498] [−0.849, 0.563] [−0.737, 0.451]
Pa 0.73 0.65 0.61 0.66
Itching
Mean 1.821 −0.643 −0.821 −0.643 −0.75
95% CI [1.361, 2.282] [−1.14, −0.145] [−1.339, −0.304] [−1.162, −0.124] [−1.284, −0.216]
Pa 0.02* 0.007** 0.02* 0.01*
Foreign 
body 
sensation
Mean 1.571 −0.786 −1 −0.964 −0.393
95% CI [1.061, 2.082] [−1.328,−0.244] [−1.615, −0.385] [−1.497, −0.432] [−1.055, 0.269]
Pa 0.008** 0.009** 0.003** 0.30
Tearing
Mean 1.893 −0.929 −1.036 −1.393 −1
95% CI [1.321, 2.464] [−1.466, −0.391] [−1.673, −0.398] [−1.934, −0.851] [−1.517, −0.483]
Pa 0.004** 0.009** <0.001*** 0.002**
Dry eye 
sensation
Mean 2.071 −0.357 −0.536 −0.679 −0.607
95% CI [1.555, 2.588] [−0.855, 0.14] [−0.951, −0.12] [−1.247, −0.11] [−1.294, 0.08]
Pa 0.16 0.03* 0.03* 0.09
Table 2. Changes in clinical symptoms between baseline and the visits after medication switch. CI, confidence 
interval. *P < 0.05; **P < 0.01; ***P < 0.001; a2-group Wilcoxon Signed Rank Test.
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FTBUT increased significantly for groups 1 and 2 together but not for group 3. Similarly, conjunctival redness 
and lid redness decreased throughout the study for groups 1 and 2, but the changes for group 3 were not consist-
ently significant. Same analysis was also performed for the clinical symptoms (Fig. 5). Groups 1 and 2 had more 
significant decreases in itching and foreign body sensation while irritation/burning/stinging, tearing and dry eye 
sensation changes were not as consistent with previous findings.

In our study, as with previously published studies, patients experiencing adverse effects from long-term use of 
BAK-preserved topical glaucoma medication benefitted from a switch to a preservative-free topical treatment 
according to majority of the clinical signs. However, based on our previous clinical data7,8 and the present pro-
teomic data stratification, the level of this improvement varied among patients. In order to examine differences 
between patients on proteome level, we stratified patients based on expression changes between baseline and 
final visit (V1-V5) and identified differences in proteins connected to inflammation. Our results showed that the 
patients had different patterns of protein expression, which became more consistent and clear with time, forming 
three patient groups towards the end of the study: greatly improved (group 1), moderately improved (group 2) 
and unimproved (group 3) proteomic profiles.
When comparing baseline protein expression levels of the three patient groups, we identified 22 proteins 
that were differentially expressed. The most improved patients (group 1) had higher baseline expression lev-
els of several known pro-inflammatory proteins, which were in relation low in expression for the unimproved 
patients (group 3). These proteins included the 14-3-3 protein epsilon (YWHAE) and 14-3-3 protein zeta/delta 
(YWHAZ), which belong to the same protein family and YWHAZ has been previously found to be upregulated 
Figure 1. Outline and results from the patient stratification. The top row explains the outline of data processing, 
protein clustering and patient stratification. The heat maps visualize the change in protein expression between 
baseline and time points after the medication switch. V refers to visits and focus is on the V1-V5 comparison. 
Two protein clusters associated with pro-inflammation are indicated in grey rows, and proteins linked to 
ocular surface protection in white rows. The differences between the patient groups become clearer with time, 
as is visualized by the additional heat maps (V1-V2, V1-V3 and V1-V4) showing expression differences in 
comparison to baseline. Two patients were excluded due to missing baseline expression and in addition, two 
patients had no V4 data. ALB, albumin; C3, complement C3; ENO1, alpha-enolase; LPO, lactoperoxidase; LYZ, 
lysozyme; PROL1, proline-rich protein 1; TF, serotransferrin.
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in the tears of patients using topical anti-glaucoma medication13. Similarly heat shock proteins (HSP) HSPA5 
and HSPA8, had increased expression levels among most improved patients in our results. These proteins tend 
to be highly expressed in glaucomatous eyes27 and are associated to environmental stress; however, their con-
nections to glaucoma medication have not been examined. Other similarly expressed proteins connected to 
ocular inflammation were iron transport protein transferrin (TF)28, which has been found to be upregulated in 
glaucoma and in particular with patients using preserved medication14,29, and protein S100A6, which is upreg-
ulated in dry eye disease30. In addition, myosin light polypeptide 6 (MYL6) had expression level similar to the 
other pro-inflammatory proteins and interestingly, the myosin light chains (MLC) have previously been linked to 
BAK-related inflammation31,32.
The proteins with low expression among the most improved patients (group 1) and higher expression for 
the unimproved patients (group 3) included several cystatins (cystatins S (CST4), SA (CST2) and SN (CST1)), 
lacrimal gland secreted PROL1 and B2M. Of these proteins CST4, CST1, B2M and PROL1 have been found to 
be decreased in dry eye disease20,33–35. Based on these “beneficial” proteins, as well as the pro-inflammatory pro-
teins previously described, the patients who experience the greatest improvement are patients with the highest 
initial expression levels of pro-inflammatory proteins and lowest expression of protective proteins. This suggests 
Figure 2. Proteins (y-axis) with differing baseline log2 expressions (x-axis) between the patient groups. Protein 
expression of several pro-inflammatory proteins is highest at baseline for patients in group 1, intermediate 
in group 2, and lowest in group 3 (a). Protein expression levels of various cystatins, proline-rich protein 1 
(PROL1), and beta-2-microglobulin (B2M), considered to be beneficial, are lowest for group 1 patients, 
intermediate in group 2, and highest in group 3 (b). A collection of proteins not following the same order as 
in A and B (c). Measures are shown as mean ± s.e.m. and all proteins missing a specification (*, a or b) have 
a statistical difference between patient groups 1 and 2, and 1 and 3 (Welch’s analysis of variance). *Significant 
differences between all patient groups; aPatient group 3 differs significantly from other groups; bPatient groups 1 
and 2 differ from each other significantly.
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that patients with more severe ocular surface condition benefit from the switch the most and that the differences 
among patients can be discovered using proteomics.
Next, we wanted to combine all the clinical and proteomic information in the light of our results. More specif-
ically, we wanted to see if there were any statistically significant correlations between the proteins of interest and 
the clinical signs. We observed that low Schirmer’s test and FTBUT values were associated with high expression 
of pro-inflammatory proteins and low expression of cystatins, PROL1 and B2M. These statistically significant 
correlations between the protein expression levels and clinical signs further confirmed the roles of the proteins, 
which we have previously described.
Finally, we compared the patient groups’ clinical sign and symptom development after the switch and noted 
that the signs and symptoms were significantly improving for many patients in groups 1 and 2, i.e. those who 
were benefitting from the drug switch based on proteomics data. Patients in group 3 were also moderately 
improving, but for the majority of signs and symptoms, this was not statistically significant. This suggests that the 
pro-inflammatory and protective proteins do identify patients benefitting from the switch also based on clinical 
parameters, such as Schirmer’s test, FTBUT, corneal staining, lid redness, tearing and foreign body sensation.
Our results suggesting there is a subgroup of patients not benefitting from the switch was not surprising, since 
the growing consensus is that individual response to medications can widely vary and has been also indicated by 
Figure 3. Schirmer’s test and fluorescein tear break-up time (FTBUT) correlate with statistically significant 
proteins identified in the study. Serotransferrin (TF), S100A6 and 14-3-3 protein zeta/delta (YWHAZ) 
expression levels correlate negatively with Shirmer’s test, while proline-rich protein 1 (PROL1), cystatin 
S (CST4) and beta-2-microglobulin (B2M) have a positive correlation (a). TF, heat shock cognate 71 kDa 
protein (HSPA8) and YWHAZ expression levels correlate negatively with FTBUT (b). Statistically significant 
correlations were identified using mixed model regression and the data are shown as boxplots displaying 
median, 25 and 75 quartiles, 5 and 95 percentiles (error bars). Black dots represent potential outliers.
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previous clinical studies8. However, with other studies, the sample sizes have been relatively large and it is pos-
sible that smaller subgroups get overrepresented in smaller studies such as ours. One hypothesis to explain the 
varying changes after switch is that these patients could be more sensitive to active compound of the drug, such 
as prostaglandin analogue, which is also known to cause adverse reactions on ocular surface36,37. Alternatively, 
these unimproved patients could be suffering from other ocular surface conditions, which are unrelated to the 
BAK-effects. Either way, this topic deserves further examination.
In our current study, the analysis of the protein expression levels was done with respect to the follow-up data 
of other patients suffering from adverse effects and by analysing the changes after the omission of preservatives. 
A control population could have helped us make concrete conclusions about up- or downregulation of proteins. 
Figure 4. Changes in clinical signs between baseline and the visits after medication switch for groups 1 and 2 
(improved patients), and group 3 (unimproved patients). As seen from the visits (x-axis), as time progresses, 
the mean (±se) change (y-axis) of conjunctival redness (a) and lid redness (b) decreased for groups 1 and 2 as 
well as for group 3, yet the changes were only statistically significant for the former. Similarly, fluorescein tear 
break-up time (FTBUT) (c) and Schirmer’s test (g) were increased for all patients, however only group 1 and 2 
patients had statistically significant improvement. Corneal (d) and conjunctival staining (e,f) were not showing 
similar signs of improvement, which matches previous results. Measures are shown as mean ± s.e.m change 
from baseline and continuous signs (c,d) were analysed with paired t-test and the rest with paired 2-group 
Wilcoxon signed rank test. *P < 0.05; **P < 0.01; ***P < 0.001.
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However, we have already begun work to identify the normal expression levels of these proteins in population of 
normal subjects of various ages.
In conclusion, by implementing SWATH method for quantitative analysis of individual tear protein profiles, 
we discovered that patients react differently when switched to preservative-free glaucoma medication and their 
condition continues to change for at least 12 months. This study demonstrates that when analysing the pro-
teomic profiles, the patients should be analysed separately as they experience different changes in expression 
of inflammation-related proteins. In addition, knowledge of the baseline protein expression is crucial in stud-
ies focusing on patient stratification. Hence, in order to obtain versatile data needed for patient stratification, 
mass spectrometry method should be chosen carefully. The overall results of this study suggest that the patients 
who have the most severe BAK-induced adverse effects benefit most from the switch and that these patients 
could be detected using tear proteomics. This further suggests that a subgroup of the patients are suffering from 
some other, BAK-independent, ocular surface-related conditions, and should be treated accordingly to improve 
the well-being of these patients. We identified several potential biomarkers, such as pro-inflammatory proteins 
YWHAE and YWHAZ and various beneficial cystatins, which may indicate whether the patient will benefit from 
a switch to other therapeutic treatments. Proteomic tear fluid biomarkers provide efficient tools for developing 
precision therapeutic strategies for glaucoma patients and deserve further studies.

Ǥ The study was conducted in accordance with the International Conference of 
Harmonization Good Clinical Practice guidelines and the Declaration of Helsinki. Study was approved by the 
Ethics Committee at Tampere University Hospital and was registered in EU Clinical Trials Register (EudraCT 
Number: 2010-021039-14, registration date: 3/28/2010, online: https://www.clinicaltrialsregister.eu/ctr-search/
search?query=eudract_number:2010-021039-14). Each patient signed a written informed consent before inclu-
sion in the study.
The patients were assessed during the baseline visit and eligible patients had primary open angle or capsu-
lar glaucoma. The included patients had also been receiving preserved latanoprost treatment for 6 months or 
Figure 5. Changes in clinical symptoms between baseline and the visits after medication switch for groups 
1 and 2 (improved patients), and group 3 (unimproved patients). Irritation/burning/stinging (a) was not 
changing significantly in any time point (x-axis), while itching (b) and foreign body sensation (c) were 
significantly reduced for groups 1 and 2. Some evidence of reduction was also present for tearing (d) and dry 
eye sensation (e). Measures are shown as mean ± s.e.m change from baseline and were analysed with paired 
2-group Wilcoxon signed rank test. *P < 0.05; **P < 0.01; ***P < 0.001.
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longer for both eyes and exhibited at least two ocular symptoms or one symptom and one sign of ocular surface 
irritation/inflammation. Thirty patients were selected for this study based on these inclusion criteria. One of the 
patients died during the follow-up and one discontinued the study and hence, the final study population was 
reduced to 28 patients. Although both eyes were examined for each patient, only the right eyes were included in 
the analysis.
Patients who were excluded from the study had pigmentary or angle-closure glaucoma, IOP higher than 
22 mmHg in baseline, corneal abnormalities affecting tonometry, had undergone a recent (within 6 months) 
ocular surgery including laser procedures, wore contact lenses, or were using artificial tears containing preserv-
atives. In addition, pregnant and nursing women as well as women of childbearing potential without adequate 
contraception were excluded.
Ǥ The study consisted of 6 visits: screening/baseline visit, visits at 1.5, 3, 6 and 12 months after 
the baseline, and 1–4 weeks after the 12-month visit (Fig. 6). At baseline visit, the patients were switched from pre-
served latanoprost (Xalatan, Pfizer Inc., New York, NY, USA) to preservative-free tafluprost (Taflotan, Santen Inc., 
Osaka, Japan) and their clinical signs and symptoms, and medical history were recorded. The preservative-free 
eye drops were administered once a day for the duration of the study. The tear fluid samples for proteomics anal-
ysis were collected using a Schirmer’s strip and in addition, ocular examinations and procedures were performed 
during each visit including ocular symptoms (irritation/burning/stinging, itching, foreign body sensation, tear-
ing, dry eye sensation), conjunctival hyperaemia, fluorescein staining of cornea and nasal and temporal conjunc-
tiva, FTBUT, lid redness, and Schirmer’s test. The ocular symptoms were graded between 0 and 4 in the following 
scaling: none (0), trace (1), mild (2), moderate (3) and severe (4). For the ocular signs, conjunctival hyperaemia 
was assessed using reference photographs and a similar scale as with ocular symptoms. Fluorescein staining of 
the cornea and nasal and temporal conjunctiva was measured according to the Oxford grading scale from 0 to 5 
and FTBUT was evaluated under a slit lamp microscope (seconds). Lid redness was evaluated as none (0), mild 
(1), moderate (2) and severe (3) and tear secretion was measured using Schirmer’s test (mm), from which tear 
proteins were isolated for proteomics analysis. Clinical examinations and sample collections were performed at 
the same time of the day during each visit. No tear samples were collected during the last visit (V6, ~12.5 months 
after baseline).
ƪǤ Patients’ tear fluid samples were collected with Schirmer’s 
strips without anaesthesia (Tear Touch, Madhu Instruments, New Delhi, India). The strips were inserted under 
patients’ lower eyelids and removed after 5 min. Tear amounts (mm) were recorded and strips were then stored at 
−80 °C until proteomic analyses.
For extraction of tear proteins, Schirmer’s strips were first cut into small pieces and solubilized in 50 mM 
ammonium bicarbonate solution containing Protease Inhibitor Cocktail (Thermo Fisher Scientific Inc., Waltham, 
MA, USA) for 3 h. Samples were then centrifuged and total protein concentration of the supernatants was meas-
ured. Up to 50 μg of protein from each sample was dried in a speed vacuum concentrator. Further information of 
the methods, including denaturation, alkylation, reduction and tryptic digestion as well as analysis with Eksigent 
425 NanoLC coupled with high speed TripleTOF 5600+ mass spectrometer (Ab Sciex, Concord, Canada) can be 
found from the Supplementary methods and from our previous publication15.
Ǥ SWATH library was created with ProteinPilot soft-
ware version 4.6 (Sciex, Canada). The library was used to analyse MS/MS data and search against the Uniprot 
reviewed library (Swiss-Prot) for protein identification. Some important settings in the Paragon search algorithm 
in ProteinPilot were configured as follows. Sample type: identification, Cys-alkylation: IAA, Digestion: Trypsin, 
Instrument: TripleTOF 5600+, Search effort: thorough ID. False discovery rate (FDR) analysis was performed in 
the ProteinPilot and FDR < 1% was set for protein identification. The data from all the identification runs from 
patients were combined as a batch and used for library creation. PeakView software 2.0 with SWATH was used 
Figure 6. Study outline summary. During the screening/baseline visit (V1), the patients were switched from 
preserved latanoprost (L) to preservative-free tafluprost (T) in unit dose dispensers. Clinical measurement 
together with the tear sample collection were performed at visits V1-V5. At the post-study visit (V6), final 
clinical measures were recorded but tear samples were no longer collected. FTBUT, fluorescein tear break-up 
time.
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to assign the correct peaks to correct peptides in the library. iRT peptides (Biognosys, Switzerland) were used for 
retention time calibration with PeakView. 1–12 peptides per protein and 5 transitions per peptide were selected 
to be used in SWATH quantification. All shared peptides were excluded from analysis. SWATH plug-in FDR 
Analysis was used to select the proper peptides for use in quantification. All proteins with significant or interest-
ing findings in the data analysis were subjected to manual inspection of peptides. This consisted of checking cor-
rect peak selection in the chromatogram (FDR 1%, 99% peptide confidence level), sufficient signal to noise ratio 
inspection (>7) and chromatogram inspection in relation to library chromatogram. All peptides were eliminated 
from results processing if manual inspection requirements were not fulfilled.
Ǥ Log2-transformation and quantile normalization were applied 
to all quantification results. The majority of the samples had two replicate MS analyses and the variation between 
them was evaluated by intraclass correlation (ICC package in R) and by permutation tests using Spearman’s rank 
correlation coefficients. The replicate MS analyses were then combined by taking geometric means.
For the clinical data, two-tailed paired t-test for continuous and paired 2-group Wilcoxon signed rank test for 
ordinal clinical signs and symptoms were used to evaluate how the clinical signs and symptoms changed during 
visits. For proteomic data, fold changes (log2) between baseline and other visits were analysed using hierarchical 
clustering (Euclidean distance measure and Ward’s method as the criteria) in order to identify clustered groups of 
proteins with association to ocular surface complications. The clusters of interest were identified using Ingenuity 
Pathway Analysis (IPA) and confirmed by identifying well-known biomarkers. The chosen protein clusters were 
used to group patients based on their proteome changes, again using the same hierarchical clustering method. 
Welch’s analysis of variance (ANOVA) was used to establish proteins, which could separate these patient groups 
based on their baseline expression levels alone. Pairwise comparisons were conducted to the statistically signifi-
cant results, which did not suffer from heteroscedasticity according to Levene’s test for homogeneity of variance 
(p-value > 0.05). The linear relationship between proteins and the clinical signs was measured either by mixed 
model regression (lmer function from lme4 package in R38) or cumulative link mixed model (clmm function 
from ordinal package in R39) in order to account for the repeated measures from the same patients. The changes in 
clinical signs and symptoms among patient groups were again analysed conducting paired t-test for continuous 
and paired 2-group Wilcoxon signed rank test for ordinal variables.
Manual peak checking was implemented for the proteins of interest and as a result, some statistically signifi-
cant proteins were omitted from the results due to poor peptide matching. Benjamini & Hochberg correction was 
applied to p-values and only proteins with an adjusted p-value below threshold (alpha = 0.05) were considered 
unless otherwise stated. All statistical analyses for the proteomics data were performed using R software ver-
sion 3.2.3 (R Core Team. Foundation for Statistical Computing, Vienna, Austria) and QIAGEN’s IPA (QIAGEN 
Redwood City, USA).
Ǥ The data generated and analysed during the current study are not publicly available due to 
a pending patent application but are available from the corresponding author on reasonable request.
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Age-associated changes in human tear 
proteome
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Abstract 
Background: Prevalence of many eye and ocular surface diseases increases with age. While the clinical characteris-
tics and pathophysiologic mechanisms of these conditions are often either known or extensively studied, the eﬀects 
of normal aging on tear ﬁlm and ocular surface have not been as widely researched.
Methods: In order to examine the eﬀects of aging on tear ﬂuid proteomics, tear ﬂuid samples were collected preop-
eratively from 115 subjects undergoing strabismus or refractive surgery using glass microcapillary tubes. In addition to 
their refractive error or strabismus, the subjects did not have any other current, known eye diseases. The non-pooled 
samples were analysed using NanoLC-TripleTOF implementing a sequential window acquisition of all theoretical frag-
ment ion spectra mass spectrometry, resulting in quantiﬁed data of 849 proteins.
Results: According to correlation results, 17 tear proteins correlated signiﬁcantly with increased age and many of 
these proteins were connected to inﬂammation, immune response and cell death. According to enrichment analy-
sis, growth and survival of cells decreased while immune response and inﬂammation increased with aging. We also 
discovered several well-known, activated and inhibited upstream regulators, e.g. NF-κB, which has been previously 
connected to aging in numerous previous studies.
Conclusions: Overall, the results show the common age-dependent alterations in tear ﬂuid protein proﬁle, which 
demonstrate similar age-associated alterations of biological functions previously shown in other tissue and sample 
types.
Keywords: Aging, Mass spectrometry, Ocular surface, Proteomics, SWATH-MS, Tear ﬂuid
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Background
Older age is a major risk factor for various chronic eye 
diseases, such as age-related macular degeneration, glau-
coma, dry eye and other ocular surface diseases [1, 2]. In 
the future, the number of patients with these conditions 
is likely to increase due to population aging but also, in 
the case of ocular surface diseases, due to increased 
use of digital displays and environmental factors such 
as poor air quality. Therefore, there is a need for better 
understanding of normal molecular aging-eﬀects in the 
eye in order to tackle the growing ocular surface issues. 
Fortunately, in recent years, research of ocular surface 
and its molecular functions has advanced due to techno-
logical developments in diagnostic methods. Tear ﬂuid, 
that is nourishing and lubricating the underlying eye, 
provides a non-invasive source for sensitive proteomic 
analyses by means of mass spectrometry to detect puta-
tive biomarkers of ocular surface health.
The normal clinical eﬀects of aging in the eye are rela-
tively well-known and aﬀect all parts of the eye. In ocu-
lar surface of the eye, the tear ﬂuid, consisting of lipid, 
aqueous and mucin layers, which are produced respec-
tively by meibomian glands, lacrimal glands and con-
junctival goblet cells, is known to be altered during aging 
in many ways. Increased age results in lowered tear ﬁlm 
stability and lacrimal gland secretion [3–9]. Tear ﬁlm 
composition is also altered [10], similar to meibomian 
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gland-produced lipid proﬁles [7, 11], while tear evapo-
ration rate is elevated [12]. Despite the various studies 
on the clinical changes, the normal molecular changes 
in aging eye are not yet fully understood. On molecular 
level, increased inﬂammation and dysregulation of innate 
immune response have been connected to normal aging 
[13, 14] as well as ocular surface conditions [15, 16] and 
hence it can be hypothesised that aging could aﬀect these 
biological pathways in ocular surface as well.
It has been further hypothesised that ocular surface 
aging patterns between women and men are diﬀerent as 
women are more likely to suﬀer from age-related ocular 
surface conditions, such as dry eye and Sjögren’s syn-
drome [2, 17, 18]. Some evidence suggests that for exam-
ple the lipid layer, while thinner and more contaminated 
among all elder people, is more aﬀected by age with elder 
women [8] resulting in higher tear evaporation rate [12]. 
One hypothesis to explain the diﬀerences between ages 
and sexes, are the shifting levels of sex hormones, which 
have been connected to meibomian and lacrimal gland 
functions [19], and which are more prominent among 
post-menopausal women. However, as ocular surface dis-
eases are often multifactorial, the underlying causes are 
expected to vary and be far more complex.
In this study, we focused on tear ﬁlm proteomics in 
particular, which we hoped to provide further insight into 
the normal changes in ocular surface during aging and 
possibly also provide further information on the diﬀer-
ences between sexes. Previously, McGill et al. [10] stud-
ied speciﬁc tear proteins and their age-related changes 
and discovered that there was an age-associated decline 
in the expression levels of antimicrobial lysozyme, 
lactoferrin and IgA, while ceruloplasmin and IgG were 
increased. More recently, Micera et al. [20] implemented 
protein array data to evaluate age-associated changes in 
tear ﬂuid and conﬁrmed that several pro-inﬂammatory 
interleukins and other proteins were increased with age. 
Although various age-related diseases have been stud-
ied using tear ﬂuid proteomics [21–23], any wider mass 
spectrometry discovery studies have not been performed 
on the tear ﬂuid proteome changes during normal aging, 
since methods enabling this type of research have only 
been developed quite recently. We gathered tear ﬂuid 
samples from normal, healthy subjects of all ages under-
going either strabismus or refractive surgery and imple-
mented mass spectrometry methods to obtain quantiﬁed 
proteomics data on individual patients. Our aims were to 
identify those proteins, which are increasing or decreas-
ing in their expression with increasing age and to see 
how sex of the patient aﬀects these changes. We hypoth-
esized that the statistically signiﬁcant proteins would be 
connected to age-associated biological functions such as 
immune and inﬂammatory response. To our knowledge, 
this is the ﬁrst proteomics study to implement mass spec-
trometry to examine the tear ﬂuid diﬀerences among 
people of diﬀerent ages.
Methods
Study population
Subjects in this study originate from two separate stud-
ies, which implemented these subjects as healthy control 
populations. The subjects of the ﬁrst study underwent a 
strabismus surgery (n = 30) and the subjects in the sec-
ond study a femtosecond laser in  situ keratomileusis 
(FS-LASIK) (n = 85). In both cases, open-eye tears were 
collected from the lower conjunctival cul-de-sac with 
capillaries prior to any manipulation or anaesthesia of the 
eye, including surgery.
The subjects undergoing refractive surgery had a com-
plete preoperative ophthalmologic examination, includ-
ing biomicroscopy, measurement of corneal thickness 
and three-dimensional corneal topography (Allegro 
Oculyzer, Wavelight AG, Erlangen, Germany) prior to 
the surgery and they had to discontinue wearing soft 
contact lenses at least 1  week before testing. Any ante-
rior or other pathology of the eye that might be a con-
traindication for the refractive surgery, including dry eye 
disease, lid infection, corneal pathology, any prior ocular 
surgery or recent ocular infection, was an exclusion cri-
terion. Other additional exclusion criteria were similar to 
any other refractive surgery: age (under 18 years old) and 
pregnancy. The subjects undergoing strabismus surgery 
similarly had a preoperative ophthalmic examination 
including biomicroscopy, ﬂuorescein staining, conjunc-
tival redness and Schirmer’s test in order to identify any 
clinical pathologies, which would be an exclusion crite-
rion. Similarly, no subjects aged under 18 years or preg-
nant were included.
Tear collection and sample preparation
The tear ﬂuid samples were taken before installation of 
any surgery-associated eye drops. Tear samples were col-
lected into 2 or 3 μl glass microcapillary tubes and stored 
at − 80 °C until assessed.
Samples were ﬂushed from capillaries with 0.5% 
sodium dodecyl sulphate (SDS) in 50  mM ammonium 
bicarbonate supplemented with protease inhibitor cock-
tail and total protein concentration of the tear samples 
was measured by DC protein assay (Bio-Rad laboratories 
Inc, Hercules, USA) using bovine serum albumin as a 
standard. Total protein concentration of 5 μg was consid-
ered as a limit for proteomic analyses. 15 samples did not 
have suﬃcient amount of protein in the samples.
For protein analysis, acetone-precipitated pro-
teins were dissolved in 2% SDS in 0.05  M triethylam-
monium bicarbonate buﬀer (TEAB) and reduced by 
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tris-(2-carboxyethyl)phosphine (TCEP) for 1 h at +60 °C. 
The reduced samples were transferred into 10–30  kDa 
molecular weight cut-oﬀ ﬁlters and ﬂushed with 8  M 
urea in 0.05  M Tris–HCl (Thermo Fisher Scientiﬁc, 
Waltham, USA) to remove the excess reagent. Cysteine 
residue blocking was done by iodoacetamide (IAA) at 
room temperature in the dark. Alkylation was terminated 
by centrifugation and the samples were washed with urea 
and 0.05 M TEAB prior to digestion with trypsin (Sciex, 
Framingham, USA) for 16  h at + 37  °C at a trypsin-to-
protein ratio of 1:25. Digests were eluted from ﬁlters 
with 0.05  M TEAB followed by 0.5  M NaCl and dried 
in a speed vacuum concentrator. Samples were recon-
stituted in 0.1% triﬂuoroacetic acid (TFA), cleaned and 
desalted with Pierce C18 tips (Thermo Fisher Scientiﬁc) 
according to manufacturer’s instructions. After clean up 
the samples were vacuum dried and stored in − 20  °C 
until reconstituted to loading solution (2% ACN, 0.1% 
FA) at equal concentrations. Unless otherwise stated all 
reagents were purchased from Sigma-Aldrich (St. Louis, 
MO, USA). The samples were analysed with NanoLC-
TripleTOF instrumentation using Eksigent 425 NanoLC 
coupled to high speed TripleTOF™ 5600 + mass spec-
trometer (Sciex, Concord, Canada). The analysis was 
performed using sequential window acquisition of all 
theoretical mass spectra (SWATH-MS). Further detailed 
information of the methods and parameters of NanoLC 
and TripleTOF have been published in our previous 
papers [21, 24].
Protein identification and quantification and SWATH-MS 
library creation and peak integration
For SWATH-MS analysis method, we created a relative 
protein quantiﬁcation library, consisting of > 950 pro-
teins. This library was created using tear samples of this 
study as well as two other clinical studies consisting of 
glaucoma patients and dry eye patients. Overall library 
consisted of 55 diﬀerent subjects/samples and over 80 
data-dependent acquisition (DDA) runs with same liquid 
chromatography (LC) gradient and instrument settings, 
which were used for SWATH-MS analyses. Library was 
created using Protein  Pilot® 4.5 (Sciex, Redwood City, 
USA) and all DDA runs MS/MS spectra were identiﬁed 
against UniProtKB/Swiss-Prot. Quantiﬁcation was per-
formed using  PeakView® and  MarkerView® (Sciex, Red-
wood City, USA). False discovery rate (FDR) of 1% was 
used in the library creation and only distinctive peptides 
were used in the quantiﬁcation. Retention time cali-
bration was done for all samples using 8 peptides from 
lysozyme and 5 peptides from albumin. Five transitions 
per peptide and 1–15 peptides were used for peak area 
calculations. All proteins with signiﬁcant or interesting 
ﬁndings in the data analysis were subjected to manual 
inspection of peptides. This consisted of checking cor-
rect peak selection in the chromatogram (FDR 1%, 99% 
peptide conﬁdence level), suﬃcient signal to noise ratio 
inspection (> 7) and chromatogram inspection in rela-
tion to library chromatogram. In addition, variation of 
replicate MS analyses results was calculated as means to 
all samples/protein. If manual inspection requirements 
were not fulﬁlled, peptides were eliminated from results 
processing. Results are presented as combination of pro-
tein speciﬁc peptides peak intensities from SWATH-MS 
measurement and referred to as protein expression.
Data processing and statistical analysis
Log2-transformation and central tendency normalization 
were used to normalize the protein quantiﬁcation data. 
Majority of the samples had two replicate MS analyses 
run and their variation was calculated by intraclass corre-
lation (ICC package in R) and by permutation tests using 
Spearman’s rank correlation. The replicate MS analyses 
were combined by taking geometric means.
The correlations between age and relative quantiﬁ-
cation data were performed with Pearson’s product-
moment correlation. Ingenuity Pathway Analysis  (IPA®) 
was implemented to evaluate the enriched biologi-
cal functions and diseases based on correlation results 
(included measurements were p-value as “Expr p-value” 
and Pearson’s Rho as “Expr Other”). Sex diﬀerences 
were tested using Wilcoxon rank sum test. Benjamini–
Hochberg adjustment was applied to all p-values and 
only proteins with an adjusted p-value below threshold 
(alpha = 0.05) were considered statistically signiﬁcant 
unless otherwise stated. All statistical analyses for the 
proteomics data were performed using R software ver-
sion 3.4.3 (R Core Team, Vienna, Austria) and QIAGEN’s 
 IPA® (QIAGEN Redwood City, USA).
Results
Clinical patient data
The study consisted of 115 subjects. Tear samples of 30 
subjects undergoing strabismus surgery and 85 undergo-
ing refractive surgery were collected prior to their opera-
tions. None of the subjects had any other current, known 
eye diseases; however, four strabismus surgery subjects 
had previously undergone a cataract surgery. The data 
consisted of 61 females (13 strabismus and 48 refractive 
surgery subjects) and 54 males (17 strabismus and 37 
refractive surgery subjects). The median age for subjects 
was 41  years [95% CI 38–43.9] and ranged from 18 to 
83. The median age for females was 40 [95% CI 37–43.8] 
and for males 42 [95% CI 37.3–46.7]. The age was not sig-
niﬁcantly diﬀerent between female and male groups was 
(p = 0.6) according to Wilcoxon signed-rank test.
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Proteomics data
We identiﬁed 30,358 peptides from 115 samples, includ-
ing MS analysis replicates, corresponding to 660,966 
identiﬁed spectra in an assembly of 1497 protein groups 
using FDR of 1.0%. We included 950 proteins with dis-
tinctive peptides to quantiﬁcation library, of which 849 
proteins had distinct peptide sequences with matching 
spectra to SWATH-MS analysis. These proteins were 
quantiﬁed in all samples. The quality checks performed 
with the MS replicate analyses suggested that the prot-
eomic data was of good quality as the mean of intraclass 
correlation coeﬃcient was 0.957 and performing permu-
tation tests (Spearman’s correlation) resulted in 86.6% of 
p-values < 0.05.
Age affects tear proteins associated with inflammation 
and immune response
Tear protein proﬁles of the analysed 115 subjects were 
used to evaluate the relationship between tear protein 
expression and age as well as sex diﬀerences. Age was 
signiﬁcantly correlated with several well-known tear pro-
teins, many of which were associated with biologically 
important functions such as cell death and inﬂammatory 
and immune response based on IPA and gene ontology 
(GO) databases (Table 1). The positively correlating pro-
teins included: cytoplasmic actins (ACTB and ACTG1), 
albumin (ALB), annexin A1 (ANXA1), carcinoembryonic 
antigen-related cell adhesion molecule 7 (CEACAM7), 
neutrophil defensin 1 (DEFA1), gelsolin (GSN), neu-
trophil gelatinase-associated lipocalin (LCN2), proﬁ-
lin-1 (PFN1), retinoic acid receptor responder protein 1 
(RARRES1), mammaglobin-A (SCGB2A2), serotransfer-
rin (TF), proteins S100A8 and S100A9. Ubiquitin-like 
modiﬁer-activating enzyme 1 (UBA1) and Golgi mem-
brane protein 1 (GOLM1) correlated negatively with 
age. Further information on the expression level pro-
ﬁles of these proteins within diﬀerent age groups can be 
found from Additional ﬁle 1, which also lists the associ-
ated median and mean protein expression values as well 
as interquartile ranges and pairwise t-test p-values for 
patients grouped by age (5 groups: < 30, 30–39, 40–49, 
50–59, and ≥ 60). These results suggest that for majority 
of the statistically signiﬁcant proteins, the largest changes 
take place among the aging subjects after the age of 60, 
although for some proteins, the changes in expression 
occur already among the 50–59 year-olds’ group.
Although sex alone was not signiﬁcantly aﬀecting pro-
tein expression levels in tears, some diﬀerences were 
observed when the age-aﬀected proteins were ana-
lysed for male and female groups separately (Fig.  1). 
More speciﬁcally, the proteins were correlating with 
age similarly among both females and males, but the 
Table 1 List of proteins correlating significantly with age and the associated biological functions
a Pearson’s product-moment correlation coefficient
b Benjamini-Hochberg-adjusted p-value
† Expression based on 1 peptide only
‡ Proteins ACTB and ACTG1 are isoforms of the same protein
Uniprot Full name Symbol Ra pb Cell death Cellular 
movement
Inflammatory/
immune 
response
Viral infection
P80188 Neutrophil gelatinase-associated lipocalin LCN2 0.36 0.011 x x x x
P05109 Protein S100-A8 S100A8 0.40 0.004 x x x x
P06702 Protein S100-A9 S100A9 0.36 0.013 x x x x
P60709 Actin, cytoplasmic 1 ACTB‡ 0.31 0.036 x x x x
P02768 Serum albumin ALB 0.35 0.013 x x x x
P04083 Annexin A1 ANXA1 0.37 0.010 x x x x
P07737 Proﬁlin-1 PFN1 0.32 0.036 x x x
P06396 Gelsolin GSN 0.32 0.036 x x
P02787 Serotransferrin TF 0.37 0.010 x x
P63261 Actin, cytoplasmic 2 ACTG1‡ 0.31 0.037 x
P22314 Ubiquitin-like modiﬁer-activating enzyme 1 UBA1 − 0.32 0.036 x
P59665 Neutrophil defensin 1 DEFA1 0.40 0.004 x x
P49788 Retinoic acid receptor responder protein 1 RARRES1 0.30 0.046 x
Q8NBJ4 Golgi membrane protein 1 GOLM1 − 0.31 0.036 x
Q13296 Mammaglobin-A SCGB2A2 0.34 0.023
Q14002 Carcinoembryonic antigen-related cell 
adhesion molecule 7
CEACAM7† 0.32 0.036
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protein-age-correlations were in most cases statistically 
signiﬁcant and more consistent with males. SCGB2A2 
was the only protein, which appeared to have a higher 
correlation coeﬃcient for female subjects, while e.g. 
S100A9, ANXA1, GSN and CEACAM7 had notably 
higher age-associated increase for males according to the 
linear regression lines shown in the ﬁgure.
The connections between tear proteomics and aging 
(for data including both sexes) were further examined by 
performing pathway analysis. The pathway analysis was 
Fig. 1 Proteins correlating signiﬁcantly with age. Scatter plots display the statistically signiﬁcant correlations (from Table 1) between protein 
expression levels (y-axis) and age (x-axis). Correlation results were also evaluated for males and females separately and, unless otherwise stated, only 
males’ expression levels correlated signiﬁcantly with age for the displayed proteins. The colour and shape of the points signify males and females, 
which also have individual ﬁtted lines and corresponding Rho (R) values displayed. †CEACAM7 expression is based on only 1 unique peptide in the 
data. *p-value < 0.05, **p-value < 0.01, ***p-value < 0.001
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performed on data with relaxed thresholds, more speciﬁ-
cally using proteins with unadjusted p-value < 0.05. Addi-
tional ﬁle 1 includes further information about the results 
associated with this protein list. We focused on the 
enriched biological functions and upstream regulators. 
Some of the interesting biological function terms are vis-
ualized and grouped in Fig. 2 and more complete results 
can be found from Table 2. Increased biological functions 
include terms connected to immune response and more 
speciﬁcally migration of immune cells. In addition, there 
was evidence of increased inﬂammatory and cell death 
responses in the tears of elderly subjects. Cell viability 
and survival as well as growth of organism had negative 
z-scores, suggesting inhibition of these functions.
The upstream regulators, which could aﬀect and cause 
the protein expression level changes we have observed in 
the data, are visualized in Fig. 3 and listed in Table 3. The 
three regulators with the highest activation (bias-cor-
rected) z-scores were NF-κB complex, CCAAT/enhancer 
binding protein α (CEBPA) transcription factor and 
interleukin 15 (IL15) and the three molecules with the 
lowest activation z-scores were transcription regulators 
Myc proto-oncogene protein (MYC), cyclin D1 (CCND1) 
and cyclin-dependent kinase 4 and 6 (CDK4/6) group.
Discussion
Although aging is a widely studied subject and noted as a 
major risk factor for many chronic diseases, age-related 
changes in the tear ﬁlm have not been previously exam-
ined in a molecular level using discovery proteomics. 
Previous research studying tear protein levels during 
aging have mainly focused on individual, well-known 
targeted tear proteins alone. Micera et  al. [20] identi-
ﬁed several pro-inﬂammatory proteins increasing with 
age through chip arrays and McGill et  al. [10] found a 
decrease of lysozyme, lactoferrin and IgA and an increase 
of ceruloplasmin and IgG in tears during aging in their 
study. In order to obtain more comprehensive image of 
the protein proﬁles during aging, we analysed the pro-
teomic expression levels of tear ﬂuid samples among 
subjects, both male and female, with varying ages using 
SWATH-MS. The SWATH approach enabled us to per-
form analyses separately in each individual sample, 
avoiding this way pooling of the samples. We discovered 
Fig. 2 Enriched biological functions aﬀected by aging. Heat map displays the general terms (excluding disease-speciﬁc terms such as cancer 
terms), which have either highly increased (red) or decreased (green) functions based on activation z-score (absolute bias-corrected z-score > 1.5, 
p-value < 0.05), as age is increased. On the left, the more speciﬁc terms are provided for each row and on the right, the speciﬁc terms are grouped 
under categories that are more general
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that, among hundreds of proteins, there is a small sub-
group of proteins in tear ﬂuid, which correlated with age 
and many of these proteins were connected to inﬂamma-
tion, which is known to be increased or at least altered 
with aging [13, 20, 25]. Majority of the identiﬁed pro-
teins had the most notable increase/decrease in expres-
sion among subjects aged 60 or over, suggesting that the 
normal onset for the changes often occurs after this age. 
Although the identiﬁed protein changes may not directly 
point the speciﬁc underlying mechanism that is triggered 
during aging, these results provide a list of interesting 
proteins for future tear ﬂuid proteomic studies associated 
with aging.
Among the proteins, we found age to positively corre-
late with ALB, ANXA1, DEFA1, LCN2, TF, SCGB2A2, 
S100A8 and S100A9. All of these proteins have been 
observed to be increased in the tear ﬂuid proteom-
ics studies examining dry eye disease or other similar 
inﬂammatory ocular surface conditions [26–34]. Several 
of these proteins, most prominently S100A8 and S100A9, 
are also used as common indicators of ocular surface 
inﬂammation [26, 35]. Hence, as also suggested by other 
tear ﬂuid proteomic studies [20], it would appear that 
aging does increase the inﬂammation in the ocular sur-
face and these increased proteins could partially explain 
why higher age is one of the main risk factors of ocular 
surface conditions, which are often closely connected to 
ocular surface inﬂammation.
Other proteins increasing with age, which could not 
be directly connected to ocular surface inﬂammation, 
included two cytoplasmic actin isoforms (ACTB and 
ACTG1), GSN, PFN1, CEACAM7 and RARRES1. Of 
these proteins, CEACAM7 and RARRES1 have not yet 
been connected to ocular surface condition and while 
ACTG1 is an interesting protein, it has so far been only 
connected to treatment eﬀects of dry eye [21]. However, 
it merits further investigations of its role in ocular sur-
face functions. ACTB has been found to be decreased 
in the tear ﬂuid of subjects suﬀering from meibomian 
gland dysfunction [29], yet it was upregulated in Sjögren’s 
syndrome [34], which is often considered to be closer to 
aqueous-deﬁcient dry eye condition. GSN and PFN1 have 
also been shown to be upregulated particularly in aque-
ous-deﬁcient dry eye with and without lipid deﬁciency, 
but not in lipid-deﬁcient dry eye alone [36]. These pre-
vious ﬁndings together with our results suggest that the 
increase of at least some of these proteins would result in 
increased risk of aqueous-deﬁcient dry eye during aging. 
However, age-associated, increased risk of meibomian 
gland-associated lipid deﬁciency cannot be determined 
based on these results and instead, e.g. lipidomics could 
provide more comprehensive results.
Table 2 Enriched diseases and  biological functions filtered by  activation z-score (absolute bias-corrected z-score > 1.5, 
p-value < 0.05) and ordered based on categories and sign of z-score
Categories Diseases or functions annotation Bias-corrected z-score p
Carbohydrate metabolism Uptake of carbohydrate 1.7 6.54E−04
Cardiovascular system development and function Angiogenesis 1.8 4.98E−05
Cell death and survival Cell death of connective tissue cells 2.0 6.98E−04
Cell-to-cell signaling and interaction Response of granulocytes 1.7 2.06E−06
Immune response of leukocytes 1.7 2.60E−03
Cellular function and maintenance Internalization of cells 1.7 3.18E−03
Engulfment of leukocytes 1.6 3.29E−04
Cellular movement Cell movement of myeloid cells 1.7 1.23E−05
Cell movement 1.6 4.22E−07
Chemotaxis 1.6 1.15E−04
Cell movement of neutrophils 2.0 5.20E−05
Chemotaxis of leukocytes 1.7 5.48E−05
Chemotaxis of neutrophils 1.6 1.26E−03
Inﬂammatory response Inﬂammatory response 1.7 1.68E−05
Organismal survival Organismal death 2.3 3.17E−05
Cell-to-cell signaling and interaction Aggregation of cells − 1.6 4.10E−05
Cell death and survival Cell viability − 1.8 3.63E−04
Cell survival − 2.4 1.90E−06
Cell death of kidney cell lines − 2.4 2.15E−03
Organismal development Growth of organism − 2.5 6.72E−05
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Our data analysis also resulted in two proteins with a 
signiﬁcantly decreasing expression with increased age: 
UBA1 and GOLM1. UBA1 has been associated with 
increased expression in the tear ﬂuid of dry eye patients 
with both aqueous and lipid deﬁciency [36]. GOLM1, 
although there are currently no studies connecting this 
protein to the ocular surface, has been recently asso-
ciated with viral infection and its associated immune 
response [37].
Interestingly, protein-age correlations were in most 
cases more signiﬁcant with males, i.e. males’ protein 
expression increased/decreased more consistently with 
age. SCGB2A2 was the only protein, which had a some-
what larger correlation coeﬃcient as well as more visible 
increase for female subjects. However, the overall protein 
expression directions were not diﬀering between female 
and male groups, although a previous study by Ananthi 
et al. [38] identiﬁed some upregulated proteins in female 
tear samples including lipocalin and mammoglobin B 
precursor, which belongs to the same secretoglobin fam-
ily as SCGB2A2. Clinical studies have also shown that the 
dry eye disease, Sjögren’s syndrome and other ocular sur-
face conditions are more common among older women 
[17, 18], which does suggest that our ﬁndings are not 
associated with increasing prevalence of ocular surface 
diseases alone but rather normal aging, which appear 
to be aﬀecting males more signiﬁcantly. Older women, 
often suﬀering from ocular surface disease and its symp-
toms, are not fully represented in this study, since they 
are unlikely to participate in ocular surgeries and are in 
fact excluded in severe cases.
The pathway analysis was performed based on the cor-
relation results originating from complete data, in order 
to discover general eﬀects of aging. The results showed 
that while cell survival and organismal growth were 
decreased, organismal death, inﬂammation, angiogenesis 
Fig. 3 Upstream regulators associated with aging of the ocular surface. The graph displays the top 3 activated (in orange) and inhibited (in 
blue) upstream regulators based on the protein-age-correlation directions obtained. Proteins with increased (in red) and decreased (in green) 
measurements originate from the protein-age-correlation results, i.e. increased measurements suggest a positive correlation between the protein 
expression level and age, and decreased measurements a negative correlation
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and immune response-related actions increased. These 
biological functions display similar results, which have 
already been identiﬁed previously [13, 14, 20, 25]. Several 
studies have also discussed of the increased immunose-
nescence, i.e. how the immune system slows down as we 
age, but also that innate immune system is at the same 
time incorrectly activated. Therefore, our results with an 
increase in immune cell chemotaxis and response could 
refer to the increased innate immune response.
The upstream regulators, which are associated with or 
aﬀecting protein expression levels observed in the data 
were also evaluated. Transcription regulator CEBPA, 
cytokine IL15 and NF-κB complex were the top three 
activated upstream regulators and of these, NF-κB 
appears to be the most interesting. This complex is not 
only connecting to or regulating the other upstream 
regulators looked at more closely in this study, but vari-
ous studies and reviews link it to aging, inﬂammation 
and dry eye. In fact, NF-κB is considered as a hallmark 
of aging and master regulator of innate immunity [39, 
40]. It has also been identiﬁed in rat cornea, conjunctiva 
and lacrimal gland [41] and a very comprehensive review 
shows how it links to several ocular surface diseases [42]. 
Our results therefore comply well with the previous ﬁnd-
ings and suggest that activation of NF-κB is also present 
in the aging ocular surface and its tear ﬂuid. Targeting 
this complex in ocular surface treatment methods could 
provide good results, especially for elder subjects.
Of the two other activated upstream regulators, 
CEBPA has been associated to regulation of aging in 
mouse gene expression as well as fat metabolism [43] and 
it also inhibits CDK4 and therefore cell proliferation and 
growth [44]. IL15, which is closely connected to immune 
system response, has been noted to be increased in the 
sera of subjects above the age of 95 years [45].
The top three inhibited regulators included transcrip-
tion regulators CCND1 and MYC as well as CDK4/6 
group. In fact, CDK4/6 and CCND1 form together a 
complex, which regulates cell cycle [46] and has been for 
that reason covered in various cancer studies. In addi-
tion, MYC has also been connected to the CDK4/6 and 
that way to CCND1 through these cancer studies [47]. 
Table 3 Upstream regulator analysis filtered by  p-value (p-value < 0.05) and  ordered based on  molecule type  and sign 
of z-score
Upstream regulator Molecule type Bias-corrected z-score p of overlap
NFκB (complex) Complex 1.5 3.01E−04
IgG Complex 0.5 3.65E−05
IL15 Cytokine 2.2 2.08E−05
IL13 Cytokine 0.9 1.63E−02
IFNG Cytokine 0.1 7.23E−03
IL1B Cytokine 0.1 7.27E−04
TNF Cytokine 0.0 3.60E−09
MGEA5 Enzyme 0.2 3.28E−02
ERK1/2 Group 1.3 8.18E−05
Estrogen receptor Group 0.8 4.54E−03
EGFR Kinase 0.9 2.58E−03
EFNA4 Kinase 0.1 7.28E−05
ESRRA Ligand-dependent nuclear receptor 1.5 3.00E−05
ESR1 Ligand-dependent nuclear receptor 1.0 2.70E−03
PCGEM1 Other 1.1 2.21E−06
EFNA1 Other 0.1 1.82E−04
CEBPA Transcription regulator 2.2 3.28E−07
IL6 Cytokine − 0.4 4.76E−03
TGM2 Enzyme − 0.2 2.29E−02
CDK4/6 Group − 1.4 1.66E−06
MAPK1 Kinase − 0.5 2.71E−03
TP53 Transcription regulator − 0.4 9.19E−03
HIF1A Transcription regulator − 0.5 9.82E−04
MYC Transcription regulator − 1.5 4.88E−05
CCND1 Transcription regulator − 1.6 1.54E−04
SYVN1 Transporter − 0.1 7.30E−04
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Since all three regulators promote growth and regu-
late cell cycle, it seems feasible that these regulators are 
inhibited as our results suggest decreased cell survival 
and organismal growth.
Conclusions
In conclusion, we discovered several tear ﬂuid proteins, 
which are signiﬁcantly aﬀected by increasing age. These 
proteins are connected to several age-associated func-
tions, e.g. cell death and inﬂammation, as well as well-
known upstream regulators, NF-κB being one of the most 
interesting of these. In the future tear ﬂuid proteomics 
studies, the information presented here should motivate 
researchers to ensure age is properly controlled for in the 
studies and in addition, the knowledge of the proteins, 
pathways and upstream regulators can be implemented 
in the research of dry eye and other ocular surface dis-
eases, which are associated with increased age.
Additional file
Additional file 1. Analysis results of proteins with unadjusted 
p-value < 0.05.
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